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Thesis Summary 
Orally disintegrating tablets (ODTs) are an attractive solid dosage form for patients who 
suffer from dysphagia, a difficulty in swallowing, which is particularly prevalent in 
paediatric and geriatric populations. ODTs and fixed dose combination (FDC) 
formulations are popular as they improve patient compliance and combination of the two 
has not previously been explored.  
The requirement for ODTs to disintegrate rapidly whilst also being mechanically robust 
means that high drug loading is a significant challenge.  An ODT formulation for the beta-
lactam antibiotic flucloxacillin was developed at doses of 250 and 125 mg. ODTs were 
mechanically robust, however this limited disintegration to within 3 mins, with mannitol 
fragmentation being a major limitation.  
Polymeric film coating was devised as a potential technique to enhance ODT mechanical 
properties. Due to high attrition during fluidisation a novel stationary coating technique 
was developed as a proof of concept. ODTs coated in this way, coupled with a post-
coating curing step, demonstrated an increase in hardness of almost double and 
essentially zero friability. This novel coating technique could prove hugely beneficial in 
the formulation of high dose or poorly compactable drugs.  
The application of ODTs for FDCs was tested with four model drugs: amlodipine (5 mg), 
atorvastatin (10 mg), isoniazid (50 mg) and rifampicin (75 mg). ODT formulations for 
single and FDCs showed rapid disintegration and good mechanical properties. 
Comparison of single and FDC dissolution profiles was performed using FDA 
recommended f1 and f2 testing. Bioavailability from ODTs was assessed using in vitro 
Caco-2 permeability and dissolution data and in silico physiologically based 
pharmacokinetic modelling. Bioequivalence was demonstrated between single and FDC 
for each drug in both fed and fasted states, whilst atorvastatin showed a positive food 
effect (enhanced peak plasma concentration and area under the curve), due to reduced 
metabolism by CYP3A4. 
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1.1 Paediatric Medicines 
Over the past two decades there has been an effort to increase the number of 
prescription drugs designed for use in the paediatric population due to poor availability. 
There are many reasons for the lack of medicines that are labelled for paediatric use, 
which arise as a result of a significant paediatric knowledge gap. These include a lack of 
understanding of acceptable dosage form and size, volume of administration, taste and 
importantly safe dosage levels of both the active drug and all excipients included in a 
formulation. The lack of suitable medicines for the paediatric population means that 
unlicensed formulations are often prepared and administered by healthcare 
professionals. Improving understanding of the effect of medicines on children is of vital 
importance, however it is complicated by the requirement to protect the wellbeing of 
children in clinical trials and fears over ethical issues and causing harm [1].  
The lack of paediatric approved medications has in the past resulted in missed 
opportunities for paediatrics to receive potentially useful or even lifesaving drugs. 
Conversely, the use of medicines in paediatrics, that only have evidence from adult 
studies, has, on occasion, had drastic consequences. Guidelines, first laid out by the 
FDA (Federal Drug Administration) and then the EMA (European Medicines Agency), 
have so far been successful in closing this knowledge gap and providing new, safe and 
suitable formulations for paediatrics. These guidelines describe both regulations and 
incentives in order to achieve this goal [2]. 
 
1.1.1 Legislation, Regulations and Incentives 
The FDA has introduced numerous rules and regulations to promote the reporting of 
safety information and incentivise the conductance of studies for new paediatric 
therapeutics by offering extensions of market exclusivity. These include the 1994 
Pediatric Labelling Rule, the 1997 Food and Drug Administration Modernization Act 
(FDAMA) and the1998 Pediatric Rule [3, 4]. The Best Pharmaceuticals for Children Act 
(BPCA) in 2002 extended the incentives program for 5 years, encouraging off-patent 
paediatric drug studies and requiring public transparency of study results [5]. The 
Pediatric Research Equity Act (PREA) of 2003 enforced mandatory studies for drugs and 
biologics, whilst the FDA Safety and Innovation Act (FDASIA) in 2012, extended previous 
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regulations to October 2017 and also required manufacturers to submit a Pediatric Study 
Plan (PSP) at an early stage of drug development [6].  
Similarly, the European Medicines Agency (EMA) introduced the 2007 Paediatric 
Regulation to improve research into medicines for children, avoid needless risk to 
children and make authorised medications more accessible. It requires manufacturers to 
submit a drug development plan, known as a Paediatric Investigation Plan (PIP) in order 
for approval and offered a 6-month patent extension for new drugs upon PIP approval. 
Incentives for paediatric specific, older, off-patent drugs are also addressed. Other efforts 
include the European Paediatric Formulation Initiative’s development of an online Safety 
and Toxicity of Excipients for Paediatrics (STEP) database, which includes input from 
research and industry [2, 7, 8].  
 
1.1.2 Excipient Considerations 
It is not just the active pharmaceutical ingredient (API) that is of concern in paediatric 
formulations. In order for a formulation to be successful a wide range of functional 
excipients are included, the choice of which will be determined by the dosage form and 
delivery method. Despite the traditional view that excipients are inert, no substance is 
completely free from toxicity. As excipients generally represent a substantial share of a 
formulation’s composition, caution must be taken to select excipients that offer as little 
harm to the patient as possible. Due to differences in physiology, excipients which are 
safe in the adult population may offer a significant risk to paediatrics, due to 
pharmacokinetic differences altering their administration, distribution, metabolism and 
elimination when compared to adults. Safety concerns for paediatrics regarding 
commonly used excipients exist and include examples such as propylene glycol, benzyl 
alcohol and a selection of additive “E numbers”, to name a few. With benzyl alcohol for 
instance, a commonly used preservative, its metabolism to hippuric acid which can be 
readily excreted, is reduced in neonates resulting in high toxicity [9, 10].  
Published guidelines concerning the use of excipients in paediatric formulations [11] 
state that the selection of excipients for paediatric formulations should be done with 
special care and with consideration of different sensitivities between different age 
groups. The inclusion of any excipient in a formulation should be justified by its function 
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and should be included at the lowest possible concentration for the desired effect. 
Inclusion should also be reinforced using as much information from toxicological data, 
scientific guidelines, food legislation and literature as possible. Information about 
compatibility of excipients with the active and with other excipients should be disclosed. 
It is also agreed that any new excipient be examined in preclinical and clinical trials to 
ensure safety. No organisation, however, recommends the conductance of ADME 
studies over the entire paediatric age group, despite paediatrics being a target population 
[9, 12]. 
 
1.1.3 Considerations for Paediatrics 
There are a number of reasons why formulations for adults are often not suitable for 
children. Infants experience rapid growth and development with different rates of growth 
of organs and maturation of active transport systems, metabolic pathways, and body 
systems. These differences mean that infants cannot be viewed as young adults as they 
often exhibit different responses to both active pharmaceutical ingredients (APIs) and 
excipients [13]. These include differences in pharmacokinetics, pharmacodynamics and 
adverse effects to different formulations. For example, pharmacokinetic differences 
between adults and paediatrics include gastric emptying rate and pH, gastrointestinal 
permeability and surface area for absorption [14]. Paediatric dose size changes from 
infancy to childhood, with doses calculated by body weight or surface area at older ages. 
As a result, paediatric formulations must be flexible enough and accurate enough to allow 
for this large dose range. A child’s mental development will also determine their ability to 
tolerate different dosage forms, with many young children being unable to swallow 
conventional tablets or capsules. Indeed, the dosage must be in a form that can be 
accepted by a child or administered to that child by a caregiver [12, 15]. Palatability of 
oral medication is also crucial for paediatric compliance, since taste acceptance differs 
between adults and paediatrics and children will be less willing to tolerate a medicament 
they find to have an unacceptable taste [16]. 
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1.1.4 Paediatric Relevant Dosage Forms 
The oral route is the most favoured for long term dosing, with liquid formulations being 
the most popular and prevalent in the market due to dose flexibility and difficulties in 
swallowing tablets and capsules. Taste-masking oral formulations requires careful 
selection of excipients and can drive up costs, lead to long term instability and may not 
even be completely achievable (especially for bitter drugs). Although technologies such 
as encapsulation or complexation can be employed in taste masking they can be difficult 
to achieve and costly [17]. Selection of a suitable vehicle, most often water, can also 
present significant formulation challenges. Limitations of dose and volume due to drug 
solubility are also common issues, as is chemical, physical and microbial stability, which 
must be controlled for by the addition of antioxidants, buffers, suspending agents and 
preservatives [14] 
Due to these limitations, a range of solid oral dosage forms suitable for children are 
available. Multiparticulates such as granules and pellets, for example, can be 
administered directly into the mouth or mixed with certain food or drink. These offer 
advantages such as ease of swallowing, dose flexibility and the possibility of drug 
combination, however incomplete ingestion (and therefore reduced dose), packaging 
and stability issues add complications [15]. Mini tablets are another popular innovation. 
These are 3 mm or smaller in diameter and can be produced using conventional tablet 
presses, limiting cost. Studies in young children indicate that they offer no risk of choking 
or aspiration and are fairly well accepted, although the ability to swallow increases with 
age. They also allow for flexible dosing and can be adapted to dispenser devices for 
ease of use and accuracy [18].  
Orally disintegrating tablets (ODTs) are another suitable dosage form for paediatrics, 
which overcome dysphagia by disintegrating in the mouth upon contact with saliva. They 
can be produced by a variety of conventional and more specialised techniques. 
Production by direct compression offers the greatest ease and cost-effectiveness, 
however tablet performance is highly dependent on the API properties and taste masking 
for bitter drugs can be a complex necessity [19].  
Chewable tablets and gums have also been developed for paediatrics. They do not 
require water, offer stability and ease of transport and are palatable. That said taste 
masking can prove difficult to achieve. Oral wafers are also suitable dosage forms for 
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children. These are small thin strips that adhere to the mucosa and dissolve, negating 
swallowing and avoiding the problem of spitting out. They benefit from containing small 
amounts of excipients, however have a limit for drug incorporation of around 50 mg and 
are also highly dependent on taste masking [20]. 
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1.2 Orally Disintegrating Tablets 
In recent years there has been increasing interest in orally disintegrating tablets (ODTs) 
as a preferable alternative to conventional solid oral dosage forms. ODTs rapidly 
disintegrate upon contact with saliva and the API disperses or dissolves. This rapid 
disintegration is of benefit to patients who experience dysphagia, a difficulty in 
swallowing that is particularly common amongst the elderly, paediatrics and patients 
suffering from a variety of disorders such as stroke or neurological problems. Difficulty in 
swallowing may also result from nausea, a lack of access to water, or from restricted-
fluid-intake diets [19, 21, 22]. It has been estimated as much as 50% of the population 
suffer from dysphagia [23] resulting in serious problems with drug compliance and 
ineffective therapy. 
ODTs may offer enhanced absorption and pharmacokinetic profiles and a faster onset 
of therapeutic effect [24]. Rapid dissolution in the mouth allows for absorption of some 
APIs from the oral cavity, pharynx and oesophagus and thus avoids, to some extent, 
gastric absorption. Pre-gastric absorption has the benefit of improved bioavailability and 
rapid systemic absorption (and thus high plasma levels) due to the avoidance of first-
pass metabolism in the liver [25]. This has important implications for drugs that undergo 
significant hepatic metabolism, for instance and drugs that are inactivated by hepatic 
metabolism. Additionally, pre-gastric absorption of drugs that generate toxic metabolites, 
through hepatic and gastric metabolism, will be of benefit to the patient [26]. Conversely, 
prodrugs that require hepatic metabolic activation to their active form may not be suitable 
candidates for this technology. 
Pharmaceutical companies see ODT technologies as attractive as they provide the 
opportunity for product differentiation and new dosage forms for drugs with which patent 
protection is expiring, in order to extend market exclusivity [27]. This increases revenue 
for the company, which is enhanced by the opportunity to sell to underserved patient 
populations. Consumers also benefit from a more convenient dosage form or dosing 
regimen [28]. Indeed, the interest in ODTs can be further understood by market studies 
showing that, once experienced, 70% of consumers would ask for ODTs from their doctor 
and purchase ODTs and 80% would prefer ODTs over regular tablets or liquid forms 
[29]. In addition to the ease of use, the pleasant mouthfeel of ODTs makes them 
favourable to patients [30]. 
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There are a number of properties that a successful ODT must possess. Firstly, they must 
not require water for administration and must be able to disintegrate within a matter of 
seconds in contact with saliva. They must be able to tolerate the manufacturing process 
and handling without fracturing or fragmenting. They should be cost effective and allow 
for high drug loading if possible, although this is highly dependent on API properties. 
Preferably they should be unaffected by environmental conditions like temperature and 
humidity, so that conventional low-cost packaging can be used. Perhaps most 
importantly, they must have an agreeable taste that masks any unpleasant taste of the 
API or excipients, otherwise patient compliance will be detrimentally affected. Finally, the 
tablet must possess a pleasant mouth feel, with the tablet forming small particles after 
disintegration to avoid a gritty sensation [31-33]. 
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1.3 Technologies Involved in ODT Manufacture 
The interest in ODTs is exemplified by the 80 new patents that were filed for ODT 
technologies between the years of 1999-2010. A variety of techniques have been 
employed in the manufacture of ODTs, the main three being compression-based, 
moulding and freeze-drying, with compression technologies being by far the most 
favoured for drug production [19]. ODT properties will depend on the technology used 
for their production. The extent of drug loading is also dependent on the technology and 
as such APIs that require a high dose will be unsuitable for certain technologies [31]. 
The basic principles of each technology, including the benefits and challenges 
associated with each and the different classes of excipients involved, is discussed below, 
with an emphasis on direct compression. 
 
1.3.1 Moulding 
1.3.1.1 Compression Moulding 
The moulding process involves moistening of a powder blend with a solvent before 
moulding the mixture into a tablet at low pressure. The moulded tablet then undergoes 
air drying to remove the solvent and thus volatile solvents, such as ethanol, are 
commonly used, although water is an option. Due to the low pressures (relative to that 
of conventional compression) used, the tablets formed are very porous which aids in 
disintegration. Powder sieving prior to moulding to reduce particle size can also be 
employed to enhance disintegration [34]. 
 
1.3.1.2 Heat Moulding 
In addition to conventional moulding, heat moulding has been employed in the production 
of ODTs. This involves dissolving or dispersing the drug in a molten matrix followed by 
moulding. Using this technique a solution or suspension of drug, agar (as a binder) and 
sugar is poured into blister packaging and then solidified at room temperature before 
drying at 30°C under vacuum [35, 36]. 
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1.3.1.3 No-Vacuum Lyophilisation 
No-vacuum lyophilisation involves moulding a paste or slurry and then freezing to form 
a solid matrix. The solvent is then evaporated at a standard pressure resulting in a tablet 
with a partially collapsed matrix. This differs from standard lyophilisation in that 
evaporation occurs through the liquid phase to a gas, whereas with regular lyophilisation 
the solvent evaporates by sublimation. This method of drying improves the mechanical 
strength of the tablet by densifying the matrix [34, 37]. Depending on the solubility of the 
drug in the matrix, it may exist as either discrete particles or microparticles and may be 
fully or partially dissolved in the matrix [38]. 
 
1.3.1.4 Advantages and Challenges of Moulding 
The dispersion matrix is generally comprised of water soluble sugars and this offers an 
advantage for moulded tablets as they facilitate a desirable rapid dissolution and 
pleasant taste. Compared to lyophilisation, moulding is easier and more adaptable to 
production on an industrial scale. Additionally, as mentioned, moulding produces highly 
porous tablets which aids in disintegration [35]. 
The high porosity of moulded tablets, however, compromises mechanical strength, with 
erosion and breakage through handling and opening of blister packets commonplace, 
with the confounding problem that hardening excipients, such as sucrose or polyvinyl 
pyrrolidone, will adversely affect disintegration rate. Tablets with sufficient mechanical 
strength and disintegration rates can be produced through the use of novel equipment 
and multi-step processes, however these are more complex and expensive [36, 37]. 
 
1.3.2 Freeze Drying/Lyophilisation 
This process involves freezing the product and then subsequent removal of water by 
sublimation using a low pressure vacuum. The preparation is first poured into pre-formed 
blisters to form the tablet shape. Next, the blisters undergo controlled cryogenic freezing 
to control the size of the ice crystals that are formed and thus control pore size.  The 
blisters are then sublimated using large scale freeze dryers to remove moisture. Finally, 
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the blisters are sealed using a heat-seal process for stability and protection [37]. This 
process forms the basis of a number of patented technologies such as Zydis, Quicksolv 
and Lyoc [31]. The tablets formed through this method are generally very light and highly 
porous and as a result disintegrate rapidly upon contact with the tongue, releasing the 
active drug. The process imparts a glossy amorphous structure to the diluent and 
sometimes to the API [33, 39]. 
Rapid disintegration of these highly porous and amorphous ODTs may also enhance 
absorption and hence bioavailability of the drug. Fast disintegration also imparts a 
pleasant mouth feel. Since this technology uses non-elevated temperatures it has the 
benefit of allowing for incorporation of thermo-labile drugs. The usefulness of freeze 
drying is limited however due to the high cost of machinery and processing and also the 
time involved in processing and handling. In addition, the tablets are fragile in standard 
blister packs and therefore more robust packaging is often required [32, 33, 37, 40, 41]. 
 
1.3.3 Mass Extrusion 
This involves softening of an API excipient blend using a solvent mixture of water soluble 
polyethylene glycol and methanol, followed by extrusion, through an extruder or syringe, 
to form a cylindrical soft mass. The soft mass can then be divided into smaller segments 
using a heated blade [42]. This method can be used to form coated granules of bitter 
tasting drugs by crushing of the extrudate. These granules can then be compacted into 
ODTs through direct compression. This technology benefits by ease of preparation and 
a relatively low cost when compared to other methods [43].   
 
1.3.4 Cotton Candy Process 
This technology involves formation of a floss-like matrix of saccharides and 
polysaccharides. This is achieved by flash melting and spinning using a novel spinning 
technique. The sugar mixture is subjected to a temperature gradient of 180-250˚C and 
spun at 3000-4000 rpm and then cooled rapidly upon leaving the system through an 
opening in the perimeter. The cotton-candy-like fibre produced is then milled and 
combined with the API and other excipients and compressed using conventional 
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equipment. The initial floss produced is in an amorphous state and in order to improve 
flowability it may be left to recrystallize. Recrystallization also improves mechanical 
strength and allows for higher drug loading [34, 44]. 
The cotton candy process is useful as it can accommodate high drug loading and infers 
good mechanical strength on the resultant tablet. It is limited however, in that due to the 
high temperatures employed this technology is not suitable for thermo-labile compounds. 
Additionally,  multiple steps are involved using specialist equipment, which increases 
cost [44].  
 
1.3.5 Granulation and Spray Drying 
The vast majority of ODT patents are produced using compression technologies, as 
these are both simple and cost-effective. Granulation methods have been used in the 
production of ODTs, prior to compression of the granules into tablets [19]. Granulation is 
generally employed to improve the flow characteristics and homogeneity of the drug and 
excipient blend and may also improve compression characteristics [45].  
 
1.3.5.1 Wet Granulation 
Wet granulation is the most common method used in ODT production. To begin, a binder 
solution is added to a powder blend and mixed for a given time at a given speed, a 
process known as wet massing [45]. Granulating fluid often contains a volatile fluid such 
as ethanol that can be evaporated off. The use of a solvent in this way enhances the 
porosity and therefore disintegration of the finished tablet. The wet mass can be forced 
through a sieve or milled to produce wet granules which are then spread onto a tray and 
dried [19, 46]. 
 
1.3.5.2 Melt Granulation 
Melt granulation is another common form of granulation used in ODT formation. This 
involves incorporation of a meltable hydrophilic waxy binder known as Superpolystate, 
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PEG-6-stearate with the powder blend. The mixture is heated above the Superpolystate 
melting point of 33-37°C and mixed using high shear mixers. This method increases both 
physical resistance of the tablet and aids in disintegration [33, 40]. 
 
 
1.3.5.3 Spray Drying 
Spray drying involves the continuous transformation of a solution, slurry or emulsion to 
produce porous granules by drying using a hot medium. First the solution is atomised 
into fine droplets and the droplets are then mixed with a heated gas stream to evaporate 
the solvent. The dried granules are then separated from the gas stream and collected. 
The aqueous solution contains a particulate support matrix composed of both hydrolysed 
and non-hydrolysed gelatins as supporting agents, bulking agents such as mannitol, 
disintegrating agents such as sodium starch glycolate and an acidic or alkalinising agent 
such as citric acid/sodium bicarbonate to maintain the net charge of polypeptides. The 
polypeptide components included share the same charge and repel each other, and thus 
maintaining the net charge aids in disintegration [34, 36, 47].  
Spray dried particles such as spray dried mannitol, erythritol or MCC have been shown 
to possess improved compactability as a result of increased plasticity conferred to the 
particles through the spray drying procedure. This improved plasticity is believed to be 
due to the increased deformity of the amorphous particles produced, in comparison to 
the original crystalline form. On the other hand, the shift towards an amorphous state 
may generate problems with stability with some excipients. The spherical particles 
formed through spray drying show improved flow characteristics and more readily 
rearrange in the tableting die, which again enhances compactability. Importantly, the 
thermostability of compounds should be considered when spray drying due to the high 
temperatures used [48, 49]   
 
1.3.5.4 Advantages and Challenges of Granulation 
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As well as the usual benefits such as enhanced flowability, granulation offers advantages 
for ODT production. Both wet granulation and spray drying improve tablet porosity and 
as such can impart tablets with rapid dissolution. Due to the wax binder Superpolystate 
used in melt granulation, both physical strength and dissolution are enhanced [50]. 
On the other hand, these methods are more expensive than standard compression 
techniques and are more time consuming. In addition, wet granulation and spray drying 
are unsuitable for drugs susceptible to hydrolysis and may require the use of organic 
solvents [34]. 
 
1.3.6 Post-Compression Treatment 
Due to certain limitations of compressed tablets, post compression technologies have 
been developed in order to improve ODT tablet properties, namely by improving the 
mechanical properties and the dissolution profile. 
 
1.3.6.1 Sublimation 
A common method for improving tablet dissolution rate is to improve porosity. 
Sublimation describes a process where volatile excipients such as urea, ammonium 
bicarbonate, naphthalene and urethane are added to the pre-compaction mix. These 
volatile ingredients are then removed after compaction through sublimation, resulting in 
a highly porous matrix. Typical dissolution times in the mouth for ODTs produced in this 
way are 10-20 s [32, 39]. 
 
1.3.6.2 Humidity Treatment 
The mechanical strength of compressed tablets can be improved through moisture 
treatment after compression. The increased stability is due to liquid bridge formation 
upon moisture treatment and then formation of solid bridges upon drying. The liquid 
adsorbs onto the particles and forms a film into which the solid dissolves, eventually 
forming solid bridges upon drying [34]. 
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1.3.6.3 Sintering 
Sintering involves a process intended to improve mechanical strength of ODTs through 
sintering the tablet at 50-100°C and then re-solidifying by returning to ambient 
temperature. Disintegration times using this method can be rapid, with times between 3-
60 s. Bulking agents, structure agents and binding agents are included in the initial mix. 
The structural mix should impart a porous structure to aid dissolution and commonly 
used agents include agar and albumin. Binding agents melt at the sintering stage and 
form bonds between granules, before re-solidifying as the temperature returns to 
ambient levels [34, 51] 
 
1.3.6.4 Advantages and Challenges of Post Compression Treatment 
The three common treatments described here each provide a different mechanism for 
improving either the strength or dissolution properties of ODTs. Typically, humidity 
treatment and sintering can improve the mechanical strength of lightly compressed 
tablets and sublimation increases the porosity of the tablet, enhancing disintegration 
rates [50]. 
These technologies do have limitations however. Importantly, all three treatments will 
require additional equipment and production costs, as well as an increased production 
time. Furthermore, humidity treatment will not be suitable for drugs vulnerable to 
hydrolysis, sintering will be unsuitable for thermo-labile compounds and sublimation will 
be unsuitable for drugs vulnerable to heat and volatile drugs [34]. 
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1.4 Direct Compression 
Direct compression describes compaction of a powder, after blending, into tablet form, 
using a conventional tablet press. Since only two operations are involved, direct 
compression is the most cost-effective and easiest technology for ODT production and 
is also attractive as it uses conventional equipment. The disintegration characteristics of 
directly compressed ODTs depends on the API, excipients and combination of excipients 
involved, such as disintegrants, water-soluble excipients and effervescent agents [35, 
46]. Other directly compressed ODT properties are influenced by powder flow, 
compressibility and also dilution potential [52] and thus selection of suitable excipients is 
of paramount importance. Successful excipients for direct compression demonstrate 
good compressibility, flow and low moisture and lubricant sensitivity [53]. 
 
1.4.1 Advantages and Challenges of Direct Compression 
In addition to their low cost and ease of production, directly compressed ODTs can be 
easily and rapidly produced and include readily available excipients. Since the process 
involves no water it is suitable for drugs that are susceptible to hydrolysis. Moreover, 
direct compression thus does not involve any drying steps and is suitable for drugs that 
are vulnerable to heat (thermo-labile), whose stability would otherwise be compromised. 
Direct compression also allows for the incorporation of high drug doses, which can be a 
serious limitation for ODTs produced using different technologies, in particular 
lyophilisation. Finally, directly compressed ODTs are mechanically strong and do not 
require expensive specialised packaging [31, 35, 46]. 
The major limitation of compression based ODTs is their relatively low porosity, as a 
result of the high pressures used to ensure tablet strength. This is important as uptake 
of water into ODTs is necessary for rapid disintegration and high porosity is necessary 
for this [54]. Directly compressed ODTs demonstrate good tablet hardness and have 
reasonable disintegration times. The disintegration time is however highly affected by 
both tablet size and hardness. Large, hard tablets disintegrate slowly and thus smaller, 
weaker tablets are more favourable. Consequently, ODT size can be a limitation and 
high friability and tablet rupturing are significant problems for ODTs that display 
satisfactory disintegration times. As a result, producing ODTs that rapidly disintegrate 
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whilst displaying sufficient mechanical strength is a major challenge [32, 39]. Finally, 
direct compression is not suitable for compounds that exhibit poor flowability, and 
specific excipients or granulation steps are needed to overcome this limitation [50]. 
 
1.4.2 Importance of Excipients 
Since porosity is limited in directly compressed ODTs due to the high pressures involved, 
it is the careful selection of process parameters and excipients that determine dissolution 
time. In order to impart rapid dissolution three types of excipient are incorporated into a 
formulation, which operate by different mechanisms. These are disintegrants 
(superdisintegrants), water soluble excipients and effervescent agents [27]. Water 
soluble excipients improve the wettability of the tablet and improve water absorption. 
Amino acids have received interest in this respect, with studies into the use of amino 
acids to aid in disintegration with lyophilised tablets [19] and directly compressed tablets 
[55].  
Superdisintegrants have received the most significant interest as excipients to achieve 
rapid disintegration in directly compressed ODTs. Superdisintegrants swell in contact 
with water and mechanically force the tablet apart. In addition, superdisintegrants such 
as crospovidone and croscarmellose sodium show wicking ability. Wicking describes 
uptake of water into the tablet through capillary action [19, 46]. This ability is especially 
advantageous for tablets with higher porosity, as wicking agents draw water into the pore 
space. Effective superdisintegrants also improve overall compressibility and 
compactability. Counter intuitively, it has been shown that more water-soluble 
superdisintegrants produce slower disintegration than less water-soluble 
superdisintegrants, due to the formation of a viscous water barrier upon swelling [32, 33]. 
Similarly, ODTs composed primarily of water soluble excipients, like sugar alcohol fillers, 
suffer from slower disintegration times as the soluble components on the outermost 
surface layer dissolve and form a concentrated viscous barrier that prevents further water 
absorption [56].  
The amount of superdisintegrant added to formulations for directly compressed ODTs is 
generally low (typically 1-10%) and care should be taken to select the optimum 
concentration of superdisintegrant to ensure rapid disintegration. Disintegration 
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efficiency is governed by the force-equivalent concept, a combined measurement of 
disintegrating (swelling) force and water uptake. Crucially, superdisintegrants have 
critical concentrations, below which disintegration time Is slower and above which 
disintegration time remains constant or even increases, as a result of an increase in 
viscosity caused by gelling. Determination of an optimum superdisintegrant 
concentration is therefore important in limiting disintegration time, especially with 
disintegrants that display limited swelling ability [57]. Furthermore, sparing use of a 
superdisintegrant is beneficial as a combination of superdisintegrant with water soluble 
excipients and/or effervescent agents can augment disintegration ability [35]. 
 
1.4.3 Patented Systems 
A number of different technologies for ODT production have been developed that 
incorporate compression, such as Orasolv, Durasolv, Flashtab and Wowtab [58]. Each 
of these systems uses other techniques prior to compression and tablets are therefore 
not produced purely by direct compression. Subsequently, development of effective 
ODTs from direct compression of a primary powder is an inviting prospect. 
Orasolv and Durasolv are patented by Cima Labs Inc. and are similar in their production. 
Orasolv tablets contain taste-masked drug microparticles along with polyols as diluents, 
a disintegrant, an effervescent agent and also flavours, colours and lubricants. The 
tablets can incorporate drug in a range of 1 mg to 750 mg and are compressed at low 
force giving a tablet with poor hardness (6-25N) but rapid disintegration (10-40 s). As a 
result of low hardness, the tablets are contained in specialised aluminium blister 
packaging. Durasolv tablets have a similar formulation to Orasolv, including taste-
masked drug microparticles but may not contain effervescent agents. They are 
compressed at higher forces than Orasolv tablets and can incorporate APIs in a range 
from 125 µg to 500 mg. These tablets disintegrate more slowly than the Orasolv 
technology, (10-50 s) but show an improved hardness (15-100N) and as a result the 
tablets can be contained in blister packaging or bottles [59-61]. 
Flashtab involves incorporation of a swelling agent and a super disintegrant, with the API 
being taste masked by direct coating. A highly water soluble sugar alcohol may be 
incorporated instead of the swelling agent, depending on the need. Excipients are first 
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granulated (wet or dry) and are then mixed with the coated drug, before compression 
into tablets with satisfactory mechanical integrity, that can withstand opening of blister 
packaging [60, 62].  
Wowtab, developed by Yamanouchi Pharma, includes a mixture of high and low 
mouldable sugars that are granulated in a fluidised bed granulator along with other 
excipients and the API. The resultant granules are then mixed with lubricant and flavours 
and compressed using conventional equipment. The ODTs are then stored at controlled 
temperature and humidity before packaging into blisters or bottles. The technology 
benefits from rapid disintegration times (15-20 s) and sufficient strength to withstand 
manufacture, packaging, opening and handling [60, 63].  
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1.5 Excipients Suitable for Compressed ODTs 
A large number of different excipients have been used in ODT formulations. The focus 
of this work is on directly compressed ODTs and, with this is mind, a list of excipients 
commonly used in ODTs formed by compression techniques is summarised in Table 1.1, 
along with their roles and their advantages and disadvantages. All excipients are 
compatible with direct compression and also granulation or moulding processes pre-
compaction.  
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Excipient Role Comment 
Conc. 
Range 
(w/w) 
Advantages Disadvantages 
Aspartame Sweetener 
Intense sweetening agent, 
sweetening power is 180-200 
times that of sucrose; Slightly 
soluble in ethanol; Poor 
solubility in water 
<1% 
Masks unpleasant 
tastes; Intense 
sweetener, requiring 
very low 
concentrations 
Incompatible with 
dibasic calcium 
phosphate, 
magnesium stearate 
and some sugar 
alcohols; Will not 
replace characteristics 
of sugars if sugar is 
removed 
Calcium carbonate Binder; Diluent 
Odourless and tasteless 
powder or crystals; Insoluble 
in ethanol and water; Water 
solubility increased by 
ammonium salts or carbon 
dioxide 
10-
90% 
Stable; Relatively non-
toxic 
May interfere with the 
absorption of other 
drugs from the GIT 
Table 1.1 Commonly used excipients in the production of ODTs by compression
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Calcium phosphate Diluent 
Milled grade material is used 
in wet granulation and roller 
compaction and unmilled 
coarse grade is used in direct 
compression; Insoluble in 
ether, ethanol and water; 
Soluble in dilute acids 
10-
90% 
Good flow properties; 
Good compaction; 
Non-hygroscopic and 
stable 
Lamination and 
capping at high 
compaction forces; 
Requires lubricant; 
Unmilled has acidic 
surface, milled has 
alkaline surface; 
Incompatible with a 
number of drugs and 
excipients 
Calcium sulphate Diluent Used as a dessicant due to hygroscopicity 
10-
90% 
Non-toxic at excipient 
concentrations 
May cake on storage; 
Incompatible with 
tetracycline antibiotics, 
indomethacin, aspirin, 
aspartame, ampicillin, 
cephalexin and 
erythromycin due to 
calcium salts 
Citric acid monohydrate 
Effervescent 
couple; Flavour 
enhancer 
Odourless; Acidic taste; 
Crystalline 1-20% 
Safe - found naturally 
in the body Incompatibility issues 
Colloidal silicon dioxide Disintegrant; Adsorbent 
Insoluble in organic solvents, 
water and acids; Forms a 
colloidal suspension in water; 
Hygroscopic but does not 
liquefy with water absorption 
0.1-1% Imparts good flow properties 
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Croscarmellose sodium Superdisintegrant 
Odourless; Insoluble in water, 
ethanol, acetone and toluene; 
Rapidly swells to 4-8 times 
original volume; Promotes 
water absorption by wicking 
2-5% 
Stable; Rapid 
swelling; Can obtain 
good purity 
Incompatible with 
strong acids or soluble 
salts of iron, zinc, 
aluminium and 
mercury; Ideally should 
not be combined with 
other hygroscopic 
materials 
Crospovidone Superdisintegrant; Binder 
Larger particles disintegrate 
faster; Suggested as a 
replacement to MCC to aid in 
pelletisation; Hygroscopic; 
2-5% 
High capillary activity; 
High hydration 
capacity; Low 
tendency gel; 
Compatible with most 
organic and inorganic 
ingredients 
Risk of metabolite 
phenylalanine in 
patients who suffer 
from phenylketonuria 
Erythritol Sweetener; Diluent 
Non-hygroscopic; Zero 
calorie; Freely soluble in 
water; Slightly soluble in 
ethanol; Insoluble in ether 
and fats 
10-
90% 
Stable; Good 
flowability; Cooling 
effect 
Incompatible with 
strong oxidising agents 
and strong bases 
Ethylcellulose 
Water insoluble; 
Binder; Diluent; 
Taste masking 
agent 
Can be dissolved in ethanol 
to form a binder; Slightly 
hygroscopic; Stable 
5-80% Tasteless; Free flowing; Stable 
Produces hard tablets; 
Produces tablets with 
low friability; 
Incompatible with 
paraffin and 
microcrystalline wax 
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Fructose Sweetener; Diluent Hygroscopic; Sweeter than mannitol, and sorbitol 5-20% 
Very sweet tasting; 
Imparts good crushing 
strength 
Incompatible with 
strong acids or alkalis; 
Risk of reacting with 
amines, amino acids, 
peptides and proteins 
in the aldehyde form 
Glucose Binder; Sweetening agent 
Water soluble; Low 
mouldability 5-20% 
Sweet tasting; Stable; 
Forms strong 
compacts 
Incompatible with a 
number of drugs; May 
cause browning 
(Maillard); 
Decomposition can 
occur with strong 
alkalis 
Hydroxypropyl cellulose 
(HPC) Binder 
Increases viscosity; Soluble in 
water and polar organic 
solvents 
2-6% Acceptable flow characteristics 
Compatibility with 
inorganic salts varies 
Hydroxypropyl cellulose, 
low-substituted (L-HPC) 
Binder; Diluent; 
Disintegrant 
Number of different grades: 
LH-11 and LH-B1 used in DC 5-50% Swells in water 
Poor flowability; 
Insoluble in ethanol 
and ether 
Hypromellose (HPMC) 
Binder; 
Solubilising agent; 
Modified release 
agent 
Wet granulation binder; 
Coating agent; Hygroscopic; 
Odourless and tasteless; 
Soluble in cold water; 
Insoluble in hot water, 
ethanol, ether and chloroform 
2-80% Stable 
Incompatible with 
some oxidising agents; 
Does not complex with 
metallic salts or ionic 
organics 
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Lactose Binder; Diluent 
Susceptible to Maillard 
reaction; Milling improves 
compactability but is 
detrimental to flow 
10-
90% 
Can be used with 
moisture-sensitive 
drugs; Odourless; 
Slightly sweet tasting; 
Suitable for spray 
drying to improve flow 
May develop brown 
colouration (Maillard 
reaction) on storage; 
Many people are 
lactose intolerant 
Magnesium stearate Lubricant Faint odour 0.2-5% Stable 
Incompatible with 
strong acids, alkalis, 
oxidising agents, iron 
salts, aspirin and some 
vitamins and alkaloid 
salts; Compromises 
disintegration and 
tablet strength 
Maize starch gum 
(Dextrin) Binder; Diluent 
Slight odour; Insoluble in 
ethanol, chloroform and ether; 
Soluble in boiling water 
5-50% Non-toxic Incompatible with strong oxidising agents 
Malic acid 
Effervescent acid; 
Acidifying agent; 
Flavouring agent 
Is combined with an 
effervescent base and forms 
CO2 in contact with water; 
Hygroscopic; Freely soluble in 
water and ethanol 
1-20% 
Masks bitter tastes; 
Slight apple flavour; 
Freely soluble in water 
Combination with 
excipients and drugs 
with moisture content 
only, to prevent 
triggering a reaction 
Maltitol Binder; Diluent; Sweetener 
Odourless; Water soluble; 
Relatively non-hygroscopic 
10-
90% 
Non-cariogenic; Low 
glycaemic index so 
suitable for diabetics; 
Highly mouldable 
Poor compactability 
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Maltodextrin Binder; Diluent 
Non-sweet, odourless; 
Slightly hygroscopic; Freely 
soluble in water, slightly 
soluble in ethanol 
5-30% No adverse effect on dissolution rate 
Susceptible to 
browning (Maillard) 
Maltose Sweetener; Diluent Odourless; 30% sweetness of sucrose 
0.5-
25% 
Sweet taste; Highly 
mouldable 
May react with 
oxidising agents; May 
brown (Maillard) 
Mannitol Sweetener; Diluent 
Non-hygroscopic and may be 
used with moisture-sensitive 
ingredients; Occurs as 
crystalline powder or free-
flowing granules; Stable in dry 
and aqueous states 
10-
90% 
Mouth-feel; Cooling 
sensation; Sweet 
tasting 
Poor compactability 
Menthol Flavouring agent Soluble in ethanol; Normally sprayed onto granules 
0.1-
10% 
Cooling sensation; 
Tendency to sublime 
and has been used to 
increase the porosity 
of granules 
Incompatible with 
several compounds; 
Risk of hypersensitivity 
Methyl cellulose 
Disintegrant; 
Binder; Viscosity 
increasing agent 
Low-medium viscosity grades 
used as binders, High 
viscosity grades used as 
disintegrants; Odourless and 
tasteless 
2-10% Stable Incompatibility issues 
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Microcrystalline 
cellulose Binder; Diluent 
Strong binding; Good 
disintegration due to porosity 
and wicking; Variety of grades 
differing in method of 
manufacture, particle size, 
moisture and flow 
5-15% 
Hygroscopic; Good 
flowability; Good 
compactability due to 
plastic deformation 
Practically insoluble in 
water, dilute acids and 
most organic solvents; 
Incompatible with 
strong oxidising agents 
Polyvinylpyrollidone 
(PVP, povidone) 
Disintegrant; 
Binder 
Wet granulation binder; Very 
hygroscopic; Soluble in water, 
ethanol, acids, methanol, 
ketones and chloroform 
0.5-
90% 
Shown to enhance 
dissolution of poorly 
soluble drugs 
Forms adducts with 
some compounds 
Silicic acid Disintegrant Used as a disintegrant for rapidly disintegrating granules 
0.1-
0.5% Free flowing; Stable 
Practically insoluble in 
water 
Sodium Carbonate 
Effervescent base; 
Diluent; Alkalising 
agent 
Is combined with an 
effervescent acid and forms 
CO2 in contact with water; 
Hygroscopic 
2-10% 
Rapid effervescence 
in presence of water 
and acid; Freely 
soluble in water 
Requires combination 
with excipients and 
drug that possess low 
moisture contents, to 
prevent triggering a 
reaction 
Sodium carboxymethyl 
cellulose 
Disintegrant; 
Binder; Adsorbent 
Insoluble in ether, acetone, 
ethanol and toluene; Forms 
colloidal solutions with water 
0.1-
90% 
Absorbs significant 
amounts of water; 
Stable 
Incompatibility issues; 
Lowers tablet 
hardness 
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Sodium lauryl sulphate Surfactant; Lubricant 
Smooth feel, bitter taste, faint 
fatty odour; Possesses some 
bacteriostatic action; Not 
hygroscopic; Insoluble in 
chloroform and ether 
0.1-2% 
Fairly stable; 
Compatible with mild 
acids 
Incompatible with 
cationic surfactants, 
aluminium, lead and 
zinc; Precipitates with 
potassium salts; 
Moderately toxic, may 
cause skin irritation 
Sodium starch glycolate Superdisintegrant 
Rapidly swells (300x volume); 
Disintegration efficiency 
unimpaired by hydrophobic 
excipients; Very hygroscopic 
2-8% 
Stable; Unimpaired by 
presence of 
hydrophobic 
excipients; Increased 
compaction pressure 
does not affect 
disintegration time 
May cause caking if 
not stored in well-
closed container; 
Disintegration times 
slower with high levels 
of soluble excipients; 
Interacts with 
glycopeptide 
antibiotics and basic 
drugs 
Sodium stearyl fumarate Lubricant 
Sparingly soluble in water; 
Particles around 5-10 µm in 
diameter 
0.5-2% 
Non-toxic and non-
irritant; Much more 
water soluble than 
magnesium stearate 
Not as effective a 
lubricant as 
magnesium stearate 
Starch 
Binder; 
Disintegrant; 
Diluent 
Insoluble in cold ethanol and 
cold water; Swells 
immediately in water (about 
5-10%) 
3-50% 
Low concentrations 3-
10% w/w can act as 
antiadherent and 
lubricant 
Wheat proteins 
(gluten) unsuitable for 
celiacs 
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Xylitol 
Sweetener; Taste 
masking agent; 
Diluent 
Enhances product stability 
due to bacteriostatic and 
bactericidal action 
0.5-
25% 
Non-cariogenic; 
Sweet taste; Cooling 
sensation; Enhances 
stability 
Slightly hygroscopic; 
Incompatible with 
oxidising agents 
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1.6 Film Coating 
1.6.1 History of Tablet Coating 
The coating of tablets has a long history with its origins lying in sugar coating, a process 
borrowed largely from the confectionary industry. Despite the effectiveness of sugar 
coating in masking the taste of bitter tasting drugs, coating of tablets was a laborious 
task requiring great skill, with multiple steps that could take as longs as 5 days and 
resulted in large, heavy coated tablets. The resultant pressure to develop alternative 
coating methods manifested in the development of compression coating and film coating 
[64].  
Compression coating received attention in the mid-twentieth century, promising far 
shorter lead times than sugar coating. The process involved tablet compression using 
one machine followed by transfer to a different machine that would compress coating 
material around the core. This process suffered from a variety of limitations, namely size 
and weight related, whilst significant drawbacks such as coat splitting due to core 
expansion, poor bonding between coat and core and low speed meant the techniques 
popularity did not endure [64]. 
Like compression coating, tablet film coating arose in the mid-twentieth century, largely 
due to the emergence of new materials, most importantly cellulose derivatives. Early film 
coating used organic based solvent coating solutions to avoid the risk of decomposition 
of active ingredients and benefited from greater ease of use. Significantly, the use of 
volatile organic solvents benefit from rapid evaporation and therefore their use provides 
a reduced risk of over wetting, which can cause substantial problems. Indeed, one of the 
major complications with using water as a coating solvent is its much greater latent heat 
of evaporation of 539 kcal/kg when compared to organic solvents such as ethanol at 204 
kcal/kg [64-66]. Despite this however, there has been an increasing shift towards the use 
of aqueous based coatings due to a number of problems with organic solvents, to a point 
where now aqueous based coatings are much preferred. Most importantly, the use of 
organic solvents has been phased out due to toxicity concerns, including environmental 
pollution as well as safety concerns to operators and consumers, with ICH guidelines 
recommending the avoidance of organic solvents in pharmaceutical formulations [67-
69]. This shift has also stemmed from escalating solvent costs, as well as technological 
advances and savings due to the removal of the need for solvent recovery systems [64, 
70]. 
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1.6.2 Applications and Objectives of Film Coating 
Application of a film coat increases the cost, manufacturing time and complexity of drug 
production, and as such its use must be carefully considered. Clearly therefore, a film 
coating must provide a variety of applications and advantages, a number of which 
typically include [64, 66, 67, 71-74]: 
 To mask the taste of a bitter drug 
 To mask unpleasant odours 
 To improve the stability of an API or excipient e.g. protection from light, moisture 
or oxidation 
 To physically protect vulnerable cores 
 To improve the aesthetics of inelegant cores e.g. by use of colours or glaze to 
provide a glossy sheen effect 
 To provide product identity through the use of colours or logos. This extends to 
patient compliance and safety e.g. the use of different colours to avoid confusion 
for patients taking multiple medications 
 To control drug release. This can be achieved in a number of ways depending 
on the requirement, for example: 
 For protection of an acid labile API from the gastric environment through 
the use of an enteric coating 
 For sustained release of the API in order to achieve a desired 
pharmacokinetic profile 
 For the purposes of different release technologies, such as osmotic 
pumps 
 To form a barrier to coloured APIs that may stain 
 To aid in swallowing of the dosage form 
 To reduce the friction of the drug with packaging machinery 
 To increase mechanical strength 
 To segregate incompatible APIs, adjuvants and excipients by incorporation of 
one in the coat and the other in the core 
With these numerous benefits of coating comes a complexity in coating techniques and 
processes and the materials required. 
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1.6.3 Conventional Coating Process 
Polymeric film coats are thin coatings, usually 20-100 µm thick [75], that are generally 
applied to tablets using an atomisation spray process. Aqueous polymeric coats 
comprise of a coating polymer either dissolved or dispersed in water. Polymer 
dispersions exist as polymer spheres suspended in water, which importantly differ to 
polymer solutions in that viscosity is independent of polymer concentration, allowing for 
higher polymer concentrations.  Atomisation of the coating solution is achieved using 
high pressure air. The coating fluid liquid sheet is first deflected away from the air stream, 
causing waves in the sheet that lead to formation of unstable ligaments, which break 
down further into fine droplets [76, 77]. Upon contact with the tablet, droplets impinge 
and spread across the surface. For polymer solutions a film is formed upon evaporation 
of the solvent, whereby the polymer chains interpenetrate, passing through a gel stage, 
followed by film formation with additional drying. The mechanism of film formation from 
polymeric dispersions is more complex; before polymer chains can interpenetrate 
polymer spheres must first coalesce, that is they must deform and fuse together, before 
a continuous film can form [78-80]. An important consideration in the film formation 
process is the minimum film forming temperature (MFT), above which film formation 
takes place. and is highly dependent on the polymer’s glass transition temperature (Tg). 
It is recommended that coating temperatures around 10-20°C above the MFT are optimal 
[81]. 
Tablets are moved within the spray by mixing to ensure an even coating, and 
intermittently reside either within the spray path or outside of the spray path in drying 
zones. The two major techniques for this are drum or pan coating and fluidised bed 
coating, although pan coating is more common for tablet coating, whereas fluidised bed 
is more suited to coating of smaller objects such as granules. Pan coating involves the 
tablet cores being placed inside a rotating drum on an inclined axis, with tablets falling 
through the spray path from one or several atomisers. Perforated coating pans offer 
improved drying efficiency over conventional pans by passing drying air through the 
tablet bed. In fluidised bed coating, tablets are suspended and circulated by heated air 
from below, continuously passing through the spray path originating from atomisers 
placed either above or below the tablet bed, with the bottom spray technique being more 
popular. With either pan or fluidised bed coating, tablets are subject to a constant cycle 
of coating and drying, accumulating coating layers over time. Water evaporation from 
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fluidised bed systems is more efficient due to the greater extent of airflow [82, 83]. With 
either technique tablets are subjected to substantial mechanical stress which can lead 
to breakage or attrition. This problem is augmented during scale-up processes due to 
the greater weight of tablets used and increasing pan sizes. Tablet cores must therefore 
be mechanically robust enough to withstand these processes, with friability being a 
particularly important property to measure this ability and ideally cores should exhibit a 
friability of less than 0.1% [84].  
 
1.6.4 Recent Tablet Coating Technologies 
Despite the substantial evolution in sophistication of conventional coating processes and 
materials over the past half a century, new techniques for tablet coating have been 
developed. The various drawbacks of organic solvent based coatings have already been 
outlined. Despite the advantages of aqueous solutions, there are circumstances where 
their use is unsuitable, for example with APIs that are sensitive to water. Migration of 
water into the tablet core either during coating or storage and the energy needed to 
evaporate water are also drawbacks. New coating technologies are thus primarily 
concerned with dry coating [85]. 
The mechanisms concerning dry coating are similar to that of solvent based coating and 
generally involves pre-treatment of coating material, application of the coating material 
to the tablet and film formation. To soften the coating polymer and increase its adherence 
to the tablet surface, the coating material is often heated above its Tg before being 
applied to the tablet. Sintering and coalescence is then performed on the powder layers, 
followed by levelling and densification of the coating layer and finally hardening of the 
coating through a final cooling stage [86, 87].  
Electrostatic dry coating involves application of a finely ground conductive ionic coating 
material to a tablet to which a strong opposite electrostatic charge has been applied. 
Film formation is then achieved through a curing step. Two variations of spraying units, 
Corona charging and Tribo charging units, exist for this application and differ by their 
charging mechanism [87].  Magnetically-assisted impaction coating is another example 
of a dry coating technology, where magnetic coating material is accelerated in a chamber 
using an alternating electromagnetic field, resembling a fluidised bed coater. Collision of 
particles with the tablet core and intra-particle collisions occur, resulting in attachment of 
coating material to the core. This technique is suitable for temperature sensitive 
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compounds since very little heat is generated [88-90]. A final example of a dry coating 
technology is hot melt coating whereby coating material is applied to the tablet core in a 
molten state. Hot melt coating using lipids is implemented for sustained drug release, 
which is the main application of this technique [91, 92] 
 
1.6.5 Polymers for Film Coating 
Polymers used for conventional film coating, that is coatings concerned with imparting 
improved appearance or mechanical properties for example, are generally water soluble. 
Due to their solubility they do not impede drug release and therefore are not useful in 
controlled release systems. These include cellulose based polymers and synthetic 
materials such as polyvinylalcohol-polyethylene glycol and polyvinylpyrrolidone-vinyl 
acetate copolymers. Cellulose derivatives are a major class of polymers used in 
convention film coating, the majority of which are in fact ethers, produced through 
reactions in alkaline solutions. HPMC, produced by the reaction between cellulose and 
methyl chloride is one such ether, with other examples including hydroxyethyl cellulose 
and HPC [79, 93]. The degree of substitution of hydroxyl groups and the molar 
substitution (which also includes the substitution of hydroxyl groups belonging to side 
chains), greatly influence the solubility and gel point of cellulose ethers. The use of 
HPMC is particularly prevalent in film coating procedures, due to a number of benefits 
such as solubility in both water and organic solvents. Furthermore, HPMC solutions are 
non-tacky, have relatively low viscosity and also have an established history of safe use 
[64]. 
Conversely, water insoluble polymers are used for controlled or sustained release 
coatings. Sustained release systems benefit from lower dosing frequency, which in turn 
enhances patient adherence. Due to the control over the pharmacokinetic profile of the 
API that these coatings can provide, plasma drug concentration can be maintained within 
a desired therapeutic window, and as such the risk of dangerously high plasma levels is 
reduced. Should the coating be compromised however, due to mechanical failure or 
concomitant alcohol consumption (with coats that are soluble in ethanol), there is a risk 
of dose dumping, where the entire drug dose is rapidly and unintentionally released, 
resulting in potentially devastating repercussions [79, 94-96]. 
Standard controlled release coatings work by delaying the rate at which intestinal fluid 
diffuses into the tablet core. Once the core has been exposed, either by coat erosion or 
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fluid penetration through the coating, the API then diffuses out from the core along a 
concentration gradient. The solubility of the drug is an important factor in its rate of 
release, with more water soluble APIs demonstrating faster release [97]. The diffusion 
of drug through the coat is also dependent on the coat density and thickness [98, 99]. 
One method for improving and further controlling the release rate of APIs (particularly, 
poorly water soluble APIs) from this type of coated dosage form is through the 
incorporation of hydrophilic material such as HPMC within the coating, which in contact 
with water forms pores within the coat that facilitate API release [100].  
More sophisticated controlled release technologies have also been developed. Osmotic 
pump technology, for example, utilises a film coat (formed most commonly from cellulose 
acetate) containing a laser drilled orifice. The tablet core contains osmotic agents such 
as sodium or potassium chloride which generate an osmotic gradient, drawing in the 
intestinal fluid through the coating and resulting in an increased osmotic pressure within 
the core. The high pressure in the core then forces either dissolved or dispersed drug 
through the orifice, releasing the API into the gastro-intestinal tract [79, 101]. Another 
example of a sophisticated controlled release technology is that of enteric (delayed-
release) coatings. This approach involves coating of the core with a weakly-acidic 
polymer, containing ionisable carboxylic acid groups. At the low pH of the stomach these 
polymers remain unionised and the coating remains intact; however, upon reaching the 
near neutral pH of the small intestine (around pH 6) the carboxylic acid groups ionise, 
causing the coating polymer to dissolve, whereby the API is released from the core. This 
system is particularly useful for acid-labile drugs or those, such as aspirin, known to 
cause irritation to the gastric mucosa [102, 103]. 
 
1.6.6 Coating Additives 
Additives are often combined with coating polymers to improve film properties, alter film 
permeability or to aid in film formation. Plasticisers are used to improve the flexibility of 
brittle polymers films and thus reduce the potential for brittle fracture and also assist in 
aqueous based polymer sphere coalescence. Plasticisers work by weakening 
intermolecular forces between polymer chains and this is believed to occur through a 
combination of hydrogen bonding, dipole-dipole and dipole-induced-dipole interactions 
[87]. The choice and concentration of plasticiser has a major impact on the mechanical 
and adhesive properties of the polymer film and also on drug release [104-106]. 
Plasticisers should be non-volatile and thus contribute to the weight gain of a coated 
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tablet. It is also important that plasticisers are miscible with the coating polymer; in 
aqueous polymer dispersions this requires that plasticisers partition within the polymer 
spheres. The effectiveness of a plasticiser can be determined by its effect on Tg of the 
coating polymer, with more effective plasticisers causing greater decreases in Tg, 
reflecting the added flexibility imparted by the plasticiser [79, 107]. Three main types of 
plasticiser are commonly used which include: polyols, such as polyethylene glycols 
(PEGs), organic esters and oils/glycerides, such as castor oil [87]. 
Anti-adherents are a major additive for film coat polymer solutions and dispersions and 
are included to prevent substrate agglomeration during coating and storage. Talc is 
amongst the most common employed anti-adherents, although it must be included at 
very high quantities, which can lead to processing complications related to its 
sedimentation and subsequent clogging of the atomiser nozzle. This property may be 
attributed to its hydrophobic nature, a property which is also likely responsible for its 
tendency to reduce the dissolution rate of APIs [79, 108]. Its use also reportedly affects 
film mechanical and adhesive properties, and as a result, glyceryl monostearate has 
been suggested as a favourable alternative [109]. 
Surfactants can be added to improve droplet wettability and spreading ability on the 
tablet surface and are also used stabilise suspensions and emulsify poorly soluble 
plasticisers. Surfactants achieve this by lowering the surface tension of the polymer 
solution or dispersion. Droplet spreading, for example, is dependent on the surface 
tension between liquid-air and liquid-solid interfaces. Despite the low concentrations 
used surfactants can have pronounced effects on film coat properties and impact drug 
release [78, 79, 110]. 
Pigments are another important additive to film formulations and are used to improve the 
elegance and identification of coated dosage forms. Pigments such as titanium dioxide 
are also used to enhance the stability of light sensitive drugs. The pigments most 
commonly used are metal oxides and water insoluble lake dyes. Their use is complicated 
however, as they are known to significantly affect film permeability and mechanical 
properties and are also to prone to clog the spray nozzle [111, 112]. A number of other 
additives are also included in polymeric film coats including antioxidants, antimicrobials 
and sweeteners and flavours [87]. 
As discussed, film coatings offer one approach to modify solid-dosage forms, to offer 
enhancements or overcome problems. Similarly, combination of multiple APIs into a 
single formulation can offer a variety of benefits.  
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1.7 Fixed Dose Combinations 
Fixed dose combinations (FDCs) involve the incorporation of two or more APIs into a 
single dosage form. These can include oral dosage forms such as tablets, capsules or 
liquids and parenteral forms including inhalation and intravenous or subcutaneous 
injections. Oral dosage forms comprise the vast majority of approved FDC formulations. 
Drug dose in FDCs can be increased or decreased, but must be maintained at a fixed 
ratio. There are a number of arguments behind combination of drugs into FDC form 
which broadly include compliance, efficacy and safety and financial benefits [113]. 
Indeed, the interest in FDCs in the pharmaceutical industry is steadily increasing, with 
the FDA approving 12 new FDC formulations in 2010 alone [114]. In certain therapeutic 
areas FDCs have been in use for over 50 years [115]. 
FDCs improve patient compliance due to simplification of the dosing regimen. 
Combination of medications into one form reduces the number of products required to 
take per day. Simplification of dosing to avoid confusion is particularly prevalent if two 
medications follow different dosing schedules, whereby doses can be adjusted to allow 
for once, or if necessary, twice daily dosing. FDCs thus offer greater ease of use to 
patients when compared to multiple medications, especially in patients who may also be 
being treated for other unrelated indications. This results in enhanced patient compliance 
and also drug efficacy, since the success of treatment is often highly dependent on 
consistent dosing [114]. It has been reported that FDCs reduce non-compliance to 
dosing regimens by 24-26% and are recommended for the treatment of chronic 
conditions, such as hypertension, where enhanced compliance translates into improved 
clinical outcomes [116].  
Improved efficacy of FDCs may be achieved, as previously mentioned, through 
enhanced patient compliance, resulting in improved outcomes due to consistent dosing. 
Combination of drugs that have a synergistic activity is a popular strategy for improving 
treatment efficacy. Using this approach, the efficacy of a medication can be substantially 
improved without the need to increase the dosage levels and compromise safety, since 
the concurrent action of two drugs at well tolerated levels is greater than either drug 
alone [113]. Examples of such synergistic FDCs include glipizide/metformin in the 
treatment of diabetes, or artemether/lumefantrine to treat malaria. Bioavailability 
enhancement is another strategy by which FDCs can improve efficacy. This can be 
achieved by API combination, of which one inhibits the metabolism of the other.  In some 
cases, efflux transport may also be inhibited. One such example is the combination of 
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lopinavir/ritonavir to treat HIV. Lopinavir is a substrate for CYP 3A4 and Pgp whereas 
ritonavir inhibits CYP3A4 and Pgp; inhibition of CYP3A4 and Pgp by ritonavir increases 
lopinavir plasma concentration and efficacy [117]. APIs are also combined to treat 
multiple indications in co-morbid disease states, such as amlodipine/atorvastatin 
treatment for hypertension and hyperlipidaemia, respectively, in cardiovascular disease. 
Finally, FDCs may also be employed where an API is included to counteract an adverse 
effect caused by the other. For example, the proton pump inhibitor famotidine can be 
combined with ibuprofen, to counteract gastric hyperacidity caused by ibuprofen [118]. 
FDCs are also attractive for business reasons, as they represent generally low-cost and 
low-risk ventures and offer the ability to extend market exclusivity past the expiration of 
patents. In the USA, if a FDC is deemed novel, non-obvious and useful then the FDA will 
allow patenting and enforce exclusivity by excluding competitors [119]. FDCs may also 
demand higher prices. Indeed, they can be highly lucrative, with 19 FDA approved 
products achieving sales in excess of $1 billion by the year 2014. Patients may also 
benefit financially since the number of prescriptions will be reduced [114].  
A limitation of FDCs are that they offer little dosing flexibility due to their fixed drug ratio. 
In some cases, such as in the treatment of hypertension, FDCs should only be prescribed 
once management using a single medication has proven ineffective. This however does 
not always occur, raising concerns regarding patient exposure to unnecessary therapy 
[120]. Adverse side effects are common to many medicines and often the only way to 
determine whether a certain symptom is due to the medication is to stop treatment. Due 
to multiple drug inclusion in FDCs it is thus difficult to identify the active causing adverse 
side effects and the patient may also risk losing the benefits of a safe, beneficial drug  
[121]. FDCs are also limited by chemical and physicochemical incompatibilities between 
certain API combinations. This also extends to compatibility between API and excipients 
included in the formulation. Any incompatibilities should be investigated during early 
formulation development under stress conditions [122]. Drug interactions may alter the 
therapeutic effect, or similarly cause bioavailability issues, for example, in the case of 
the impaired bioavailability of rifampicin when combined with isoniazid in FDC 
formulations [123].  
To avoid such issues with bioavailability and altered therapeutic effect it is favourable to 
perform in vitro assessment of FDCs. 
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1.8 In Vitro Intestinal Permeability 
1.8.1 Different Techniques 
Although advancements in drug delivery via alternative routes provide a vast array of 
administration options, the oral route remains the most popular for convenience and 
compliance reasons. Assessment and prediction of intestinal permeability of APIs is of 
vital interest in understanding the in vivo performance of oral dosage forms and in the 
drug discovery field its use is widespread during lead selection and optimisation. Drug 
absorption from the gastrointestinal tract is a crucial determinant of bioavailability and is 
governed by the physicochemical properties of the API. Permeability evaluation can be 
performed in vitro by various cell based, membrane based and excised tissue assays 
and by analysis of psychochemical properties. Each technique carries its own 
advantages and limitations which influence technique selection depending on the 
circumstance [124, 125].  
 
1.8.2 Intestinal Absorption 
For intestinal absorption a drug must traverse the epithelial cell membrane consisting of 
a phospholipid bilayer around 10 nm thick. Lipophilic tails confer a lipophilic core to the 
bilayer, whilst hydrophilic heads point outwards forming two adjacent hydrophilic 
surfaces. The hydrophilicity and hydrophobicity of an API will greatly influence its 
interaction with this bilayer and its ability to permeate as well as its transport pathway. 
This is conventionally measured by observing the distribution of a compound between a 
hydrophobic phase (usually octanol) and a water phase, referred to as the log of the 
partition coefficient (LogP), with LogP values above or below 0 indicating a lipophilic or 
hydrophilic compound, respectively. In general, lipophilic drugs offer enhanced 
absorption, however at LogP values above 5 permeability declines, due to sequestration 
of the highly hydrophobic compound within the membrane [126, 127].  Since the 
vast majority of drugs consist of weak acids or bases, the pH of the environment will also 
greatly influence permeability, since ionised forms are generally more water soluble and 
vice-versa. A drugs pKa is thus another important parameter when considering intestinal 
permeability [128]. 
Passive diffusion is the predominant mechanism for absorption of drugs through the 
intestinal epithelium. It follows Fick’s law whereby the compound flux is driven by the 
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concentration gradient across the membrane, and is proportional to the diffusional area 
and drug permeability coefficient and is inversely proportional to the membrane 
thickness [129]. For unionised lipophilic compounds, passive diffusion occurs 
transcellularly, whereas polar and ionised molecules traverse paracellularly through 
intercellular tight junctions between adjacent epithelial cells [130]. Facilitated influx and 
efflux of compounds also occurs at both the apical and basolateral membrane of 
intestinal epithelial cells by ATP-binding cassette transporter proteins, such as P-
glycoprotein (Pgp) and multidrug resistance-associated proteins [131]. Lastly, 
transcytosis and endocytosis are a mechanism by which larger compounds may be 
absorbed [132]. 
 
1.8.3 Cellular Models and Caco-2 
Cell culture models are extensively used in the study of intestinal drug absorption. Cells 
are cultivated on permeable growth membranes, forming a monolayer by which transport 
across either the apical or basolateral membrane can be studied. They are superior to 
membrane models, such as the parallel artificial membrane permeability assay, in that 
they are characteristic of intestinal epithelial cells, being structurally and biologically 
similar and they express transporters and metabolic enzymes found in vivo. Cell models 
do possess a number of limitations however, suffering from high variability due to their 
polyclonal nature. Variations also stem from differences in culture conditions such as 
passage number, culture time, seeding density and culture media. Furthermore, they 
cannot represent the complexity of the intestine since they consist of only one cell type 
and do not offer high throughput due to long culturing times. Several different cell lines 
are employed for in vitro transport studies, including Caco-2, HT29-MTX, MDCK, TC7 
and 2/4/A1 [133, 134].  
The most popular cell line used in cellular models is the Caco-2 line. Caco-2 are an 
immortalised line of heterogeneous human epithelial colorectal adenocarcinoma cells, 
that differentiate to express features characteristic of mature polarised enteroctyes. They 
require extensive culture times of 21 days on porous transwell membrane inserts, 
although there have been efforts to develop protocols as short as 7 days [135]. Formation 
of confluent, differentiated and polarised cells, possessing tight junctions is most often 
assessed using transepithelial electrical resistance (TEER) measurements. Transport 
assays using Caco-2 cells yield apparent permeability coefficient (Papp) values, which 
give an indication of the permeability of a compound and can be compared to a vast 
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number of Papp values for different compounds in the literature. As well as passive 
permeability, Caco-2 cells can provide information on active transport of compounds, 
due to the presence of membrane transporters such as P-gp which is known to be highly 
expressed in these cells [133, 136].  
To gain a further understanding of in vivo performance of FDCs, in silico tools offer a 
powerful approach to safely and rapidly investigate bioavailability and provide 
substantially more detail than cellular models can offer. 
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1.9 In Silico Pharmacokinetic Modelling 
1.9.1 Modelling Background 
The development of new drugs and drug delivery technologies has historically been 
plagued by high attrition, with a general rule of thumb that from 10,000 compounds only 
1 will successfully make it to regulatory approval after an average of 15 years of study 
[137]. Pharmacokinetic modelling is a powerful tool employed to optimise drug discovery 
and reduce high attrition and the associated escalating costs [138]. For candidate 
identification and lead optimisation, consideration of drug metabolism and 
pharmacokinetics (DMPK) is crucial and encompasses the absorption, distribution, 
metabolism and excretion (ADME) properties of the compound [139]. Due to 
pharmacokinetic modelling, development failures due to poor pharmacokinetics have 
dropped from around 50% in 1990 to 10% [138].  
The basis of any model involves the application of mathematical and statistical 
techniques to an existing data set in order to represent and predict the system being 
studied. Numerous models exist however none is perfect, each with their own strengths 
and limitations, and as such they are constantly being developed driven by theoretical 
considerations and new clinical information [138]. Methods to quantitatively predict 
pharmacokinetic outcomes involve simple models to predict certain parameters and 
increase substantially in complexity and sophistication, to physiologically based 
pharmacokinetic (PBPK) models, that are able to predict drug plasma concentration 
profiles. From plasma concentration time curves key clinically relevant information can 
be extrapolated, such as the peak plasma drug concentration, absorption kinetics and 
elimination. PBPK models have their roots in academic and toxicological applications, 
however in recent years it has been enthusiastically adopted for drug development and 
regulatory assessment. This is reflected by, and likely in part due to, a variety of open 
and commercially available user-friendly software packages that make PBPK modelling 
more accessible [140].  
1.9.2 Modelling Approaches 
Different modelling approaches have developed over time. The simplest of these is the 
classical empirical model, which draws upon existing in vivo drug plasma concentration 
profiles and aims to replicate them. These models require little theoretical understanding 
of the system and instead involves using a number of compartments with which the drug 
is instantaneously distributed, to describe ADME. Empirical models are most commonly 
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described by the sum of exponential terms representing the event in each compartment. 
Although these models can satisfactorily describe concentration-time profiles and derive 
information such as clearance parameters and even dosing regimens, they are limited 
in their extrapolation. This is a result of the simplicity of the system, with the descriptive 
parameters within each compartment lacking any physiological relevance [141].  
Non-compartmental analysis is a model independent approach and was the most 
commonly used pharmacokinetic analysis tool before the dawn of modern computational 
power. A non-compartmental approach can determine certain pharmacokinetic 
parameters using calculations based on the area under the plasma concentration curve 
(AUC), which itself can be calculated using the trapezoidal rule. From the AUC, total 
body clearance, apparent elimination rate constant, mean residence time and apparent 
volume of distribution at steady state can be calculated [138, 142].  
 
1.9.3 PBPK Modelling 
Mechanistic pharmacokinetic PBPK models were first described in 1937 by Teorell  [143] 
and developed during the 1960s and 1970s by Bischoff and Dedrick [144]. PBPK models 
are based on compartmental models but differ in complexity: instead of including a small 
number of compartments all organs and tissues are included as defined compartments. 
Another distinction is that compartmental models are primarily determined by clinical 
data whereas compartments in PBPK models are arranged anatomically and are 
connected to the vasculature, and therefore visualisation of the entire system as a whole 
is vital. PBPK models also demonstrate far greater complexity by including a vast range 
of drug independent variables. These include parameters such as age, ethnicity, 
genetics and disease states. Importantly, this means that PBPK models can be used to 
investigate potential differences in pharmacokinetics between different populations 
[145].  
Compartments in PBPK models are designed based upon physiological information and 
its effect on ADME. The complexity may vary depending on the specific tissue or organ 
of interest. This approach is referred to as bottom-up, in that interactions between the 
drug and all included components are considered in order to predict the overall 
pharmacokinetic effect and make effective extrapolations. Each compartment is given a 
physiologically relevant volume and tissue partition coefficient and linked to the systemic 
circulation. Despite the discretion regarding the complexity of the model, at a minimum, 
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the route of administration, metabolism, excretion and storage sites of the drug must be 
considered for accurate ADME purposes. To aid in model design, a generic whole-body 
PBPK model (WB-PBPK) offering sufficient complexity is extensively used as a 
foundation for PBPK studies [146, 147]. WB-PBPK models comprise of 14 compartments 
that assume instantaneous and homogenous drug distribution. Basic perfusion rates are 
considered for all compartments, with the exception of dosing and target tissues, which 
are more complexly defined through introduction of rate-limiting factors, such as 
metabolising enzymes [138, 148].  
As well as relevant systems data, when establishing a PBPK model compound-specific 
data is also included. This includes physicochemical properties and data on permeability 
and metabolism from in vitro and in vivo sources. A wealth of information is available for 
most drug compounds in the literature and publically available databases and can also 
be obtained by self-study, for example, by performing in vitro cell absorption assays. 
Provided a limited amount of drug physicochemical information is available, unknown 
information can even be predicted using ADME software, whilst for some compounds 
predefined compound profiles may be included in the software [138, 148].  
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1.10 Thesis Aims and Objectives 
There is a global lack of medicines suitable for use in paediatrics and a drive by 
regulatory bodies to encourage research and development of new suitable products to 
meet this demand. Reformulation of off-patent drugs into paediatric friendly forms offers 
an opportunity to provide for this underserved population. The oral route of drug delivery 
is historically, and remains, the most popular. ODTs offer a novel approach to improve 
patient compliance and are particularly suitable to paediatrics, although they present a 
challenge in achieving desirable properties with high dose APIs. FDCs offer another 
method to enhance compliance due to ease of dosing. Combination of the two in the 
interests of increased compliance and drug efficacy has so far not been exploited. Of 
importance during reformulation studies is the demonstration of bioequivalence. PBPK 
modelling is increasingly employed for this as a powerful tool to predict drug 
pharmacokinetics by simulating clinical trials. 
The overarching aim of the work in this thesis is to engineer solutions to formulate ODT's 
for high dose drugs and to study their application in the development of fixed dose 
combinations. 
The objectives of the work include: 
 To formulate an ODT for flucloxacillin sodium, a generic antibiotic, at doses 
representing high drug loading and the challenges it represents, 
 To explore the use of polymeric film coating of ODTs to overcome formulation 
challenges, 
 To investigate the formulation of FDC ODTs of model generic drugs at 
paediatrically relevant doses and predict their in vivo performance using a PBPK 
modelling approach. 
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2.1 Introduction 
Flucloxacillin is a narrow spectrum beta-lactam bactericidal antibiotic that shows 
resistance to hydrolysis by beta-lactamase (penicillinase) producing bacteria such as 
Staphylococcus aureus [149]. Flucloxacillin is indicated for the treatment of infections of 
the chest, ear, nose, throat, skin and soft tissue. In addition, it is also prescribed for the 
treatment of endocarditis, osteomyelitis, meningitis, enteritis and septicaemia. It exhibits 
its bactericidal activity through inhibition of cell wall synthesis, by preventing cross 
linkage of peptidoglycan polymer chains by binding to penicillin binding proteins. Cell 
lysis then proceeds via the action of bacterial derived autolytic enzymes [150-152]. 
Flucloxacillin can be administered intravenously, intramuscularly and orally. For oral 
administration, flucloxacillin is commercially available under a number of different trade 
names in the UK including Floxapen® (GSK), Ladropen® (Berk) and Fluclomix® 
(Ashbourne). These are available as capsules in flucloxacillin’s sodium salt form at a 
dose of 250 mg or 500 mg, and also as powders for reconstitution with water, in sodium 
or magnesium salt form at 125 mg/5 ml. The oral dose for an adult is 250-500 mg every 
6 hours, ½ adult dose every 6 hours for children aged 2-10 years and ¼ adult dose every 
6 hours for children aged 1 month to 2 years [153]. Flucloxacillin sodium comes as a 
white or almost white, crystalline, hygroscopic powder, that is freely soluble in water. 
ODTs are an increasingly popular oral dosage form which benefit from improved patient 
compliance and do not require water for administration, due to disintegration in the oral 
cavity. ODTs offer greater convenience over reconstituted liquids, which require 
refrigeration, and enhanced stability, with reconstituted liquids providing a shelf life of 
only two weeks. Manufacture of ODTs by direct compression is cost effective, offers 
ease of production involving minimal process steps and allows the use of conventional 
tableting equipment. Formulation of a directly compressed flucloxacillin ODT is thus an 
attractive prospect. One significant drawback is the well-recognised bitter, unpalatable 
taste of flucloxacillin and would be particularly problematic for a dosage form designed 
to disintegrate in the oral cavity. This is even more problematic when considering dosing 
children, who are especially unwilling to take bitter medicines [154]. This is evident in 
powder for reconstitution formulations, which contain an intense sweetener, saccharin 
sodium, as well as other sweeteners such as sucrose and sorbitol and a variety of 
flavours.  
As mentioned previously, ODTs contain commonly used excipients that are often 
multifunctional. Correct selection of diluents and disintegrants are particularly important 
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in creating a successful solid dosage form that shows rapid disintegration, is stable and 
mechanically strong.  
Mannitol is a commonly used excipient in ODT formulations, functioning primarily as a 
diluent. It is so favoured due to its semi-sweet taste, smooth mouthfeel and negative 
heat of solution which imparts a cooling sensation in the mouth. It is water soluble, shows 
good wetting properties and is non-hygroscopic [155]. Polyols show good water solubility 
and erode in contact with water at the tablet surface, as opposed to disintegration which 
involves mechanical breakup of the tablet core due to swelling or gas formation [156]. A 
limitation of mannitol however, is that it displays poor compressibility and compactability. 
Granulation of mannitol has been shown to improve compactability, by enhancing 
plasticity and altering particle size and specific surface area [157]. Many different grades 
of mannitol are commercially available, with smaller particle sizes generating tablets with 
greater tensile strength due to increased interparticulate bonding [158] 
Microcrystalline cellulose (MCC) is one of the most popular excipients in modern 
tableting. This multifunctional excipient is employed most commonly as a diluent but can 
also be used to aid disintegration [159], as a binder [160] and has a low lubricant 
requirement due its low residual die wall pressure [161, 162]. Its popularity is primarily 
due to its high compactability which allows production of tablets with good hardness. 
This is due to hydrogen bond formation between MCC particles under compression, 
which is facilitated by significant plastic deformation which brings a large particle surface 
area into close contact [162]. The presence of moisture within MCC particles also 
facilitates hydrogen bonding by acting as a lubricant that aids slipping and flow [163]. 
Mechanical interlocking of MCC particles is also proposed as being important for 
formation of strong tablets [164, 165]. The ability of MCC to act as a disintegrant is due 
to high porosity that enables wicking. Water entry into tablets through capillary pores 
breaks hydrogen bonds between MCC particles [166]. MCC is partially crystalline (70%) 
and partially amorphous (30%) and consists of microcrystals and amorphous regions. A 
number of manufacturers provide different forms of MCC which differ in grade and 
quality, which may be due to differences in crystallinity [164]. MCC also possesses good 
flow properties[167]. 
Crospovidone is a synthetic, water-insoluble cross linked homopolymer of N-vinyl-2-
vinylpyrollidone. Crospovidone is commonly employed as a tablet disintegrant and as a 
binder and has also been used as a solubilising excipient [168]. Crospovidone is most 
commonly used as a superdisintegrant in formulations prepared by direct compression 
Chapter 2 – Development of a Flucloxacillin Orally Disintegrating Tablet 
80 
and granulation methods, with a typical concentration range of 2-5%. Exceeding this 
range can cause negative effects on powder flow, hardness and friability [169-171]. 
Different particle size grades of crospovidone are available, with larger grades reported 
to enhance flow, disintegration and dissolution, but suffer from lower tablet hardness and 
increased friability when compared with finer grades [171, 172]. Unlike other 
superdisintegrants, crospovidone promotes rapid disintegration through a number of 
mechanisms, namely swelling, wicking and to some extent deformation. The highly 
porous morphology of crospovidone particles promotes rapid water absorption into 
tablets and the generation of hydrostatic pressures through volume expansion, which 
mechanically forces the tablet apart. In contact with water, deformed crospovidone 
particles recover their original structure and swell to disrupt the tablet core. Due to the 
high density of crosslinks, crospovidone also benefits from the absence of gel formation 
when fully hydrated. It is this extensive cross-linking that make crospovidone water 
insoluble, despite being hydrophilic [173, 174]. 
This work follows formulation development of a high dose flucloxacillin ODT produced 
by direct compression. Initial development involved a placebo using mannitol as a major 
diluent and crospovidone as disintegrant and investigation into the effect of processing 
conditions. Disintegrant concentration was next investigated before incorporation of 
flucloxacillin. Inclusion of different disintegrants and disintegrant combinations and 
reduction of flucloxacillin dose was next explored, in order to improve disintegration.  
Further refinement involving inclusion of a binder, alteration of blending and lubricant 
was also carried out. 
 
Sub-sections within this chapter of work show discrete studies which appropriately follow 
the previous study (based upon findings), with the ultimate aim of producing an ODT 
formulation that overcomes some of the inherent limitations related to ODTs. 
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2.2 Materials and Methods 
2.2.1 Materials 
Flucloxacillin sodium was purchased from Carbone Scientific (UK). D-mannitol, D-
sorbitol and magnesium stearate were purchased from Sigma –Aldrich (UK). 
Polyplasdone XL-10 was obtained from ISP (Switzerland). Avicel PH102 (MCC) was 
obtained from FMC Biopolymer (USA). Primellose (croscarmellose sodium) and Primojel 
(sodium starch glycolate) were gifts from DFE Pharma (Germany). Polyplasdone XL-10 
(crospovidone) was obtained from ISP (Switzerland). Aerosil 200 Pharma (colloidal 
silicon dioxide) was obtained from Evonik Industries (Germany).  
 
2.2.2 Tablet Formation 
Direct compression of tablets (500 mg) at a compaction force of 10 kN (1 ton) or higher 
was performed using an Atlas T8 automatic press (SPECAC, UK). A manual uniaxial 
hydraulic press (SPECAC, UK) was used for production of tablets below a compaction 
force of 10 kN. A 13mm round, flat faced die was used for tablet production. All tablets 
were produced under ambient conditions and tablet characterisation was carried out 
immediately post compression 
 
2.2.3 Angle of Repose 
Angle of repose was calculated using the procedure outlined in the British Pharmacopeia 
[175]. Approximately 20 g powder was poured through a funnel onto a vibration-free 
base. The funnel was placed approximately 2-4 cm from the peak of the powder cone, 
in order to minimise the impact of falling powder on the cone formation. The height (h) 
and the diameter (d) of the cone was measured in triplicate and used to calculate the 
mean angle of repose, using the equation: 
ݐܽ݊ (ߙ)  =  ℎ / (0.5 ݔ ݀) 
Angle parameters are given in Table 2.1. A flow rating of fair or better would be 
acceptable. 
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Angle of Repose (degrees) Flow 
25-30 Excellent 
31-35 Good 
36-40 Fair - aid not needed 
41-45 Passable - may hang up 
46-55 Poor - must agitate/vibrate 
56-65 Very poor 
>66 Very, very poor 
 
2.2.4 Bulk and Apparent Particle Density and Porosity 
Particle density was measured using a helium pycnometer (Multipycnometer, 
Quantochrome Instruments, UK) on pre weighed tablets whose volumes had been 
calculated, based on Archimedes displacement principle. Porosity was calculated using 
the equation [155]: 
ߝ = 100(1 − 
ߩௗ
ߩ௧
) 
Where ߝ is the porosity and where ߩௗ  and ߩ௧ are the bulk density and true density, 
respectively. Porosity was measured in triplicates at each compaction force. 
 
2.2.5 Carr’s Index and Hausner Ratio 
Powder flow was also assessed by analysis of powder bulk and tapped densities. 
Approximately 20 g powder was added to a 250 ml volumetric cylinder and the bulk 
volume recorded. The cylinder was subjected to 5 taps, 10 taps, 500 taps and 1250 taps 
sequentially until the point that no change in density occurred and the tapped volume 
was recorded. The bulk density and tapped density were then calculated by: density = 
Table 2.1 Parameters for angle of repose to assess powder flow. A flow rating of fair or 
better shows acceptable flow for high speed tableting. 
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mass of powder / volume. Powder flow was assessed using the values generated by the 
Carr’s Index (Compressibility Index) and the Hausner ratio [176, 177]: 
Carr’s Index = (்௔௣௣௘ௗ ௗ௘௡௦௜௧௬ି஻  ௗ௘௡௦௜௧௬)
்௔௣௣௘ௗ ௗ௘௡௦௜௧௬
∗ 100 
Hausner Ratio = ்௔௣௣௘ௗ ௗ௘௡௦௜௧௬
஻௨௟௞ ௗ௘௡௦௜௧௬
 
Compressibility index and Hausner ratio parameters are given in Table 2.2. A flow rating 
of fair or better would be acceptable. 
 
Compressibility Index (%) Flow Hausner Ratio 
≤10 Excellent 1-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very, very poor >1.6 
 
2.2.6 Disintegration Time 
The disintegration time was measured in vitro using US pharmacopeia monograph ([701] 
disintegration). The disintegration apparatus used was Erweka ZT3, Appartebau, GMBH 
(Germany) and 800 ml distilled water maintained at 37˚C was used as the disintegration 
media. Tablets were measured individually by placing in the basket rack and the time 
taken for the tablets to disintegrate without leaving any solid residue in the rack, 
recorded. Disintegration time was measured in triplicates at each compaction force. 
 
Table 2.2 Parameters for compressibility index and Hausner ratio for assessment of 
powder flow 
Chapter 2 – Development of a Flucloxacillin Orally Disintegrating Tablet 
84 
2.2.7 Fourier Transform Infrared Spectroscopy 
FTIR spectroscopy was performed on powders using a Nicolet IS5 FTIR spectrometer 
equipped with an iD5 attenuated total reflectance (ATR) diamond from Thermo Fisher 
Scientific (USA). A small sample of powder was placed on the lens and the FTIR spectra 
was measured in the 4000-500 cm-1 regions. Analysis was carried out using OMNIC 
Specta Software (USA). 
 
2.2.8 Friability 
Tablet friability was determined on 6 tablets using a friabilator from J. Engelsmann AG 
(Germany). Tablets were placed inside the drum and rotated at 25 rpm, for a total of 100 
revolutions. Tablet dust was removed pre and post testing to remove excess powder that 
would contribute to tablet mass. Friability was calculated and expressed as % tablet 
weight loss from initial tablet weight. 
 
2.2.9 Hardness and Tensile Strength Measurements 
A tablet hardness tester model TBF 1000 (Copley Scientific, UK) was used to measure 
the radial crushing strength (hardness) of tablets in triplicates. This data was then used 
to calculate the tensile strength of the tablets using the equation [178]: 
ߪ =  
2ܨ௖
ߨ݀ݐ
 
Where ߪ is the tensile strength, Fc is the force needed to crush the tablet, d is the tablet 
diameter and t the thickness of the tablet. 
 
2.2.10 Heckel Analysis 
Heckel analysis to measure the compaction characteristics of the powders was 
performed out-of-die using the Heckel equation [179]: 
݈݊ (1/(1 –  ܦ)  =  ܭܲ +  ܣ 
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Where D is the relative density of the tablet at pressure P. Plotting ln(1/(1 – D) against 
the applied pressure P yields a Heckel plot, where the gradient of the linear portion is 
represented as K and the intersect is A. 1/K is used to calculate the mean yield pressure 
(Py) which is the pressure at which plastic deformation of the powder occurs. Mean yield 
pressure is therefore inversely related to the ability of a powder to plastically deform 
[180]. 
 
2.2.11 Particle Size Distribution 
Particle size distribution was carried out using a particle size analyser Helos/BF and dry 
disperser RODOS with feeder VIBRI/L from Sympatec (Germany). The lens measuring 
range for the instrument was 0 to 175 µm. Approximately 1 g powder was added to the 
feeder tray and the run commenced at a trigger condition of 2% Copt for 10 s with a 
powder dispensing pressure of 2 bar. Particle size distribution curves were electronically 
produced and the volume mean diameter (VMD) recorded. 
 
2.2.12 Scanning Electron Microscopy (SEM) 
A Cambridge Instruments Stereoscan 90 (UK) SEM was used to study tablet surface 
morphology. Tablet samples were prepared by sectioning thin vertical cross-sectional 
slices of punched tablets using a razor, which were then loaded onto a universal holder. 
The samples were coated with a layer of gold using a Polaron SC500 sputter coater 
(Polaron Equipment, UK) at 20 mA for 6 mins at low vacuum in the presence of argon 
gas. 
 
2.2.13 Statistical Analysis 
Using IBM SPSS statistics 20 software, one-way ANOVA was conducted on the data for 
both compaction force and dwell time factors. Post hoc analysis was performed using 
Tukey’s method, to ascertain significant differences between different compaction forces 
and dwell times.  
 
Chapter 2 – Development of a Flucloxacillin Orally Disintegrating Tablet 
86 
2.3 Studying the Effect of Compaction Force and Dwell Time Variation 
In this study, tablets composed of a simple formulation containing mannitol (diluent), 
crospovidone (superdisintegrant) and Mg stearate (lubricant and anti-adherent), were 
assessed at a range of compaction forces and dwell times. The tablets were formulated 
based on the criteria of an in vitro disintegration time of less than 30 s, as stipulated by 
the FDA [181]. This differs from a desired disintegration time of less than 3 min, outlined 
by the European Pharmacopeia [182].  The tablets were required to possess sufficient 
mechanical strength to withstand storage and handling.  
 
2.3.1 ODT Preparation 
Tablets (500 mg) consisting of mannitol (94%), crospovidone (5%) and Mg stearate (1%) 
were produced by direct compression. Mg stearate was mixed with the powder for a 
short time to prevent over-mixing, as this is known to negatively impact its ability as a 
lubricant, decrease tablet hardness and increase drug disintegration time [183]. The 
powder mixture was compressed at forces of 10, 20, 30, 40, 50 and 60 kN at a dwell 
time of 30 s. Tablets of the individual excipients (500 mg) mannitol and crospovidone 
were produced in the same manner, at forces of 5, 10, 15, 20, 25, 30 and 50 kN and 5% 
w/v Mg stearate suspended in acetone was applied to both the upper and lower punch 
as an anti-adhesive.  
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2.3.2 Results 
2.3.2.1 Tablet Characterisation 
Tablet characterisation was performed at each stage of development to assess tablet 
properties and guide development. Tablet compressibility, compactability and 
tabletability analysis were initially performed to provide information on the major 
excipients and their suitability and shortcomings with regard to this dosage form. These 
are important characteristics and determine the success of producing a mechanically 
robust tablet.  
 
 
2.3.2.1.1 Compressibility 
The compressibility of a material is defined as its ability to reduce in volume under 
pressure during loading [46]. In the context of solid dosage forms this is important as 
compressibility is a determinant of tablet strength, with highly compressible powders 
having enhanced interparticulate bonding due to close particle proximity [184, 185]. 
Powder compression is accompanied by a concurrent reduction in porosity, another 
important consideration with respect to directly compressed ODTs. The rapid 
disintegration of ODTs is often due in part to high porosity and resultant high specific 
surface area. It is for this reason that lyophilised tablets provide such rapid disintegration 
[32, 54]. Thus it is important to form a balance between porosity and tablet hardness, to 
produce tablets with sufficient structural integrity, yet with the ability to disintegrate 
rapidly. This can be achieved through careful selection of excipients and alteration of 
process parameters, for example through modifying compaction force.  
Powder compressibility was assessed at a range of pressures (Figure 2.1) by measuring 
tablet porosity using the out of die method. Compressibility increased as compaction 
force exceeded 10 kN, with porosity values at 20, 30, 40 and 50 kN ranging from 0.49 to 
0.50 showing no statistically significant differences (p>0.05). Powder compressibility 
unexpectedly decreased at the greatest compaction force of 60 kN, with a porosity of 
0.53 ± 0.01, which was not deemed different to the porosity demonstrated at the lowest 
compaction force of 10 kN.  
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2.3.2.1.2 Compactability 
The compactability of a powder is its ability to yield and compact into a tablet with 
sufficient strength [186] and is assessed by plotting tensile strength against porosity 
[187]. Powder characteristics and compaction force are important factors in 
compactability, as bond formation through close contact under compression is necessary 
for formation of strong tablets [185]. Indeed, it is the ability of a powder to form strong 
particle-particle interactions (consolidate) under compression, that defines powder 
compactability.  Ideally a mixture will exhibit high tensile strength, ensuring that the tablet 
formed is able to withstand storage and handling. For ODTs, high porosity is a key 
determinant of rapid disintegration times [42] and therefore powder compactability is of 
significant importance. 
The compactability profile of the powder formulation is shown in Figure 2.2. Linear 
regression shows a general reduction in tensile strength with increased porosity. At 30 
kN compaction force tablets demonstrated intermediate porosity and tensile strength and 
as such for this formulation 30 kN compaction force is suitable. 
 
Figure 2.1 Porosity as a function of compaction force, showing compressibility of the 
powder mix. ODTs (500mg tablets) consisting of mannitol (94%), crospovidone (5%) 
and Mg stearate (1%) underwent direct compression at a range of forces with a dwell 
time of 30 s (mean ±SD, n=3). 
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2.3.2.1.3 Tabletability 
Tabletability concerns the mechanical properties of a tablet upon compaction and is 
assessed by plotting tensile strength against compaction force [188]. Generally an 
increase in compaction force results in increased tablet crushing strength, exponentially 
at first and then plateauing at higher forces [189].  
The data (Figure 2.3) shows a strong correlation between increases in tablet tensile 
strength with increased compaction force up to a compaction force of 50 kN, with non-
linear regression giving an R2 value of 0.99. This gave a maximum tablet tensile strength 
of 2.54 ± 0.15 N/mm2. Tablet tensile strength dropped drastically to 0.46 ± 0.06 N/mm2 
at the highest compaction force of 60 kN. This drop in tensile strength was not statistically 
different than the tensile strength displayed by tablets at 10 kN compaction. This 
coincides with the increase in porosity at 60 kN. 
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Figure 2.2 Tablet tensile strength (N/mm2) against porosity to show compactability of 
the powder mixture. ODTs (500mg tablets) consisting of mannitol (94%), 
crospovidone (5%) and Mg stearate (1%) underwent direct compression at a range 
of forces with a dwell time of 30 s (mean ±SD, n=3). 
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2.3.2.2 Heckel Analysis 
To ascertain the mechanism of powder densification, Heckel analysis was performed on 
the excipients mannitol and crospovidone (Figure 2.4 and Figure 2.5, respectively). 
Heckel analysis is a tool for assessing the plasticity of a powder, that is, how readily a 
material will deform plastically under pressure. It gives a yield pressure value that is 
calculated from porosity data at a variety of compaction forces. A low yield pressure 
signifies high plasticity. Two techniques are commonly used in Heckel analysis, known 
as the out-of-die method and the in-die method. Since particles deform elastically under 
pressure, the out-of-die method provides a more accurate representation of powder 
compaction and consolidation, as elastic recovery after cessation of compression alters 
porosity [190].    
Powders that deform plastically, as opposed to elastically, are known to produce stronger 
tablets and are associated with good compactability and reduced fragmentation [191]. 
Mannitol showed a high mean yield pressure of 2000.00 MPa, indicating poor plasticity, 
a value which was consistent with findings in the same lab [165]. In contrast, 
crospovidone appeared to behave more plastically, with a PY of 434.78 MPa and an R2 
value of 0.99.  
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Figure 2.3 Tablet tensile strength (N/mm2) against compaction force to demonstrate 
tabletability. ODTs (500mg tablets) consisting of mannitol (94%), crospovidone (5%) 
and Mg stearate (1%) underwent direct compression at a range of forces with a dwell 
time of 30 s (mean ±SD, n=3). 
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Figure 2.4 Heckel plot for mannitol using the out-of-die method, derived from relative 
density and compaction pressure. A gradient of the straight portion of the graph, 
0.0005 corresponds to a Py (MPa) of 2000 (mean, n=3). 
 
Figure 2.5 Heckel plot for crospovidone using the out-of-die method, derived from 
relative density and compaction pressure. A gradient of the straight portion of the 
graph, 0.0023, corresponds to a Py (MPa) of 434.78 (mean, n=3). 
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2.3.2.3 Friability   
The extent of tablet friability is an important consideration during formulation of solid 
dosage forms. Tablet friability tests the likely percentage of the initial mass of a tablet 
lost as a result of chipping during transit. It is calculated by inflicting tablets to 100 cycles 
in a rotating drum. A weight loss greater than 1% is unacceptable, as stipulated by USP 
29 [192]. Friability testing results are show in Figure 2.6. There is a linear decrease in 
tablet friability between 10 and 30 kN which plateaus thereafter, suggesting that at 30 
kN, compaction force ceases to be the rate limiting factor for friability. As a result, to 
improve friability other approaches such as altering the excipient formulation or changing 
the procedure/technologies used for production should be explored. 
 
2.3.2.4 Disintegration Time 
Tablet disintegration time is of prime importance when formulating ODTs due to the 
requirement for rapid disintegration. Guidelines for ODTs require a disintegration of 3 
mins or less, as stated by the European Pharmacopeia [182], whereas the FDA stipulate 
disintegration within 30 s [181]. All tablets displayed rapid disintegration within 30 s 
(Figure 2.6). Increasing compaction force had no effect on disintegration time. 
Disintegration time was therefore also unaffected by any changes in tablet porosity or 
hardness, suggesting that the choice of excipients determine rapid disintegration. This 
is likely primarily due to the wicking action and swelling ability of crospovidone. In 
addition, the high wettability and water solubility of mannitol and the good porosity 
displayed by the tablets will be important factors in rapid disintegration. 
Chapter 2 – Development of a Flucloxacillin Orally Disintegrating Tablet 
93 
 
2.3.2.5 Effect of Dwell Time 
In order to test the effect of dwell time on tablet characteristics, tablets were produced at 
dwell times of 5, 10, 15 and 20 s. An intermediate compaction force of 30 kN was chosen, 
as this showed intermediate porosity and tensile strength when compared to tablets at 
other compaction forces. Tablet hardness, tensile strength, porosity and disintegration 
time were all measured. 
The effect of dwell time on tablet characteristics is shown in Table 2.3. No difference 
(p>0.05) was seen with changes in dwell time for tablet hardness and disintegration time. 
Porosity however decreased as the dwell time increased past 5 s (p<0.05), after which 
no change was observed. High porosity is desirable to improve disintegration time. Since 
porosity was greatest at a 5 s dwell time and tablet hardness, tensile strength and 
disintegration time were not adversely affected, a shorter dwell time is preferable. 
Friability decreased after a dwell time of 5 s and remained constant from 10 to 20 s.  
 
 
Figure 2.6 Friability (% weight loss) and disintegration time (s) against compaction 
force. ODTs (500mg) consisting of mannitol (94%), crospovidone (5%) and Mg 
stearate (1%) underwent direct compression at a range of forces with a dwell time of 
30 s (mean ±SD, n=6). 
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Dwell Time 
(s) 
Hardness (N) Disintegration 
Time (s) 
Porosity Friability 
(%) 
5 100.27 ± 4.03 23.00 ± 1.00 0.54 ± 0.01 2.32 
10 102.87 ± 2.02 23.67 ± 1.53 0.49 ± 0.01 1.81 
15 100.20 ± 0.85 25.00 ± 1.00 0.50 ± 0.01 1.77 
20 101.10 ± 1.83 24.33 ± 1.53 0.49 ± 0.01 1.69 
 
2.3.2.6 Tablet Morphology 
Morphological analysis of tablets was performed using SEM (Figure 2.7). Tablets 
produced at a compaction force of 10 kN (low), 40 kN (intermediate) and 60 kN (high) 
were chosen for analysis. Tablets compacted at 60 kN had previously displayed 
unexpected porosity and hardness values. 
At 10 kN the tablet shows porous structures and round edges, suggesting plastic 
deformation. At 40 kN the tablet appears less porous and the edges are sharper. This is 
consistent with the decrease in porosity seen when compaction force is increased past 
10 kN. At 60 kN the particles no longer appear rounded, showing an elongated needle 
shaped morphology that was not apparent at lower compaction forces. This change seen 
at 60 kN is likely due to fragmentation of the powder mixture and may account for the 
observed changes in porosity and tablet hardness. 
 
 
 
 
 
 
Table 2.3 Effect of dwell time on tablet characteristics ODTs (500mg tablets) consisting 
of mannitol (94%), crospovidone (5%) and Mg stearate (1%) underwent direct 
compression at 30 kN (3 tons) at a range of dwell times (mean ± SD, n=3).     
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2.3.3 Discussion  
Overall, the disintegration time of tablets at all compaction forces was acceptable for 
ODTs at less than 30 s, as stated by the FDA. Only small changes in porosity were seen 
when the compaction force was altered, indicating that the porosity shown was an 
intrinsic characteristic of the powder mixture. Indeed, other groups have reported that 
hard crospovidone particles resist deformation in order to impart porosity to a tablet [193]. 
For further development of this formulation, it will be important to optimise the 
concentration of crospovidone. Superdisintegrants possess critical concentrations, 
below which disintegration time decreases and above which disintegration time stays 
consistent or may increase [57]. Optimising the concentration of crospovidone may 
therefore improve disintegration times and will also impact on the structural 
characteristics of the formulation. 
The formulation showed good hardness, with tensile strength rising steadily up to a 
compaction force of 50 kN. Increased compaction force increases interparticular contact 
and promotes bond formation. Powders that deform plastically are associated with 
formation of better compacts. Fragmentation however, is also known to be an important 
mechanism of bond formation under compression. Particle fragmentation creates new 
surfaces and it is thus believed that fragmentation determines the number of bonds in a 
given cross-section; conversely, it is believed that deformation determines the strength 
of bonds [194]. At 60 kN there is a substantial drop in hardness, which coincides with an 
increase in porosity, likely due to fragmentation of the powder. Plastically deforming 
powders typically show mean Py  of 40-135 Mpa, whereas powders that primarily 
 
Figure 2.7 SEM 200x magnification of ODT tablet fragments. Tablets consisted of 
mannitol (94%), crospovidone (5%) and Mg stearate (1%) and were produced by 
direct compression at a dwell time of 30 s. The images show tablets compacted at a 
force of 10 kN, 40 kN and 60 kN respectively, from left to right. 
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consolidate by fragmentation show yield pressures in the range of 340-430 Mpa [186]. 
Both mannitol and crospovidone were shown to deform primarily by fragmentation. 
Indeed, mannitol has been shown to fragment under compaction, causing an increase 
in the population of small pores and decrease in large pores, with a concomitant increase 
in powder surface area [195]. The same group have reported an increase in tablet 
breaking force after mannitol fragmentation. Fragmentation of mannitol likely occurred at 
low compaction forces and therefore the spike in porosity at 60 kN is likely due to the 
more plastic crospovidone. Despite the increase in number of interparticulate bonds as 
a result of fragmentation, tensile strength decreases at 60 kN. This may be due to a drop 
in deformation of crospovidone particles upon fragmentation and an associated 
reduction in bonding strength. This reduction in bond strength can be seen by an 
increase in porosity, large reduction in tensile strength and also an increase in tablet 
volume, when compared to tablets compacted at 50 kN. All of this would suggest that 
strong bonding interactions are important in generating compacts for this formulation, 
and fragmentation of crospovidone at high compaction force is detrimental.   
The main concern with this formulation is high friability, which exceeds 1% weight loss. 
This is likely due to the poor compactability and low plasticity of mannitol. Mannitol’s 
needle shape is reported to be prone to fragmentation, resulting in a high die wall friction 
and poorly formed compacts with high friability [196, 197]. The use of different excipients 
with greater plasticity should therefore be investigated to improve friability. Incorporation 
of binders could be explored to improve compactability and friability, although at the 
detriment to disintegration time. Other  diluents such as polyols and sugars have been 
incorporated into mannitol formulations to improve poor compactability and friability [48]. 
The incorporation of multiple diluents may therefore be another strategy for improving 
the friability of the tablets. Also, the addition of water-insoluble inorganic excipients 
should be considered, as these have been shown to impart good physical resistance, 
whilst not undermining disintegration times [35].   
Dwell time was shown to have no effect on tablet hardness and disintegration time. An 
increase in porosity was seen at a dwell time of 5 s, which is favourable as this should 
aid in tablet disintegration. This was, however, associated with an apparent increase in 
friability. Despite this, since mass production of tablets would favour short dwell times 
and due to the other strategies that can be employed to improve friability, a 5 s dwell 
time would seem suitable for further formulation development. 
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2.4 Crospovidone as a Disintegrant 
Crospovidone was included in a mannitol based, directly compressed ODT as a 
disintegrant/binder at a range of concentrations (1% to 5%) and compaction pressures 
(0.5 to 2 tons). The effect that incorporation of crospovidone had on tablet properties 
was investigated and the specific properties of crospovidone were also examined. 
Polypasdone XL-10 was the selected grade due to its small particle size [198], which it 
was hoped would improve tablet strength, as mannitol displays poor compaction 
properties.  
Powder blends were prepared at a range of concentrations of crospovidone, see Table 
2.4. Mannitol and crospovidone were blended for 5 mins, Mg stearate added and then 
mixed for a further 1 min. ODTs were compressed at a range of forces: 5 kN (0.5 ton), 
10 kN (1.0 ton) and 20kN (2.0 ton) at a dwell time of 30 s. Target tablet weight was 
500mg. 
 
Crospovidone (% w/w) Mg Stearate (% w/w) Mannitol (% w/w) 
0 1 99 
1 1 98 
2 1 97 
3 1 96 
5 1 94 
 
 
 
 
Table 2.4 Formulation of ODTs comprising mannitol as a diluent, increasing 
concentrations of crospovidone as a disintegrant and 1% Mg stearate as an antiadhesive 
and lubricant. Powder underwent direct compression at compaction forces of 0.5, 1 and 
2 tons, with a dwell time of 30 s.  
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2.4.1 Results 
2.4.1.1 Powder Flow 
The flowability of crospovidone was assessed (Table 2.5) by measuring the angle of 
repose and bulk and tapped densities to calculate the compressibility index and Hausner 
ratio. The angle of repose data indicates a good flow, whereas the compressibility index 
and Hausner ratio indicate poor flow. This is likely due to the small particle size of this 
grade of crospovidone (XL-10). An improvement in flow with grades of a larger particle 
size has been reported [198]. 
 
Angle of 
Repose 
Bulk 
Density 
(g/cm3) 
Tapped 
Density 
(g/cm3) 
Hausner Ratio Compressibility 
Index 
31.22 ± 1.95 - 
Good 
0.30 ± .00 0.44 ± .01 1.47 ± 0.04 - Very 
Poor 
32.14 ± 1.77 -  
Very Poor 
 
2.4.1.2 Particle Size Distribution 
Particle size distribution data is shown in Table 2.6 and Figure 2.8. Polyplasdone XL-10 
displayed a monomodal distribution with a slight negative skew, indicating that a small 
amount of the powder consisted of very small particles (X10 8.37 ± 0.18). The small 
average particle size, VMD 26.53 ± 1.03, would explain the poor flow seen with this 
powder  
 
 
 
Table 2.5 Angle of repose, bulk density, tapped density, Hausner ratio and 
compressibility index of crospovidone (Polyplasdone XL-10), to show flowability. Flow 
ratings of fair or better are suitable for high speed tableting. 
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Particle Size Parameter Polyplasdone XL-10 Particle Size (µm) 
X10 8.37 ± 0.18 
X50 22.4 ± 0.68 
X90 50.67 ± 2.24 
X99 84.48 ± 5.44 
VMD 26.53 ± 1.03 
 
 
 
Table 2.6 Particle size distribution described using the polydispersity index and volume 
mean diameter (VMD) for Polyplasdone XL-10 using HELOS laser diffraction technique. 
Particle sizes are given in µm (Mean ± SD, n=3) 
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Figure 2.8 Particle size distribution of Polyplasdone XL-10 powder using HELOS laser 
diffraction technique (n=3) 
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2.4.1.3 Disintegration Time 
Figure 2.10 gives the disintegration times of the mannitol based ODTs with increasing 
concentrations of crospovidone. The results for 0% crospovidone tablets have been 
excluded as they are drastically higher than those shown, with values for disintegration 
time of 872.67 ± 49.1, 762.33 ± 35.3 and 585.33 ± 44.12 s, with increasing compaction 
force, respectively. The disintegration time for all tablets containing crospovidone was 
within the 3 min margin as specified by the European Pharmacopoeia [199] and all 
tablets at the highest compaction force disintegrated within 30 s, as recommended by 
the FDA. Disintegration time was enhanced by increasing compaction force (p<0.05) 
with most rapid disintegration shown at 2 tons (p<0.005), as calculated by two-way 
ANOVA. No effect was seen with increase in crospovidone concentration, however the 
inclusion of crospovidone showed a drastic decrease in disintegration time (p<0.0001).  
 
2.4.1.4 Tablet Hardness 
Tablet hardness (Figure 2.9) increased with increased compaction force at 1 ton (p<0.05) 
and markedly at 2 ton (p<0.0001), indicating that an increase in compaction force 
facilitates interparticulate bonding by bringing the particles closer together in contact. 
Crospovidone at a concentration of 5% produced significantly weaker tablets (p<0.0001) 
when compared with the control and all other concentrations. Despite crospovidone’s 
functionality as a binder, it appears that at higher concentrations this binding activity is 
compromised.  
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Figure 2.10 Disintegration time (s) as a function of compaction force. ODTs (500mg 
tablets) consisted of mannitol as a diluent, Mg stearate (1%) and crospovidone as a 
disintegrant at a range of concentrations up to 5%. Direct compression was performed 
at a range of compaction forces with a dwell time of 30 s (mean ±SD, n=3, ** (P<0.01) 
and **** (P<0.0001) compared to 0.5 ton 
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Figure 2.9 Tablet hardness (N) as a function of compression force. ODTs (500mg 
tablets) consisted of mannitol as a diluent, Mg stearate (1%) and crospovidone as a 
disintegrant at a range of concentrations up to 5%. Direct compression was performed 
at a range of compaction forces with a dwell time of 30 s (mean ±SD, n=3, * (P<0.05) 
and **** (P<0.0001) compared to 0.5 ton 
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2.4.1.5 Friability 
Friability (Figure 2.11) generally showed a linear decrease with increase in compaction 
force, with R2 values ranging from 0.98-0.75. All tablets were above an acceptable weight 
loss of 1%. There was no clear trend between crospovidone concentration and friability. 
At 0.5 ton however, 5% crospovidone produced tablets with dramatically higher friability 
of 8.54%. 
 
2.4.1.6 Porosity 
The results showed a decrease in porosity (Figure 2.12) with increased compaction 
force. Porosity decreased significantly at 1 ton (p<0.0001), with a less pronounced 
decrease when compaction force increased further to 2 ton (p<0.005). At concentrations 
of 0% and 1% crospovidone, the tablets displayed significantly lower porosity 
(p<0.0005). At higher concentrations of 2%, 3% and 5% porosity at 2 tons compaction 
the tablets showed the same level of porosity. Overall, the tablets containing 3% and 5% 
crospovidone showed a greater porosity than the 2% crospovidone tablets across all 
compaction forces. The established view that crospovidone enhances porosity is thus 
supported by the results shown here.  
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Figure 2.11 Friability (% weight loss) as a function of compression force. ODTs 
(500mg tablets) consisted of mannitol as a diluent, Mg stearate (1%) and 
crospovidone as a disintegrant at a range of concentrations up to 5%. Direct 
compression was performed at a range of compaction forces with a dwell time of 30 
s (mean ±SD, n=6). 
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2.4.1.7 FTIR 
FTIR spectra of Polyplasdone XL-10 (Figure 2.13) was consistent with the fingerprint 
region shown for crospovidone [158]. There is a strong absorption between 3700 and 
2800 cm-1 due to high moisture content as liquid water absorbs strongly in this region, 
known as region A, due to its stretching vibrations [200]. High moisture content is 
reinforced by the carbonyl band at 1651.20 cm-1, which is shifted from an expected value 
of 1667 to 1671.5 cm-1, as a result of hydrogen bonding from the OH moiety [158, 201]. 
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Figure 2.12 Compressibility profile comparing porosity against compression force. 
ODTs (500mg tablets) consisted of mannitol as a diluent, Mg stearate (1%) and 
crospovidone as a disintegrant at a range of concentrations up to 5%. Direct 
compression was performed at a range of compaction forces with a dwell time of 30 
s (mean ±SD, n=3, **** (P<0.0001) compared to 0.5 ton, ** (P<0.01) compared to 1 
ton 
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2.4.2 Discussion 
Crospovidone shows poor flow as a result of cohesiveness due to a small particle size 
and this may necessitate the need for a glidant in formulations containing the 
disintegrant. Particle size of crospovidone is an important consideration since different 
grades convey different tablet properties [172]. Inclusion of crospovidone at as little as 
1% w/w drastically improved disintegration time, demonstrating its exceptional ability as 
a disintegrant. Its propensity as a binder is also evident, as it improved tablet hardness 
upon inclusion and was optimal at concentrations of 2-3%. There was little difference in 
fact between tablets containing 2% and 3% crospovidone which also displayed optimal 
hardness and relatively high porosity. Beyond these concentrations tablet hardness and 
disintegration time suffers. The increase in porosity of tablets containing crospovidone is 
representative of its mechanism of disintegration by wicking. Similarly, a seemingly 
counterintuitive decrease in disintegration time with increased compaction force may be 
adequately explained by crospovidone’s ability to swell, since a higher force can be 
exerted as a result of swelling when particles are less porous and packed tightly together. 
Finally, FTIR spectra appeared indicated the presence of water in the crospovidone 
powder possibly as a result of exposure to moisture in the air. A more anhydrous 
crospovidone powder may improve disintegration times.  
Figure 2.13 FTIR spectra for Polyplasdone XL-10, with the molecular structure of 
crospovidone also shown. 
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Both mannitol and crospovidone demonstrated favourable properties for ODT formation, 
particularly a rapid disintegration and good hardness. Inclusion of flucloxacillin into this 
ODT formulation was next explored, and was expected to drastically alter ODT 
characteristics due the high doses used.  
The next step of development involved including flucloxacillin in order to assess its 
influence over the ODT formulation developed thus far. 
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2.5 Incorporation of Flucloxacillin 
A formulation for a 500 mg orally disintegrating tablet (ODT) containing 250 mg dose of 
the antibiotic flucloxacillin was designed (Table 2.7), for production via direct 
compression. Inclusion of mannitol as a diluent in preliminary studies inferred good 
disintegration times due to its high water solubility. Mannitol displays undesirable 
mechanical properties however, namely brittle fracture resulting in high friability. MCC 
(Avicel PH102) is a hugely popular binder/diluent and has been used in ODTs produced 
via direct compression. It benefits by enhancing aqueous penetration regardless of pore 
size, a trait which is very attractive for an ODT [202]. MCC has acceptable flow properties 
for high speed tableting [203] and it was hoped would improve the relatively poor flow 
exhibited by mannitol, which is cohesive as a result of its small size and morphology 
[158]. Mannitol showed poor compactability in preliminary studies with a tendency to 
fragment. Various polyols, have been used in combination with mannitol to improve its 
compactability properties [204] and sorbitol was explored here. Sorbitol also benefits 
from a sweet taste and cooling sensation in the mouth and is used as a sweetening agent 
and diluent in sugar-free powder for reconstitution formulations, however it does suffer 
from being hygroscopic [205]. In addition, colloidal silicon dioxide was included as a 
glidant, aspartame as an intense sweetener due to the bitter taste of the API and Mg 
stearate as an anti-adhesive and lubricant.  
API and all excipients, with the exception of Mg stearate, were blended for 5 mins at 
which point Mg stearate was added and blending continued for a further 1 min. 
Compression was carried out at 30 kN at a dwell time of 5 s. 
 
API/Excipient % w/w 
Flucloxacillin sodium 54.5 
MCC 18.5 
Mannitol 10 
Sorbitol 10 
Table 2.7 Formulation of a 250 mg flucloxacillin ODT (500 mg). API and excipients are 
listed alongside their concentration % w/w. Powders underwent direct compression at a 
force of 30 kN with a dwell time of 5 s. 
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Crospovidone 4 
Aspartame 2 
Colloidal silicon dioxide 0.5 
Mg stearate 0.5 
 
2.5.1 Results 
2.5.1.1 Assessment of Flow 
The flow properties of flucloxacillin sodium were investigated using angle of repose, 
Carr’s index and Hausner ratio (Table 2.8). The mean angle of repose of 46.8˚ indicated 
poor flow. Both the compressibility index and the Hausner ratio demonstrate that 
flucloxacillin sodium has very, very poor flow properties. This is consistent with the 
literature [206], which reported very poor flow of the drug in powder form.  
 
Angle of Repose 
(degrees) Hausner Ratio Compressibility Index 
46.83 ± 3.52 1.90 ± 0.15 47.27 ± 3.90 
 
2.5.1.2 Particle Size Analysis 
Analysis of particle size distribution was performed for the major diluents MCC and 
mannitol (Table 2.9). Crospovidone was also analysed, see section 2.4.1.2.  
 
Table 2.8 Flow properties of flucloxacillin sodium powder, with data for angle of repose, 
Hausner ratio and compressibility index. Flow ratings of fair or better are suitable for high 
speed tableting. 
Table 2.9 Particle size distribution parameters for Avicel PH102 and mannitol, using 
HELOS laser diffraction technique. Particle sizes are given in µm (mean ± SD, n=3) 
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Particle Size Parameter MCC (Avicel PH102) (µm) Mannitol (µm) 
X10 17.43 ± 0.08 6.88 ± 0.12 
X50 59.96 ± 1.08 28.45 ± 0.65 
X90 137.13 ± 1.92 68.48 ± 0.56 
X99 170.26 ± 0.44 97.27 ± 0.93 
VMD 69.90 ± 1.23 33.41 ± 0.50 
 
2.5.1.3 Tablet Properties 
Various tablet properties for the 250 mg flucloxacillin ODTs are shown in Table 2.10. 
Tablet mechanical properties were excellent, with very high values for hardness and 
tensile strength, and low friability. The high hardness is likely largely due to good 
compactability of MCC and the small particle size of mannitol which allows for a high 
surface area for interparticular bond formation. MCC particles are somewhat larger, 
which should enhance improve powder flow. Speed of disintegration was very slow for 
an ODT at 579.67 ± 8.50 s.  
 
Parameter Mean ± SD 
Disintegration time (s) 579.67 ± 8.50 
Porosity 0.34 ± 0.03 
Hardness (N) 210.83 ± 7.02 
Tensile strength (N/mm^2) 3.78 ± 0.11 
Friability (% weight loss) 0.25 
 
Table 2.10 Characteristics of 250 mg flucloxacillin ODTs. Tablets (500 mg) consisting of 
flucloxacillin sodium (54.5%), MCC (18.5%), Mannitol (10%), sorbitol (10%), 
crospovidone (4%), aspartame (2%), silicon dioxide (0.5%) and Mg stearate (0.5%) were 
directly compressed at a compaction force of 30 kN, with a dwell time of 5 s (mean ± SD, 
n=3; friability n=6). 
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Despite displaying good mechanical strength, the formulation containing 250 mg 
flucloxacillin suffered from very slow disintegration. Clearly disintegration time is 
important for an ODT and therefore increasing disintegration speed was highlighted as 
the next focus. The mechanism by which disintegration occurs for an ODT is determined 
by the disintegrants that are included in the formulation. A number of different 
disintegrants are available and commonly used, that work by a variety of mechanisms, 
with varying results depending on the formulation or process conditions. Crospovidone 
had only been investigated thus far and so use other disintegrants was next explored as 
a means to improve disintegration. 
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2.6 Investigation of Different Disintegrants 
Disintegrants principally affect the rate of disintegration of ODTs produced by direct 
compression and must also impart good compactability [207]. In order to improve the 
rate of disintegration the effect of different superdisintegrants in differing concentrations 
was investigated. Due to the high cost of the API flucloxacillin sodium, placebo tablets 
were designed whilst maintaining the ratio of excipients, in order to mimic the 
flucloxacillin tablets as closely as possible. The placebo tablets were produced with a 
number of different disintegrants at concentrations of 2%, 4% and 8% w/w to determine 
optimal concentrations. The placebo formulation is shown in Table 2.11. The most 
commonly used superdisintegrants used in directly compressed tablets are 
crospovidone, croscarmellose sodium and sodium starch glycolate [208]. Starch is 
perhaps the most traditional disintegrant, which acts by swelling and may also aid 
disintegration by repulsion between particles [46]. All four of these disintegrants were 
included in the placebo formulation to assess their performance. 
ODTs of the formulation shown in Table 2.11, were produced using the disintegrants 
crospovidone (C), croscarmellose sodium (CS), sodium starch glycolate (SSG) and 
starch (S). All excipients, except Mg stearate, were blended for 5 min, Mg stearate added 
and then mixed for a further 1 min. Powders were compressed at 30 kN with a 5 s dwell 
time 
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Disintegrant Placebo Formulation (% w/w) 
MCC 44 43 41 
Mannitol 24 23.5 22.5 
Sorbitol 24 23.5 22.5 
Disintegrant 2 4 8 
Aspartame 4 4 4 
Colloidal Silicon Dioxide 1 1 1 
Mg Stearate 1 1 1 
Total (%) 100 100 100 
 
2.6.1 Results 
2.6.1.1 Porosity 
Porosity was measured using the out-of-die method. Each of the four disintegrants tested 
(excluding starch) showed significantly different porosity (p<0.001) between groups 
(Figure 2.14). Changing the concentration of crospovidone had no effect on porosity. 
Croscarmellose showed no change in porosity between 2-4%, however at 8% an 
increase in porosity was observed (p<0.05) to 0.24 ± 0.01. SSG showed a small 
decrease in porosity at 4% (p<0.005) and then a large increase in porosity at 8% 
(p<0.001) to 0.53 ± 0.00. Overall croscarmellose containing tablets demonstrated the 
lowest porosity which increased as concentration increased. SSG imparted the highest 
porosity of all disintegrants, followed by crospovidone.  
 
 
 
Table 2.11 Formulation of placebo tablets Excipient ratios have been maintained, 
however disintegrant concentrations have been set at 2%, 4% and 8%. The disintegrants 
used are crospovidone (C), croscarmellose sodium (CCS), sodium starch glycolate 
(SSG) and starch (S). 
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2.6.1.2 Tablet Hardness 
Tablet hardness for all disintegrant placebos (Figure 2.15) was well above a required 
acceptable threshold of 60 N. As was seen with porosity, the choice of disintegrant 
impacted tablet hardness. Crospovidone formed the hardest tablets (p<0.05) at 8% 
(244.1 ± 10.8 N) and at 4% (240.2 ± 3 N), and hardness was comparable to that of CS 
and SSG at 2%. CS initially showed an increase in hardness with increased 
concentration, but then showed a large drop in hardness at 8% (p<0.001) to 174 ± 5.3 
N, which was the poorest hardness overall. SSG showed good hardness at the lowest 
concentration, which fell at 4% (p<0.001) and showed no change at 8%.  Starch on the 
other hand showed the poorest hardness (p<0.05) at the lowest concentration which 
improved at 4% (p<0.05), showing no change with an increase to 8% concentration. At 
4% SSG, CS and starch all showed comparative hardness. Increase of disintegrant 
concentration past 4% had no effect on hardness, with the exception of CS which 
showed a substantial decrease. 
 
2.6.1.3 Friability 
All placebos displayed friability (Figure 2.16) below 1%, a maximum weight loss of 0.37% 
with starch. Indeed, starch showed the highest friability overall, with the least friable 
being SSG at a concentration of 8% showing just a 0.05% loss in weight. 
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Figure 2.14 Porosity for all disintegrants against disintegrant concentration. ODTs 
(500 mg) consisting of MCC, mannitol, sorbitol, aspartame, silicon dioxide, Mg 
stearate and a disintegrant were directly compressed at a compaction force of 30 kN, 
with a dwell time of 5 s. Disintegrants C, CS, S and SSG were included at 
concentrations of 2%, 4% and 8%. Data for ODTs containing starch was not possible 
due to technical difficulties (mean ± SD, n=3). 
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Figure 2.15 Hardness (N) against disintegrant concentration. ODTs (500 mg) 
consisting of MCC, mannitol, sorbitol, aspartame, silicon dioxide, Mg stearate and a 
disintegrant were directly compressed at a compaction force of 30 kN, with a dwell 
time of 5 s. Disintegrants C, CS, S and SSG were included at concentrations of 2%, 
4% and 8% (mean ± SD, n=3)., (mean ± SD, n=3). 
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2.6.1.4 Disintegration Time 
Choice of disintegrant was shown to affect disintegration time (p<0.001). None of the 
placebo tablets displayed disintegration within 3 mins (Figure 2.17). Crospovidone 
tablets showed the fastest disintegration time overall of 205.7 ± 11 s at 4%, which 
increased to 293.7 ± 24.9 s at 8% (p<0.005). At 2%, CS displayed the fastest 
disintegration (p<0.05), whilst the disintegration time of crospovidone was comparable 
to that of starch and SSG. CS showed a linear decrease in disintegration time (p<0.005) 
to 235 ± 9.6 s at 8%, suggesting that further increase in CS concentration may decrease 
disintegration time further. Similarly, SSG displayed a linear decrease in disintegration 
time (p<0.001) to an identical time to that of CS at 8%. Starch performed poorly as a 
disintegrant in comparison to the superdisintegrants crospovidone, CS and SSG, 
displaying times in the region of 10 mins. 
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Figure 2.16 Friability (% weight loss) against disintegrant concentration. ODTs (500 
mg) consisting of MCC, mannitol, sorbitol, aspartame, silicon dioxide, Mg stearate 
and a disintegrant were directly compressed at a compaction force of 30 kN, with a 
dwell time of 5 s. Disintegrants C, CS, S and SSG were included at concentrations of 
2%, 4% and 8% (mean ± SD, n=6). 
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2.6.2 Incorporation of Multiple Disintegrants 
Disintegration times exceeded 3 mins for all disintegrants. In order to improve this, 
combinations of superdisintegrants were investigated, with evidence from the literature 
suggesting this may enhanced disintegration [42]. For example, Patil and Das [209] 
investigated varying combinations of crospovidone, CS and SSG when formulating 
Lamotrigine ODTs comprising mannitol and MCC as major diluents. They observed that 
a combination SSG and CS showed the most rapid disintegration. Similar findings have 
been reported when investigating combinations of superdisintegrants in the formulation 
of ODTs for the non-steroidal anti-inflammatory drug meloxicam [210] .  
Superdisintegrants combinations were: crospovidone (4%) & CS (8%), crospovidone 
(4%) & SSG (8%), CS (8%) & SSG (8%), based upon the optimal concentrations 
observed previously. Other excipients were maintained in the same ratio as before. 
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Figure 2.17 Disintegration time (s) against disintegrant concentration. ODTs (500 mg) 
consisting of MCC, mannitol, sorbitol, aspartame, silicon dioxide, Mg stearate and a 
disintegrant were directly compressed at a compaction force of 30 kN, with a dwell 
time of 5 s. Disintegrants C, CS, S and SSG were included at concentrations of 2%, 
4% and 8% (mean ± SD, n=3). 
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2.6.2.1 Results – Disintegration Time and Hardness 
Disintegration time for disintegrant combinations is shown in Figure 2.18. No 
improvement was seen with disintegrant combination compared to disintegrants alone. 
Combination of crospovidone and SSG showed the slowest disintegration of all 
combinations and disintegrants alone (p<0.05). Combination of CS + SSG and C + CS 
was comparable to crospovidone alone. Combination of CS + SSG showed faster 
disintegration than the individual excipients CS and SSG alone (p<0.05). 
All of the combined disintegrant tablets showed good hardness (Figure 2.19) well above 
150 N. Crospovidone containing ODTs were substantially harder than all other tablets 
(p<0.001) at 244.1 ± 10.8 N. Addition of crospovidone to CS had no effect on tablet 
hardness. Similarly, addition of crospovidone to SSG gave an almost identical hardness 
of 198.1 ± 3.9 N when compared to SSG alone at 198.2 ± 5 N. When CS was added to 
SSG hardness decreased (p<0.05), suggesting that tablet hardness in this case was 
dependent upon the weakest disintegrant. 
Overall no improvement was seen with the incorporation of multiple disintegrants; tablet 
hardness fell markedly and disintegration time did not alter. ODTs containing 
crospovidone alone performed best and benefited from a lower optimum 
superdisintegrant concentration. 
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Figure 2.18 Disintegration time (s) against combinations of disintegrants at their 
optimum concentrations. ODTs (500 mg) consisting of MCC, mannitol, sorbitol, 
aspartame, silicon dioxide, Mg stearate and a disintegrant were directly compressed 
at a compaction force of 30 kN, with a dwell time of 5 s. Disintegrants C, CS and SSG 
were combined pairwise (mean ± SD, n=3). 
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Figure 2.19 Hardness (N) against combinations of disintegrants at their optimum 
concentrations. ODTs (500 mg) consisting of MCC, mannitol, sorbitol, aspartame, 
silicon dioxide, Mg stearate and a disintegrant were directly compressed at a 
compaction force of 30 kN, with a dwell time of 5 s. Disintegrants C, CS and SSG 
were combined pairwise (mean ± SD, n=3). 
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2.6.3 Discussion 
Despite showing good mechanical properties, all tablets disintegrated slowly (beyond 3 
mins), with crospovidone at 4% performing best. Crospovidone also showed superior 
hardness and as such would likely perform well at lower compaction forces as an 
approach to improve disintegration time. CS performed poorly compared to SSG and 
crospovidone, with relatively low hardness coupled with low porosity. Despite CS and 
SSG displaying disintegration times at a concentration of 8% close to that of 
crospovidone at 4%, the superior mechanical properties displayed by crospovidone and 
its low optimum concentration, meant its use was continued in formulation development.  
An optimum range of crospovidone between 4-6% has been reported in the literature 
[211-213]. The results suggest that disintegration times may be improved if CS and SSG 
concentrations are increased further, however it is known that past their optimum range 
formation of a viscous tablet outer layer impedes disintegration [214, 215]. Crospovidone 
has little tendency to gel and it is unclear why disintegration time decreases past its 
optimum range. Since crospovidone relies more heavily on rapid tablet wetting time 
(wicking) and less on its swelling ability compared to CS and SSG [215, 216], this 
increase in disintegration may be due in part to the insolubility of crospovidone when 
wetting time ceases to be a rate limiting factor. In order to increase disintegration speed, 
reduction of flucloxacillin dose to 125 mg was explored. 
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2.7 Reduction of Flucloxacillin Dose to 125mg 
Reduction of the flucloxacillin dose to 125 mg was investigated as an approach to 
improve disintegration speed of the formulation. Reduction of the dosage could may offer 
additional benefits In addition, 125 mg solid oral dosage forms are currently not available 
presenting an opportunity for and ODT that would be suitable for administration to both 
adults and children aged 2-10 years alike; moreover, a further reduction of the dose may 
allow administration to even younger patients. Additionally, a dose reduction would ease 
taste masking of the drug.  
The ratio of excipients was maintained as the original formulation (Table 2.7), although 
concentrations of aspartame and Mg stearate were maintained as these were at 
standard concentrations (Table 2.12). Powders were blended and compacted in the 
same manner as previously. 
Tablet characterisation is summarised in Table 2.13. When compared to the 250 mg 
dose, the 125 mg ODTs showed significantly slower disintegration time (p<0.001) with 
increased hardness and tensile strength (p<0.05). Despite displaying improved hardness 
and tensile strength, friability remained at a similar level, possibly due to the greater 
mannitol content. 
 
125 mg Flucloxacillin ODTs 
 % (w/w) 
Flucloxacillin Sodium 27.25 
MCC 30.75 
Mannitol 17.5 
Sorbitol 17.5 
Crospovidone 4 
Aspartame 2 
Table 2.12 Formulation of ODTs (500 mg) with a reduced dose of flucloxacillin sodium 
to 125 mg. Excipients concentration ratios have been maintained from 250 mg 
flucloxacillin dose tablets and are shown as % w/w. 
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Colloidal Silicon Dioxide 0.5 
Mg Stearate 0.5 
 
 
 
 
 Disintegration 
Time (s) Hardness (N) 
Tensile 
Strength 
(N/mm2) 
Friability (% 
Weight Loss) 
Flucloxacillin 
125 mg 388.67 ± 14.29 
294.80 ± 
19.31 5.39 ± 0.35 0.23 
Flucloxacillin 
250 mg 579.67 ± 8.50 210.83 ± 7.02 3.78 ± 0.11 0.25 
 
Despite a reduction at a 125 mg dose, disintegration time far exceeded 3 mins. Due to 
the complexity of the formulation it was not possible to determine the reasons behind the 
slow disintegration time. Consequently, a simplified formulation for 125 mg flucloxacillin 
tablets was investigated. 
  
Table 2.13 Properties of 125 mg flucloxacillin tablets. Data for 250 mg flucloxacillin 
tablets have also been included for ease of comparison. Powder underwent direct 
compression at a compaction force of 30 kN and a dwell time of 5 s (mean ±SD, n=3; 
friability n=6) 
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2.8 Effect of Varying Concentrations of MCC and Mannitol as Diluents in 
Flucloxacillin ODTs 
Previous formulations for flucloxacillin ODTs comprising MCC, mannitol, sorbitol, 
crospovidone, Mg stearate and silicon dioxide showed excellent mechanical properties, 
but exhibited slow disintegration. Sorbitol has been shown to retard disintegration by 
decreasing the effectiveness of superdisintegrants [170] and was thus removed from the 
formulation. The effect of varying the concentrations of the major diluents, MCC and 
mannitol, was studied in order to optimise the formulation for faster disintegration. Silicon 
dioxide and aspartame were also removed from the formulation, to provide a clearer 
understanding of the combination of these two excipients and their compatibility with 
flucloxacillin sodium. MCC and mannitol were combined at different ratios to see the 
effect on tablet properties, see Table 2.14. 
All excipients and drug, with the exception of Mg stearate, were blended for 5 mins. Mg 
stearate was then added and the powder was blended for a further 1 min. Direct 
compression was performed at a compaction force of 1 ton and a dwell time of 6 s. 
 
MCC: mannitol 3:1 2:1 1:1 1:2 1:3 
 F1 F2 F3 F4 F5 
Flucloxacillin sodium 27.25 27.25 27.25 27.25 27.25 
MCC 50.00 44.50 33.38 22.25 16.75 
Mannitol 16.75 22.25 33.38 44.50 50.00 
Crospovidone 5.00 5.00 5.00 5.00 5.00 
Mg st 1.00 1.00 1.00 1.00 1.00 
 
 
 
Table 2.14 Formulation of 125 mg flucloxacillin sodium ODTs (500 mg), with varying 
ratios of MCC: mannitol. Concentrations of excipients and API are expressed as % w/w. 
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2.8.1 Results 
2.8.1.1 Disintegration Time 
ODT characterisation is shown in Table 2.15. Disintegration time decreased when 
mannitol concentration was increased past an MCC: mannitol of 3:1 (p<0.05), with the 
exception of F3 (1:1) which did not show a significant reduction in disintegration when 
compared to F1, although F3 showed relatively high deviation. The performance for F2, 
F4 and F5 were similar, with the most rapid disintegration time seen with F4 at 138.33 ± 
2.52 s. The improvement in disintegration time with increased incorporation of mannitol 
is likely due to the high water solubility of mannitol, as opposed to the insoluble MCC 
[158]. 
 
2.8.1.2 Hardness 
Tablet hardness was compromised with increased mannitol concentration. Formulations 
F4 and F5 showed similar hardness (p>0.05), of 95.77 ± 5.74 N and 91.13 ± 3.19 N 
respectively. The strongest tablets (p<0.001) at 3:1 MCC: mannitol showed far superior 
hardness of 129.9 ± 4.40 N, demonstrating that inclusion of mannitol at even a low level 
was detrimental to tablet hardness. 
 
2.8.1.3 Friability 
Friability increased with increasing mannitol concentration, peaking at an MCC: mannitol 
of 1:2, before dropping at 1:3. Only formulations F1 and F2 displayed sufficiently low 
friability of less than 1%. 
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Disintegration Time 
(s) 
Hardness (N) Friability %) 
F1 180.33 ± 6.35 129.90 ± 4.40 0.59 
F2 144.33 ± 5.86  109.00 ± 7.33 0.93 
F3 148.00 ± 15.72 107.00 ± 5.62 1.31 
F4 138.33 ± 2.52 95.77 ± 5.74 1.60 
F5 139.67 ± 1.53 91.13 ± 3.19 1.16 
 
2.8.2 Discussion 
Increased mannitol concentration improved disintegration time, but mechanical 
properties were compromised due to brittle fracture of mannitol particles and poor 
compactability. Increased MCC concentration improved mechanical properties. A ratio 
of MCC: mannitol of 2:1 showed optimal properties, with good hardness, acceptable 
friability values and the most rapid disintegration, comparative to that of tablets with a 
greater mannitol content. This increased rate of disintegration was due to a drop in 
compaction force, optimisation of MCC and mannitol concentrations, reduction of 
flucloxacillin dose and also possibly to the omission of sorbitol. Sorbitol was included 
originally to counter poor mannitol compactability, however a low mannitol content and 
inclusion of MCC has allowed for production of strong tablets. 
With the improvements in ODT performance shown, alteration of the blending process 
was hypothesised as a means to improve ODT characteristics. 
  
Table 2.15 Characterisation of ODTs containing 125 mg flucloxacillin where MCC: 
mannitol has been varied. ODTs compressed at 1 ton for 6 s (mean ± SD, n=3; friability 
n=6) 
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2.9 Blending Alteration and Exclusion of Mg Stearate 
At a ratio of 2:1 MCC: mannitol, ODTs demonstrated acceptable mechanical properties 
although disintegration times, despite showing improvement, were still longer than 
desired. The order of blending was explored to see the effect, if any, on tablet 
characteristics, potentially through coating or co-localisation of excipients.  
Water insoluble lubricants like Mg stearate slow tablet wetting [217]. It is known that the 
inhibition of water penetration by Mg stearate is roughly proportional to its concentration 
[218]. It was believed that reduction of Mg stearate would improve disintegration for this 
formulation. The impact of Mg stearate on disintegration and hardness was therefore 
also examined by running another set of tablets in parallel where Mg stearate was not 
included.  
A number of different blending orders were examined, with the theory that this would 
provide different excipient/API localisation within the powder blend and perhaps even 
some particle coating repercussions. The standard blend involved mixing API and 
excipients for 5 mins. Another variation involved blending of mannitol with flucloxacillin 
for 5 mins, then adding crospovidone and blending for 5 mins and then blending with 
MCC for 5 mins. Similarly, another variation involved using the same protocol, adding 
MCC first instead of mannitol. Lastly, ½ the MCC was blended with flucloxacillin for 5 
mins, then crospovidone was blended for 5 mins, then mannitol for a further 5 mins, 
followed by the final ½ MCC for 5 mins. Mg stearate was or was not included as a final 
blending step for 1 min. Powders were compacted into tablets at a compression force of 
1 ton with a dwell time of 6 s. 
 
2.9.1 Results 
Tablet characteristics are given in Table 2.16. Exclusion of Mg stearate greatly increased 
speed of disintegration (p<0.001) as was expected, with the standard blend 
disintegrating in 75 s. In the absence of Mg stearate, no improvement in disintegration 
time was seen as a result of altered blending. In the presence of Mg stearate 
disintegration was slower when blending was altered, particularly when mannitol was 
added first. The effect of omission of Mg stearate on hardness was more complex, with 
a drop (p<0.05) seen with the standard blend, an increase (p<0.05) in hardness when 
mannitol was blended first and no change seen with MCC blended first. Blending order 
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had no impact on hardness when Mg stearate was included, however it did increase 
hardness in all cases in the absence of Mg stearate. 
The improvement in disintegration time without Mg stearate was as expected. Initial 
blending of flucloxacillin with mannitol slowed disintegration, possibly due to a drop in 
tablet wettability. A particle interaction or coating effect may have meant that MCC 
particles were more exposed, causing a drop in tablet wettability. This would also explain 
how when MCC was added first, tablets gave comparable disintegration times when Mg 
stearate was not present. Why this is not true when Mg stearate was present is unclear, 
but could be due to an attenuation of the wettability of mannitol at the tablet surface, due 
to interaction with Mg stearate. It is difficult to ascertain any interaction of Mg stearate 
with crospovidone, since crospovidone was added at the same stage in each blending 
variation. Finally, an increase in tablet hardness as a result of changing blending order, 
in the absence of Mg stearate is encouraging since when MCC was added first and ½ 
first, disintegration time did not differ to the standard blend. An increase in blending time 
could therefore conceivably be employed to improve tablet hardness, for example if 
compaction force was lowered in order to achieve more rapid disintegration.  
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  Disintegration time (s) Hardness (N) 
  Mean ± sd Significant? Mean ± sd Significant? 
1%
 M
g 
st
 Standard blend 144.33 ± 5.86  109.00 ± 7.33  
Mannitol first 243.67 ± 4.73 Yes**** 98.67 ± 2.45 No 
MCC first 167.00 ± 11.27 Yes* 110.07 ± 6.62 No 
      
N
o 
M
g 
st
 
Standard blend 75.00 ± 2.00  97.77 ± 4.05  
Mannitol first 105.67 ± 18.50 Yes* 112.83 ± 4.54 Yes** 
MCC first 80.67 ± 9.50 No 109.60 ± 0.46 Yes** 
MCC 1/2 first, 
1/2 last 85.67 ± 9.87 No 110.23 ± 2.27 Yes** 
 
  
Table 2.16 Disintegration time and hardness values, for tablets containing flucloxacillin 
sodium (27.25%), MCC (44.5%), mannitol (22.25%), crospovidone (5%) and Mg stearate 
(1%) with altered blending orders. Powders were compacted into tablets at a 
compression force of 1 ton with a dwell time of 6 s. Differences between blend variations 
and the standard blend were assessed and any significance reported (*p<0.05, **p<0.01, 
****p<0.0001, mean ± SD, n=3). 
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2.10 Conclusion 
Despite several formulation development steps flucloxacillin containing ODTs were not 
quite able to fulfil the requirements of rapid disintegration (<30 s) whilst maintaining 
sufficient mechanical strength (>60 N), including low friability (<1%). Despite the benefits 
of mannitol, its tendency to fragment at low compression hinders the production of 
mechanically strong tablets with the concomitant problem of high friability. Investigating 
different disintegrants and disintegrant combinations revealed that crospovidone alone 
conveyed the most rapid disintegration. From initial placebo development, the inclusion 
of flucloxacillin retarded disintegration and lowering of the dose not only improved ODT 
properties but could allow for administration to paediatrics once formulation development 
is complete. A blend of MCC and mannitol at a ratio of 2:1 as major diluents was shown 
to be effective at lowering disintegration time within 3 min, whilst presenting good 
hardness values and friability below 1% for ODTs containing a 125 mg dose of 
flucloxacillin.  
A number of challenges in formulation development remain. For example, although not 
included, flucloxacillin sodium exhibited poor flow due to a bi-modal particle size 
distribution with a large proportion of fines (data not shown), which was overcome 
through use of granulated flucloxacillin sodium. Use of PEG as an alternative water-
soluble lubricant also showed some promise (data not shown) although it is likely that 
other well-established more water-soluble lubricants such as sodium stearyl fumerate 
would be more useful in further development. Use of a different grade of crospovidone, 
with a larger particle size, was also investigated as a means to improve disintegration 
and showed early promise (data not shown). Taste-masking remains a major problem 
and despite preliminary work to explore solutions for this (not included) this requires 
attention. Further development should include alteration of ODT shape, from a round flat 
faced geometry to a shape with softer edges, such as caplet or lozenge forms, in order 
to address the high friability across the majority of formulations. 
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3.1 Introduction 
Historically sugar coating was the primary form of tablet coating, derived from technology 
used in the confectionary industry and, although still used today, has been replaced 
largely by polymeric film coating processes [78]. This technique has the advantage of 
being able to control drug release, through careful selection of polymers and 
combinations of polymers, at varying thickness [98]. Additionally film coating using 
polymers constitutes a considerably lower increase in tablet weight, is single stage as 
opposed to multiple stage and is rapid in comparison to sugar coating [46]. Polymeric 
film coating is commonly employed for the design of drugs that disintegrate at target 
locations along the gastro-intestinal tract, for example, by optimising for enzymatic 
degradation [98].  
Polymeric films are most commonly applied through spray atomisation. Spray 
atomisation involves dissolving the polymer in a solvent and atomisation by passing the 
solution through a nozzle under pressure, to form fine droplets. There are three general 
equipment types for film coating by spray atomisation; these are standard coating pans, 
perforated coating pans and fluidised bed systems. Coating pans are composed of a 
metal drum rotated at a specified speed. Tablets are placed inside and hot air is blown 
over the tablet surface to dry. Perforated pan beds work much in the same way, however 
they allow for better air flow and more efficient drying. Fluidised bed spray coating 
involves suspending tablets in an airflow that is heated to aid drying.  Atomised solution 
is then sprayed onto the solution, either from above or below.  Fluidised bed spray 
coating is more efficient when compared to pan coating as tablets can be suspended 
and coated simultaneously. This technique is also more commonly used in the laboratory 
in comparison to pan coating [219, 220] 
During spraying droplets impinge and disperse across the tablet surface, forming a film 
after solvent evaporation [65]. The rate of solvent evaporation is critical in film formation 
and thus both the selection of solvent and the processing conditions are important 
considerations. Furthermore, the wettability of the solvent-polymer droplets on the tablet 
surface is dependent on the wettability of the droplet itself and also the tablet; therefore 
the surface properties of the tablet must also be considered[46, 78]. Traditionally highly 
volatile organic solvents were preferred, however mammalian, human and 
ecotoxicological data has shifted the focus towards aqueous-based suspension systems. 
This is important as solvents commonly constitute 80-90% of the total mass in batch 
processes [69]. As a result, various polymeric film forming agents are available 
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commercially that are suitable for suspension in water. Furthermore, a significant 
problem with the use of organic solvents is the increase in viscosity with increased 
polymer concentration which limits spreadability and thus limits the concentration of 
polymer that can be used. Aqueous based systems eliminate spreading problems when 
solvents rapidly evaporate and relative polymer concentration increases. The equipment 
used for aqueous based polymeric dispersion is the same as that used with organic 
solvents and only the processing parameters require modification [78].  
Film coating of orally disintegrating tablets (ODTs) has not been explored in the literature 
and could offer advantages for conventional directly compressed tablets. Preliminary 
studies investigating mannitol based ODTs identified tablets that displayed rapid 
disintegration (<30 s) and good hardness and tensile strength values, although suffered 
from high friability. It was believed that this issue could potentially be addressed by 
addition of a film coat. It is has been shown that addition of a film coat can increase tablet 
hardness [221, 222]. Another important consideration for ODTs is taste, as disintegration 
of the tablet in the mouth exposes the API to the patient’s taste buds. Due to 
flucloxacillin’s unpleasant bitter taste sweeteners and flavours are incorporated into 
available dosage forms.  
Mannitol based ODTs containing crospovidone as a disintegrant were used as a model 
for development of a film coating that could provide the benefits of improved friability, 
hardness and tensile strength. Despite the addition of an outer layer to the tablet it was 
paramount that speed of disintegration would not be adversely affected. 
Kollicoat IR, BASF, Germany, consists of a polyvinyl alcohol-polyethylene glycol graft 
copolymer (PVA-PEG graft copolymer), in a 3:1 ratio which has been designed for use 
as an instant release film coating. It is soluble in water and reduces water surface 
tension, which is important for aqueous based solutions since it allows for easy spraying 
and facilitates good tablet surface wetting. Kollicoat IR rapidly disintegrates in water and 
shows excellent flexibility, which negates the need for addition of plasticisers [223]. The 
film coat claims to have many favourable qualities when compared to more traditional 
water soluble polymers such as hydroxypropyl methyl cellulose (HPMC). In the context 
of rapid disintegration, inclusion of Kollicoat IR at even low concentrations has been 
shown to significantly improve drug release rates of very slow releasing ethylcellulose 
based coatings, by increasing the rate and extent of water uptake. In one study, in 
contrast to HPMC, addition of PVA-PEG to the ethycellulose based coating did not result 
in flocculation of the colloidal coating, resulting in consistent release rates [224].  
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Kollicoat IR was selected as a model film coat polymer for investigations into proof of 
concept for the application of a film coat to directly compressed ODTs. Preliminary work 
focussed on developing a protocol and process conditions that would produce a good 
uniform film coat whilst avoiding process complications such as poor adhesion and 
twinning.  
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3.2 Materials and Methods 
3.2.1 Materials 
Flucloxacillin sodium was purchased from Carbone Scientific (UK). D-mannitol, sodium 
lauryl sulphate (SLS), D-sorbitol, magnesium stearate, Tween 80, PEG 400, PEG 1000 
and eosin Y were purchased from Sigma-Aldrich (UK). Polyplasdone XL-10 
(crospovidone) was obtained from ISP (Switzerland). Kollicoat IR (polyethylene glycol 
polyvinyl alcohol copolymer) was purchased from BASF (Germany). Tween 20 was 
purchased from Fischer BioReagents (UK). Avicel PH102 (MCC) was obtained from 
FMC Biopolymer (USA). Aerosil 200 Pharma (colloidal silicon dioxide) was obtained from 
Evonik Industries (Germany).  
 
3.2.2 Film Coating 
Kollicoat IR aqueous solutions at various concentrations (% w/w) were prepared by 
addition of powder to ultrapure water and left until fully dissolved using a magnetic stirrer 
for 30 mins at room temperature. Process parameters were determined through 
preliminary trials and are shown in Table 3.1. The same conditions were used for coating 
of all tablets unless otherwise stated. A preheating stage was included to enhance water 
evaporation from the tablet surface. The fan speed was kept lower for this stage to limit 
the extent of tablet attrition but at the same time still ensure uniform heating. Film coating 
was performed using a Caleva Process Solutions Mini Coater Drier 2 (Caleva, UK) 
fluidised bed spray coater. 
 
 
Parameter Value 
Preheat  
Air temperature (°C) 60 
Fan (m/sec) 10.00 
Table 3.1 Process conditions for tablet film coating using a fluidised bed spray coater. 
Tablet batch size of 12. 
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Time (min) 10 
  
Spraying  
Air temperature (°C) 60 
Spray air pressure (bar) 2.00 
Liquid flow rate (ml/min) 0.625 
Fan (m/sec) 15.00 
Time (min) 40 
  
Drying  
Air temperature (°C) 60 
Fan (m/sec) 15.00 
Time (min) 5 
 
3.2.3 Tablet Formation 
Direct compression of tablets (500 mg) at a compaction force of 10 kN (1 ton) or higher 
was performed using an Atlas T8 automatic press (SPECAC, UK). A manual uniaxial 
hydraulic press (SPECAC, UK) was used for production of tablets below a compaction 
force of 10 kN. A 13mm round, flat faced die was used for tablet production. All tablets 
were produced under ambient conditions and tablet characterisation was carried out 
immediately post compression 
 
3.2.4 Disintegration Time 
The disintegration time was measured in vitro using US pharmacopeia monograph ([701] 
disintegration). The disintegration apparatus used was an Erweka ZT3 disintegration 
bath (Erweka GmbH, Germany) using 800 ml distilled water maintained at 37˚C as 
disintegration media. Tablets were measured individually by placing in the basket rack 
and the time taken for the tablets to disintegrate without leaving any solid residue in the 
basket, recorded. Disintegration time was measured in triplicates at each compaction 
force. 
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3.2.5 Friability 
Tablet friability was determined on 6 tablets using a friabilator from J. Engelsmann AG 
(Germany). Tablets were placed inside the drum and rotated at 25 rpm for mins, for a 
total of 100 revolutions. Excess tablet dust that would contribute to tablet mass was 
removed pre and post testing. Friability was calculated and expressed as % tablet weight 
loss from initial tablet weight. 
 
3.2.6 Tablet Hardness Measurements 
Tablet hardness apparatus (Schleungier 4M, Switzerland) was used to measure the 
radial crushing strength (hardness) of tablets in triplicate. Hardness was recorded in 
Newtons (N).  
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3.3 Film Coating Mannitol Based ODTs 
The suitability of a polymeric film coating for an ODT was tested on mannitol based ODTs 
from previous studies for which there was existing data. Disintegration time, hardness 
and tablet friability were recorded for ODTs coated with increasing concentrations of 
Kollicoat IR. Additionally, the weight change in tablets pre and post coating was 
recorded, to monitor the success of the coating procedure and compare this to any 
changes in tablet characteristics. 
 
3.3.1 Materials and Methods 
Mannitol (94% w/w) based ODTs, consisting of a disintegrant crospovidone (5% w/w) 
and Mg stearate (1% w/w) as a lubricant and anti-adhesive were chosen as they had 
been previously studied and demonstrated rapid disintegration. ODTs were blended for 
5 mins, before addition of Mg stearate followed by further mixing for 1 min. Compression 
was performed at 3 tons and a dwell time of 6 s.  
 
3.3.2 Results 
3.3.2.1 Tablet Hardness 
A Kollicoat IR film coat improved tablet hardness at 20% and 25% aqueous solution. 
Initially tablet hardness (Figure 3.1) was compromised with the addition of Kollicoat IR, 
dropping to 88.8 ± 4.43 N at 5% solution (p<0.05), but rose linearly to an improved 
hardness when compared to controls (p<0.05), of around 115 N. Tablet hardness 
declined at the highest concentration of coat solution, to a level comparable to that of 
non-coated tablets. 
 
3.3.2.2 Disintegration Time 
Coating of tablets had no effect on disintegration time (Figure 3.2) at any Kollicoat IR 
concentration. All disintegration times were within a desired time of 30 s. 
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3.3.2.3 Friability 
Friability (Figure 3.3) vastly reduced with increase in concentration of film Kollicoat IR. 
Non-coated tablets displayed a weight loss of 1.46%, whereas at the highest 
concentration of Kollicoat IR, weight loss was only 0.04%. It is important to note that 
weight loss caused by tablet attrition in the fluidised bed environment will have occurred 
during the film coating process and as such total weight loss will have been higher than 
the values shown here.  
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Figure 3.1 Hardness (N) of ODTs film coated with increasing concentrations of 
Kollicoat IR solution. ODTs (500mg tablets) consisting of mannitol (94%), 
crospovidone (5%) and Mg stearate (1%) underwent direct compression at a 
compaction force of 3 tons and a dwell time of 6 s (mean ±SD, n=3, * P<0.05 
compared to non-coated) 
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Figure 3.2 Disintegration time (s) of ODTs film coated with increasing concentrations 
of Kollicoat IR solution. ODTs (500mg tablets) consisting of mannitol (94%), 
crospovidone (5%) and Mg stearate (1%) underwent direct compression at a 
compaction force of 3 tons and a dwell time of 6 s (mean ±SD, n=3). 
 
Figure 3.3 Friability (% weight loss) of ODTs film coated with increasing 
concentrations of Kollicoat IR solution. ODTs (500mg tablets) consisting of mannitol 
(94%), crospovidone (5%) and Mg stearate (1%) underwent direct compression at a 
compaction force of 3 tons and a dwell time of 6 s (mean, n=6). 
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3.3.2.4 Mass Changes 
To estimate the extent of tablet attrition and weight loss during coating, tablets were put 
through the film coat process using the same process conditions, in the absence of spray 
solution, to provide a ‘worst case’ tablet weight loss as a result of the process. The 
change in tablet weight post film coating is shown in Figure 3.4. Non-coated tablets 
demonstrated a weight loss of 1.97%; interestingly, the weight loss was even greater 
(2.26%) in tablets coated with 10% Kollicoat IR, possibly due to variation in weight loss 
and only a very small increase in weight due to the film coat. Alternatively, the weight 
loss and poor hardness at 10% could be as a result of tablet over-wetting which affected 
mechanical properties. From concentrations at and exceeding 15%, weight gain was 
observed in a stepwise manner with increased concentration, to a maximum increase of 
3.19% at 30% concentration. 
 
 
 
 
Figure 3.4 Mass change (%) of ODTs film coated with increasing concentrations of 
Kollicoat IR solution. ODTs (500mg tablets) consisting of mannitol (94%), 
crospovidone (5%) and Mg stearate (1%) underwent direct compression at a 
compaction force of 3 tons and a dwell time of 6 s (mean, n=12). 
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3.3.3 Discussion 
Application of Kollicoat IR as a film coating was shown to be beneficial in improving 
desirable characteristics for ODTs. At concentrations of 20% and 25% hardness 
improved and friability decreased significantly. Crucially, disintegration time was not 
impacted by the presence of the film coat. Kollicoat IR may therefore be suitable for use 
as a coating for ODTs, with the view of improving the mechanical characteristics of the 
tablet, whilst not impeding disintegration. This is complicated however, due to the tablet 
weight loss from attrition during fluidisation. Weight loss will likely be at less than the 2% 
reported here, however, since the coat is being continuously applied and therefore 
improvement of mechanical characteristics will evolve throughout the process. 
Nevertheless, the literature recommends very low tablet friability, of around 0.1%, for film 
coating [220]. In order to apply film coating to friable ODTs would thus require a change 
in approach. Rounded and spherical tablets are recognised as offering greater intra-
tablet coating uniformity [225, 226], whilst a more rounded geometry would likely reduce 
friability [227]. For these reasons, rounded tablet geometries are favoured for coating 
purposes.  
Since the addition of a film coat did not retard disintegration the possibility that a film 
coating could instead enhance disintegration was explored. Surfactants are widely used 
in the chemical industry and are often used as wetting agents. Wetting agents can be 
used to lower the surface tension at a liquid-solid interface, enhancing spreadability of 
the liquid and thus improving wettability at the tablet surface [228]. Improving tablet 
wetting is a popular approach for enhancement of disintegration [229, 230]; the addition 
of wetting agents to a film coat to increase tablet wettability was thus explored. 
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3.4 Improving Disintegration Time of Flucloxacillin ODTs with a Film coat 
The application of a Kollicoat IR film coat to flucloxacillin (125mg) ODTs was investigated 
to see the effect on tablet characteristics. A 20% (w/w) concentration solution was 
maintained from previous work with mannitol based placebo ODTs, based on favourable 
performance and good liquid flow during coating when compared to higher 
concentrations. The inclusion of a wetting agent to Kollicoat IR coatings, with the 
hypothesis that it may improve disintegration times by enhancing tablet surface wetting, 
was explored. A surfactant, sodium lauryl sulphate (2% w/w) was chosen as the wetting 
agent, due to its extensive inclusion in pharmaceutical dosage forms. Inclusion of SLS 
(2% w/w) into the tablet core was also investigated as a means to improve disintegration 
time.  
 
3.4.1 Materials and Methods 
The ODTs were composed of flucloxacillin sodium (27.25% w/w, 125 mg), mannitol 
(66.75% w/w), crospovidone (5% w/w) and Mg stearate (1% w/w) and were compressed 
at both 1 ton and 3 tons with a dwell time of 6 s. All excipients and API were blended for 
5 mins, with the exception of Mg stearate, which was blended for 1 min as a final blending 
stage. The film coating parameters were maintained as per Table 3.1. The tablets 
containing SLS were produced in the same way, however for these tablets, mannitol 
concentration was reduced to 64.75% to allow for 2% SLS. 
 
3.4.2 Results 
3.4.2.1 Disintegration Time 
Disintegration time (Figure 3.5) was not affected by the application of a 20% Kollicoat IR 
film coat. Addition of 2% SLS to the film coat for tablets compacted at 1 ton slightly 
reduced the disintegration time when compared to both the control and the 20% Kollicoat 
IR alone (p<0.05), with a time of 163.67 ± 4.93 s. Increasing compaction force retarded 
disintegration (p<0.001), with tablets compacted at 3 tons disintegrating around 90 s 
more slowly. Given the poor performance of tablets and coated tablets compacted at 3 
tons, addition of SLS at this compaction force was not explored. 
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3.4.2.2 Tablet Hardness 
Tablet hardness (Figure 3.6) was significantly higher when compaction force was 
increased to 3 tons (p<0.0001), with non-coated tablets displaying a hardness of 184.90 
± 4.42 N. Addition of a film coat at this force compromised hardness, with a reduction to 
138.97 ± 3.07 N (p<0.0001). No change in hardness was observed for coated tablets 
compacted at a force of 1 ton. Furthermore, no significant effect was seen with addition 
of 2% SLS to the film coat.  
 
3.4.2.3 Friability 
Tablet friability (Figure 3.7) was reduced with increased compaction force and in both 
cases presence of a film coating essentially negated weight loss, dropping to around 
0.001%, constituting chipping of the film coat itself. Addition of SLS had no impact on 
friability. 
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Figure 3.5 Disintegration time (s) of flucloxacillin (125mg) ODTs compacted at 1 ton 
and 3 tons. Tablets were coated with a 20% solution of Kollicoat IR with and without 
the surfactant SLS (2%). ODTs (500mg tablets) consisting of flucloxacillin sodium 
(27.25%), mannitol (66.75%), crospovidone (5%) and Mg stearate (1%) underwent 
direct compression with a dwell time of 6 s (mean ±SD, n=3). 
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Figure 3.6 Hardness (N) of flucloxacillin (125mg) ODTs compacted at 1 ton and 3 
tons. Tablets were coated with a 20% solution of Kollicoat IR with and without the 
surfactant SLS (2%) ODTs (500mg tablets) consisting of flucloxacillin sodium 
(27.25%), mannitol (66.75%), crospovidone (5%) and Mg stearate (1%) underwent 
direct compression with a dwell time of 6 s (mean ±SD, n=3). 
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3.4.2.4 Incorporation of SLS into the Tablet Core 
To assess any effect of inclusion of a wetting agent into the tablet core, SLS (2% w/w) 
was incorporated into the formulation at the expense of a 2% reduction in mannitol 
concentration. Table 3.2 shows the effects on disintegration time, hardness and friability 
of addition of the wetting agent SLS into the table core of flucloxacillin (125mg) tablets. 
Despite being aimed at improving disintegration time, SLS impeded disintegration by 25 
s. No effect was seen on tablet hardness, yet friability increased markedly to over 2%.  
 
 
 
 
Figure 3.7 Friability (% weight loss) flucloxacillin (125mg) ODTs compacted at 1 ton 
and 3 tons. Tablets were coated with a 20% solution of Kollicoat IR with and without 
the surfactant SLS (2%) ODTs (500mg tablets) consisting of flucloxacillin sodium 
(27.25%), mannitol (66.75%), crospovidone (5%) and Mg stearate (1%) underwent 
direct compression with a dwell time of 6 s (mean ±SD, n=6). 
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 Control 2% SLS  
 Mean SD Mean SD Significant? 
Disintegration Time 
(s) 182.33 5.69 207.33 6.43 Yes** 
Hardness (N) 78.10 1.99 73.97 5.23 No 
Friability (%) 0.75  2.08   
 
3.4.3 Discussion 
Addition of the wetting agent SLS to the Kollicoat IR film coat caused a slight increase in 
disintegration time. At 1 ton compression, SLS compromised the mechanical strength of 
film coated tablets when compared with uncoated tablets and similarly there was no 
change in friability. The subtle increase in hardness with film coating of mannitol based 
ODTs was not seen with tablets containing flucloxacillin, and in fact a decrease was seen 
in tablets compressed at 3 ton. Weakening of tablets compressed at higher force may 
be adequately explained due to changes in tablet surface characteristics such as 
roughness, porosity or wettability affecting interfacial bonding between the coating 
polymer and the tablet surface, resulting in compromised coating adhesion [222, 231]. 
The results hint at the possibility for improvement of mechanical properties and 
enhanced disintegration of an ODT through the application of a film coating. A wide 
variety of surfactants are used in oral dosage forms [232], which can be classified by 
their hydrophile-lipophile balance (HLB) [233]. Surfactants with higher HLB numbers 
(more hydrophilic) are more suitable as solubilising agents, whereas those with low HLB 
numbers function better as anti-foaming agents. HLB numbers in the range of 7-9 are 
indicative of good wetting and spreading agents and thus surfactants in this range hold 
potential for further development [46]. Surfactants in this range consisting primarily of 
Table 3.2 Disintegration time (s), hardness (N) and friability comparison between 
flucloxacillin (125mg) tablets (500mg), with (2% SLS) and without (control) SLS. ODTs 
(500mg tablets) consisting of flucloxacillin sodium (27.25%), mannitol, crospovidone 
(5%) and Mg stearate (1%) underwent direct compression at a compaction force of 1 ton 
and a dwell time of 6 s. SLS was included into the tablet core at the expense of a 2% 
reduction in mannitol concentration to 64.75% (mean ±SD, n=3). 
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fatty-acids such as polyethylene glycol (PEG), sorbitan laurate and lecithin, are generally 
well tolerated [234-237]. 
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3.5 Investigating Different Surfactants to Enhance Disintegration 
Previous work showed that film coating could be employed as a method for improving 
mechanical properties, namely hardness and friability. Addition of SLS (2%) to the film 
coat solution showed a small but significant decrease in disintegration time and therefore 
more surfactants were chosen to test their effect on disintegration. 
Micellar solubilisation is a commonly used technique to improve the solubility of poorly 
soluble drugs [238, 239]. Micelles form when surfactants reach a critical concentration, 
known as the critical micelle concentration (CMC). Due to this ability it was decided to 
include surfactants at, above and below their CMC, in order to determine if addition of 
surfactant in the film coat would also improve the solubility of a poorly soluble drug, such 
as ibuprofen. For many surfactants CMC values are often available from the literature or 
manufacturer. Commercial surfactants however contain surface active impurities that 
alter the CMC. The true CMC for the impure sample can be determined using the dye 
micellisation method [240]. At CMC hydrophobic dyes can become incorporated inside 
the hydrophobic centre of the micelle, which causes a shift in the wavelength maximum 
(λmax) of the dye [241], by which the CMC can be determined.  
Tween (polysorbate) is a commonly used non-ionic surfactant, consisting of partial fatty 
acid esters of sorbitol copolymerised with PEG. They are highly hydrophilic, being used 
widely as an emulsifier for oil-in-water preparations. So popular is their use that Tween 
80 is the most commonly used surfactant in parenteral preparations approved by the 
FDA. Polysorbate is regarded as generally non-toxic, however there have been some 
reports of hypersensitivity reactions when administered topically and intra-muscularly 
[158, 242].  PEG is classified as a plasticising agent, solvent, diluent and lubricant [158] 
and has also been reported to reduce the surface tension of water by acting as a 
surfactant [243], although this is not generally recognised. Due to their high 
hydrophilicity, PEGs are usually used in the manufacture of many commercial 
surfactants, typically PEG ethers, where they are coupled with hydrophobic molecules.   
PEGs have been employed as poor surfactants or cosurfactants on their own [244], 
particularly the lower weight PEGs such as PEG 400. Despite this however, CMC values 
are difficult to obtain from the literature, with only scattered reports [245, 246], casting 
doubt on whether or not micellar formation occurs. Here CMC value determination was 
attempted for a lower weight PEG (400) and a higher weight PEG (8000). In addition to 
its wetting ability and high hydrophilicity, PEG is employed in film coats as a polishing 
material and has been shown to increase film coat water permeability [158]. 
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3.5.1 Materials and Methods 
3.5.1.1 ODT Preparation 
Tablets (500 mg) consisting of (w/w) MCC (47%), mannitol (23.5%), D-sorbitol (23.5%), 
crospovidone (4%), silicon dioxide (1%) and Mg stearate (1%) were produced by direct 
compression. All excipients were blended for 5 mins and then Mg stearate was added 
and the powder mixture blended for a further min. Tablets were compacted at a force of 
30 kN and a dwell time of 6 s. This formulation was selected as it would show sufficiently 
slow disintegration time to highlight any effect of addition of surfactant to the film coat 
solution. 
 
3.5.1.2 CMC Determination by Dye Micellisation Method 
CMC was determined by the method used by Patist, Bhagwat [241]. A 0.019mM eosin 
Y dye solution was made using ultrapure water. Using this, a range of solutions from 
0.002mM to 10mM for Tweens and 0.004mM to 50mM for PEGs were prepared and 
added in triplicate to a 96-well plate and left overnight, protected from direct light. Eosin 
Y in water absorbs maximally at 518nm and shifts to a maximum absorbance of 542nm 
when within micelles. By plotting dye absorbance as a function of surfactant 
concentration and then extrapolating the linear portion of the curve, the intercept with the 
absorbance at zero surfactant concentration yields the CMC. As such, absorbance 
spectra were read at 542nm at 25°C using a Multiskan GO Microplate 
Spectrophotometer (UK).  
 
 
3.5.1.3 Preparation of Coating Solution 
Kollicoat IR (20% w/w) coating solutions were used. Tweens were added at 
concentrations of ½ CMC, CMC and 10x the calculated CMC values. PEGs were added 
at concentrations of 0.02mM, 0.04mM and 0.4mM, to mimic the concentration range of 
Tweens. 
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3.5.2 Results 
3.5.2.1 CMC Determination 
CMC determination was carried out for Tween 20 and 80 and PEG 400 and 8000. The 
results for Tween 20 and Tween 80 are shown in Figure 3.8 and Figure 3.9 respectively. 
PEG 400 and PEG 8000 are shown in Figure 3.10 and Figure 3.11. For the Tween 
surfactants it was possible to calculate the CMC values, and these correlated well with 
the reported values by Patist, Bhagwat [241]. The PEG was not successful however; the 
PEG 8000 seemed to indicate micelle formation, however the curve did not plateau and 
therefore it was not possible to extrapolate from this a reasonable estimation of the CMC. 
Similarly, PEG 400 did show increased absorbance with increased concentration, 
however this was less defined and was not in a classic sigmoidal manner. As a result, it 
was decided to include the PEG at levels similar to that of Tween, in which the CMC 
could be calculated. Although it was not possible to state that PEGs would be included 
below, at and above CMC, including PEG in concentrations similar to that of Tween 
would allow us to compare the surfactants ability to affect disintegration time.  The 
surfactant Span 20 was also tested (not shown here), although this gave similar results 
to PEG 8000 and was discontinued. Despite the failure of CMC determination for PEGs, 
the results for PEG 8000 in particular suggest it does form micelles and thus may warrant 
classification as a surfactant, despite lacklustre support for this in the literature. 
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Figure 3.8 CMC determination of Tween 20 (0.044mM) by dye micellisation method 
(absorbance at 542nm, 25°C). Eosin Y in water in absence of surfactant (0.019mM) 
is displayed by a dashed line). 
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Figure 3.9 CMC determination of Tween 80 (0.026mM) by dye micellisation method 
(absorbance at 542nm, 25°C). Eosin Y in water in absence of surfactant (0.019mM) 
is displayed by a dashed line). 
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Figure 3.10 CMC determination of PEG 400 by dye micellisation method (absorbance 
at 542nm, 25°C). Eosin Y in water in absence of surfactant (0.019mM) is displayed 
by a dashed line). 
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Figure 3.11 CMC determination of PEG 8000 by dye micellisation method 
(absorbance at 542nm, 25°C). Eosin Y in water in absence of surfactant (0.019mM) 
is displayed by a dashed line). 
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3.5.2.2 Surfactant Incorporation 
Tablets coated with Kollicoat IR and a range of surfactants were tested for disintegration 
time and hardness. The results in Figure 3.12 do not show any decrease in disintegration 
time for any of the coated tablets when compared to the non-coated, with the majority 
showing that coating slowed disintegration. Only PEG 8000 and Tween 80 showed no 
change in disintegration time, at concentrations of 0.04 and 0.4mM, and ½ CMC and 10x 
CMC, respectively.  
Hardness values for coated and non-coated tablets are shown in Figure 3.13. Addition 
of a coat had varying effects on tablet hardness, with some coats showing an increase 
in hardness and others a decrease; only Tween 80 at ½ and 10x CMC showed no 
significant difference compared to non-coated tablets. No obvious pattern in the data 
could be discerned. The greatest hardness was shown by tablets coated with Kollicoat 
IR and PEG 400 at 0.4mM, which showed an increase in hardness of 16.3%; Kollicoat 
IR alone showed a hardness increase of 9.2%. Similar increases in tablet hardness have 
been reported with coating of tablets with a hydroxypropyl methylcellulose coating 
formulation containing PEG 400 as a plasticiser and SLS as a surfactant [247]. It is 
unclear as to the effect of added surfactant from the results, although it is further 
suggested here that application of a film coat can enhance tablet hardness. 
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Figure 3.12 Disintegration time for film coated tablets (Kollicoat IR, 20% w/w) 
containing different surfactants at a range of concentrations. Tablets consisting of 
MCC (47%), mannitol (23.5%), D-sorbitol (23.5%), crospovidone (4%), silicon dioxide 
(1%) and magnesium stearate (1%) were produced by direct compression at 3 tons, 
6 s dwell time (mean ±SD, n=3). 
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3.5.3 Discussion 
CMC determination of PEG 400 and 8000 was unsuccessful, although it did suggest that 
PEG does show some surfactant behaviour. PEG 8000 in particular appeared to indicate 
micelle formation, although this does not plateau at such low concentrations. None of 
the results obtained show an improvement in disintegration time with addition of a 
surfactant, and in fact a marked increase in disintegration time was often observed. Since 
the success of ODTs often depends on a balance between disintegration speed and 
acceptable mechanical properties (including friability), even a small enhancement of 
tablet hardness (a maximum here of 16.3%) could make the difference between pass or 
failure.  
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Figure 3.13 Hardness for film coated tablets (Kollicoat IR, 20% w/w) containing 
different surfactants at a range of concentrations. Tablets consisting of MCC (47%), 
mannitol (23.5%), D-sorbitol (23.5%), crospovidone (4%), silicon dioxide (1%) and 
magnesium stearate (1%) were produced by direct compression at 3 tons, 6 s dwell 
time (mean ±SD, n=3). 
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3.6 Bi-layer Coating of Tablet Cores 
Coating of tablet cores using Kollicoat IR combined with a surfactant had a mixed impact 
on disintegration time and hardness. The failure of surfactant to enhance disintegration 
may be due to its low concentration compared to, and interaction with, the coating 
polymer. As such, it was decided to segregate the coating polymer and surfactant by 
applying them as distinct coating layers (Figure 3.14). A surfactant coating solution, 
consisting of PEG as a film forming agent and plasticiser and Tween 80 as a surfactant 
was applied as a single discrete layer. A separate layer consisting of Kollicoat IR was 
also applied. Each film coat layer was tested as both an external layer and an internal 
layer. In addition, as an alternative to a surfactant coating, another PEG-based coating 
containing starch as a disintegrant was also tested. It was believed that swelling of starch 
in contact with water would aid in breaking of the film coat. Furthermore, combination of 
Tween 80 with starch as a single layer was also investigated. Film coating was applied 
to both hard tablet cores and weaker tablet cores. 
 
3.6.1 Materials and Methods 
Hard tablet cores consisting of (w/w) MCC (47%), mannitol (23.5%), D-sorbitol (23.5%), 
crospovidone (Kollidon CL, 4%), silicon dioxide (1%) and Mg stearate (1%) were 
produced by direct compression at 3 tons, 6 s dwell time. Weak cores consisting of 
Pearlitol Flash (99.6% w/w) and Mg stearate (0.4% w/w) were produced by direct 
compression at 1.6 ton, 6 s dwell time. Film coats containing a surfactant, a disintegrant 
or a combination of both were formed using PEG-8000 (10% w/w) as a film forming agent 
and plasticiser. The surfactant Tween 80 was included at 0.5% w/w and starch 1500 was 
included at 5% w/w as a disintegrant. The different film coat formulations are shown in  
  C1 C2 C3 C4 C5 C6 C7 C8 C9 
In
ne
r l
ay
er
 
Kollicoat IR (20% w/w)   ✓   ✓   ✓ 
Tween 80 (0.5% w/w) ✓ ✓     ✓ ✓  
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 Table 3.3. 
 
 
Starch 1500 (5% w/w)    ✓ ✓  ✓ ✓  
           
O
ut
er
 la
ye
r Kollicoat IR (20% w/w)  ✓   ✓   ✓  
Tween 80 (0.5% w/w)   ✓      ✓ 
Starch 1500 (5% w/w)      ✓   ✓ 
  C1 C2 C3 C4 C5 C6 C7 C8 C9 
In
ne
r l
ay
er
 Kollicoat IR (20% w/w)   ✓   ✓   ✓ 
Tween 80 (0.5% w/w) ✓ ✓     ✓ ✓  
Starch 1500 (5% w/w)    ✓ ✓  ✓ ✓  
           
O
ut
er
 la
ye
r Kollicoat IR (20% w/w)  ✓   ✓   ✓  
Tween 80 (0.5% w/w)   ✓      ✓ 
Starch 1500 (5% w/w)      ✓   ✓ 
 Table 3.3 Different film coat formulations C1-9 (coating 1-9), described as either an inner 
layer or an outer layer. Tween 80 and starch 1500 are in a 10% w/w PEG 8000 aq 
solution. 
 
Figure 3.14 Schematic of a bilayer coating (shaded regions) around a tablet core 
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3.6.2 Results and Discussion 
3.6.2.1 Coating of Hard Tablet Cores 
Hard-core coated tablets were tested for disintegration time and hardness, Figure 3.15 
and Figure 3.16, respectively. Disintegration was slowed by coating with Kollicoat IR and 
no improvement was seen with C1-C9, with C6, C7 and C8 demonstrating significantly 
slower disintegration time (P<0.05). Tablet hardness was improved by coating with 
Kollicoat IR alone, showing an increase from 305.07 ± 1.60 to 333.10 ± 6.13 N when 
compared with the uncoated tablets. Significant decreases in tablet hardness were seen 
with all other film coats, with the exception of C2. 
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Figure 3.15 Disintegration time of hard tablet cores coated with a surfactant, a 
disintegrant or a surfactant and a disintegrant, with or without an additional Kollicoat 
IR (20% w/w) layer. Tablets consisting of MCC (47%), mannitol (23.5%), D-sorbitol 
(23.5%), crospovidone (4%), silicon dioxide (1%) and magnesium stearate (1%) were 
produced by direct compression at 3 tons, 6 s dwell time (mean ±SD, n=3). 
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Figure 3.16 Hardness of hard tablet cores coated with a surfactant, a disintegrant or 
a surfactant and a disintegrant, with or without an additional Kollicoat IR (20% w/w) 
layer. Tablets consisting of MCC (47%), mannitol (23.5%), D-sorbitol (23.5%), 
crospovidone (4%), silicon dioxide (1%) and magnesium stearate (1%) were 
produced by direct compression at 3 tons, 6 s dwell time (mean ±SD, n=3, ** P<0.01 
compared to non-coated) 
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3.6.2.2 Coating of Weak Tablet Cores 
The addition of a surfactant layer alone and also as an inner layer with Kollicoat IR as 
an outer layer (C1 and C2, respectively) appeared to lower disintegration time (Figure 
3.17) by around 5 s (15%) when compared to non-coated control, although this was not 
significant (P>0.05). This was however significant when compared to coated controls. 
When Kollicoat IR was applied as an inner layer, disintegration time rose. Applying 
coating layers consisting of disintegrant, surfactant or a combination of disintegrant and 
surfactant had no beneficial effect on disintegration time and in general slowed 
disintegration. C2 and C6 (Kollicoat IR containing coats) show decreased disintegration 
time when compared to Kollicoat IR alone.  
Hardness values (Figure 3.18) did not demonstrate the same variability as disintegration 
times. No changes in hardness were seen with any of the film coated tablets.  
 
  
Film Coat
D
is
in
te
gr
at
io
n 
Ti
m
e 
(s
)
No
n-C
oa
ted
Ko
llic
oa
t 2
0% C1 C2 C3 C4 C5 C6 C7 C8 C9
0
20
40
60
80
Surfactant
Disintegrant
Surfactant +
Disintegrant
Coating
 
Figure 3.17 Disintegration time of soft tablet cores coated with a surfactant, a 
disintegrant or a surfactant and a disintegrant, with or without an additional Kollicoat 
IR (20% w/w) layer. Tablets consisting of Pearlitol Flash (99.6%) and magnesium 
stearate (0.4%) were produced by direct compression at 1.6 ton, 6 s dwell time (mean 
±SD, n=3). 
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3.6.3 Discussion 
Bilayer coating was not successful in enhancing disintegration compared to non-coated 
controls. When comparing to coated controls however, improvements were seen in 
disintegration time to the detriment of hardness (with hard cores), and improvements in 
disintegration and hardness values in some weak cores. Despite no improvement in 
disintegration compared to non-coated cores, several variations of bilayer coatings were 
able to show similar disintegration times, whilst simultaneously not compromising 
hardness. Furthermore, more favourable results were seen with weak cores, potentially 
due to greater porosity and thus wettability through capillary action. Weak cores however 
would ideally require a specialised coating that improved both disintegration time and 
mechanical properties.   
Despite not being demonstrated here, based on previous work it was hypothesised that 
improvement of tablet hardness by applying Kollicoat IR as a film coat could be employed 
for weak tablet cores. Coating of weak cores would be suitable for APIs that have a poor 
compactibility profile and thus form weak compacts and for ODTs, since these are 
inherently weak due the necessity for rapid disintegration. The problem with this however 
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Figure 3.18 Hardness of soft tablet cores coated with a surfactant, a disintegrant or a 
surfactant and a disintegrant, with or without an additional Kollicoat IR (20% w/w) 
layer. Tablets consisting of Pearlitol Flash (99.6%) and magnesium stearate (0.4%) 
were produced by direct compression at 1.6 ton, 6 s dwell time (mean ±SD, n=3). 
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is that coating through conventional techniques requires tablets with very low friability 
due to the high contact process.  
  
Chapter 3 – Film Coating of Directly Compressed ODTs 
163 
3.7 Stationary Film Coating: A Novel Approach for Application of Polymeric Film 
Coatings to Weak Cores 
Poorly compactable drugs form weak compacts and suffer from undesirable mechanical 
properties [248, 249]. Similarly, ODTs often also display poor mechanical properties due 
to their requirement for rapid disintegration in the mouth [250]. To produce an ODT that 
simultaneously displays rapid disintegration and good mechanical strength is a 
significant challenge. 
The two main techniques for application of a polymeric film coat, fluidised bed and pan 
coating, require robust tablets, with friability not exceeding 0.3% and ideally below 0.1% 
[220]. Thus, coating of weak cores to improve mechanical strength is not applicable using 
these techniques. To avoid substantial weight loss through fluidisation a novel approach 
for stationary film coating of weak cores was theorised. This would involve the tablet to 
be remain stationery during the coating process so that contact with surfaces within the 
coating chamber and other tablets is eliminated. 
 
3.7.1 Materials and Methods 
3.7.1.1 ODT Preparation and Coating 
Aqueous solutions of Kollicoat IR (20% w/w) were used in the developmental stage. 
Weak cores consisting of 99% (w/w) Pearlitol Flash and 1% (w/w) Mg stearate were used 
for coating. Total tablet weight was 500 mg and tablets were directly compressed at 1 
ton for 6 s. The fluidised bed coater was modified for stationary coating of tablets. Film 
coat solution was pumped at a low rate of 2 rpm or a high rate of 4 rpm, where stated. 
 
3.7.1.2 Confocal Microscopy 
Confocal microscopy was performed on a CLSM TCS SP5 II System (Leica 
Microsystems GMBH, UK) using a 10x dry objective. Riboflavin monophosphate sodium 
was used as a fluorescent dye (0.5% w/w) in the film coat solution, as described by 
Ruotsalainen, Heinämäki [251] and scanned at a wavelength of 458 nm. Maximum 
projection images were used to analyse the surface morphology based on the intensity 
of the fluorescence of pixels within each plane. Maximum projection images were also 
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rotated to provide a transverse view of the film coating to reveal film coat thickness, the 
morphology of the outer coating surface and also the tablet-core interface. 
 
3.7.2 Development Pathway 
In fluidised bed systems coating solution is sprayed from above onto tablets using an 
atomisation nozzle, whilst heated air from below the tablet bed suspends and dries the 
tablets within the coating chamber. For stationary coating, weak cores were initially 
tested on a fixed, perforated platform (Figure 3.19) that was inserted inside the 
fluidisation chamber. Hardness values for these tablets were 57.43 ± 16.26 N coated, 
around a 70% increase when compared to uncoated tablets which displayed hardness 
of 34.19 ± 3.20 N. 
Despite a considerable increase in hardness values, the data showed high variance. 
Furthermore, quality of the film coat was very poor, with extensive peeling of the film coat 
from a high proportion of tablets which was attributed to tablet over-wetting [252]. 
Another significant issue was scattering of tablets due to the high pressure atomising air 
from above (tablets had to be contained within a ring), meaning that drying was impeded. 
As a result of over wetting and peeling, the successful yield was low. 
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It was concluded that incomplete drying of tablets during coating had led to over wetting. 
Both the heat inside the chamber and the air flow over the tablets are important for 
efficient water evaporation. To improve this, tablets were held in place by vacuum so that 
a strong air flow over tablets could be applied without the tablets scattering. Tablets were 
placed on top of a new perforated platform within the coating chamber and held in place 
by vacuum (Figure 3.20). Numerous trials with this modified setup were necessary for 
optimisation of the process and process parameters. Although improvements in coating 
quality were seen, the yield remained low due to poor adhesion of the coat to the tablet 
surface and subsequent peeling of the coat from the tablet. This was attributed to the 
heated air from below flowing around the inner cone and not over the tablet surface. 
 
 
Figure 3.19 Schematic of modifications made to the film coater. A perforated platform 
was placed within the coating chamber so that the tablets would be stationary during 
coating. Heated air flow is shown in red and film coat solution spray is shown in blue. 
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Through modification of the coating chamber it was possible to redirect the air flow 
(Figure 3.21) over the tablet surface, instead of directly escaping from the top of the 
coating chamber, to improve drying. This modification bore an immediate improvement 
in film coat adhesion and a greater yield. Several runs optimising the process parameters 
saw improvements in hardness to around 55 N. Addition of a curing step (45C overnight) 
increased tablet hardness as high as 66.65 ± 10.22 N. The addition of extra heated air 
from above was also tested, showing similar hardness values of 62.58 ± 8.66 N. Through 
the modification of a generic fluidised bed system, hardness values of coated tablets 
were effectively doubled (from 34.19 ± 3.20 N for uncoated tablets). 
 
 
Figure 3.20 Schematic of modifications made to the film coater. A separate funnel 
with a perforated platform was placed inside the coating chamber. This was attached 
to a vacuum to hold the tablets fixed in place during coating. Heated air flow is shown 
in red and film coat solution spray is shown in blue. 
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The ability of this modified system was tested on model formulations containing a poorly 
compressible and compactable drug, metformin HCl [253, 254] and a drug that displays 
good compressibility and compactability and poor water solubility, ibuprofen [255, 256]. 
The tablets (500 mg) consisted of 10-50% API, 49-89% Pearlitol Flash and 1% Mg 
stearate w/w. Tablets (500 mg) containing a flucloxacillin sodium dose of 68 mg 
(equivalent to 62.5 mg Flucloxacillin), 85.4% Pearlitol Flash and 1% Mg stearate were 
also coated and tested.  The results for hardness are displayed in Figure 3.22 and Figure 
3.23. 
  
 
Figure 3.21 Schematic of modifications made to the film coater. The opening to the 
top of the chamber was modified to redirect air flow back towards the tablet platform. 
Heated air flow is shown in red and film coat solution spray is shown in blue. 
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Figure 3.23 Hardness values for metformin HCl tablets at varying concentrations (% 
w/w) before and after stationary coating with 20% w/w Kollicoat IR. Tablets (500 mg) 
consisting of API, 1% Mg stearate and Pealitol Flash as a diluent were produced by 
direct compression, 1 ton, 6 s dwell time (n=3, mean ± sd). 
 
Figure 3.22 Hardness values for ibuprofen tablets at varying concentrations (% w/w) 
before and after stationary coating with 20% w/w Kollicoat IR. Tablets (500 mg) 
consisting of API, 1% Mg stearate and Pealitol Flash as a diluent were produced by 
direct compression, 1 ton, 6 s dwell time (n=3, mean ± sd). 
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Ibuprofen tablets showed substantial increases (p<0.001) in hardness after coating, 
rising to as high as 107.90 ± 8.00 N for 50% ibuprofen coated tablets. An increase in 
hardness of coated metformin tablets was only present at 50% metformin concentration. 
The more modest effect seen with metformin tablets may be due to the soft cores being 
more susceptible to over wetting when compared to the stronger ibuprofen cores and 
given metformin’s high water solubility [257], a problem that may be overcome by 
improved drying efficiency. Nevertheless, the results from this small study serve as a 
convincing proof of concept.  
For the flucloxacillin tablets, hardness increased by 23% from 66.3 ± 7.48 N to 81.56 ± 
7.96 N. Both the coated and uncoated ODTs disintegrated within 2 mins 41 s, which is 
within the European Pharmacopeial limit of 3 mins [34]. Actual disintegration time is 
anticipated to be shorter as the USP test does not take into account the physiological 
conditions of the mouth [258]. 
 
3.7.3 Confocal Laser Scanning Microscopy 
Confocal Laser Scanning Microscopy (CLSM) was employed to analyse the coating 
surface characteristics, coating thickness and tablet-coating interface. Several variations 
of tablet/coating were used in order to determine the effect of the process conditions, 
tablet characteristics and the stationary coating method. Soft cores and hard cores were 
coated for 40 min using the stationary method at a low pump rate to ensure a smaller 
droplet size for efficient drying and smooth coating surface (see chapter 4). Tablets 
coated using the stationary method were flipped half way through the coating period for 
coverage on both faces. Hard cores were coated using conventional fluidisation, one set 
at the regular pump rate for 40 mins whilst the other was coated at the same low pump 
rate conditions, but required coating for 90 mins for sufficient thickness. Individual 
images of the top face of the coated tablets were taken at sequential planes of focus to 
provide a non-invasive 3-D representation of the film coating. These images were 
compressed into a single maximum projection image (Figure 3.24). The images taken at 
multiple planes also allowed for 3-D projection of the surface based on the intensity of 
the fluorescence of pixels within each plane (Figure 3.25), allowing analysis of the 
surface morphology of the film coat. Maximum projection images were also rotated to 
provide a transverse view of the coating (Figure 3.26), similar to a cross-section, allowing 
comparison of the thickness of the film coating, the morphology of the outer coating 
surface and also the tablet-core interface. 
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Figure 3.24 Maximum projections of the top surface of fluorescently coated tablets, 
providing information on the roughness and uniformity of the coating. Film coat 
consisting of Kollicoat IR 20% w/w and riboflavin 5’-monophosphate sodium 0.5% 
w/w as a fluorescent dye. Hard fluidised tablets coated at a higher pump rate (A), 
hard fluidised tablets coated at a low pump rate (B), hard stationary tablets (C) and 
weak stationary tablets (D) coated at a low pump rate. 
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Figure 3.25 3D CLSM image showing fluorescence intensity at each image layer, 
providing a visual representation of surface morphology. Film coat consisting of 
Kollicoat IR 20% w/w and riboflavin 5’-monophosphate sodium 0.5% w/w as a 
fluorescent dye. Hard fluidised tablets coated at a higher pump rate (A), hard fluidised 
tablets coated at a low pump rate (B), hard stationary tablets (C) and weak stationary 
tablets (D) coated at a low pump rate. 
Chapter 3 – Film Coating of Directly Compressed ODTs 
172 
 
A clear difference can be seen between the film coats produced by fluidisation and those 
produced by stationary film coating. Figure 3.24 and Figure 3.25 suggest that the 
fluidised coats have a rougher surface. The fluidised coats also appear to have a less 
complete and homogenous covering, with many dark patches apparent on the fluidised 
tablets indicating pores or a lack of coating coverage. It was necessary to coat the hard 
fluidised tablets at the lower pump rate for significantly longer (90 mins, as opposed to 
40 mins) in order to produce a film with adequate thickness. At the lower pump rate, 
stationary tablets are sat within the plume of the spray, receiving a constant exposure to 
the film coat solution. When this low spray rate is applied to the fluidised environment, 
contact between the tablet and the coating solution is much less frequent. Despite more 
than doubling the coating time for the fluidised tablets at the low pump rate, the thickness 
was only roughly half that of the stationary (Figure 3.26), at around 50 µm compared to 
100-110 µm, respectively, suggesting that the novel stationary method can produce a 
thicker coating in a shorter period of time. If accurate, the reduction in both financial and 
time costs could be substantial.  
Figure 3.26 Transverse view of a maximum projection image, showing coating 
thickness, the morphology of the tablet surface (top) and the coating-core interface 
(bottom). Film coat consisting of Kollicoat IR 20% w/w and riboflavin 5’-
monophosphate sodium 0.5% w/w as a fluorescent dye. Hard fluidised tablets coated 
at a higher pump rate (A), hard fluidised tablets coated at a low pump rate (B), hard 
stationary tablets (C) and weak stationary tablets (D) coated at a low pump rate. 
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One concern over the stationary coating method, visible in Figure 3.26, is the 
unevenness of the tablet-core interface when compared to the smooth tablet-core 
interface of the fluidised tablets. This can likely be attributed to over wetting of the tablet 
surface and subsequent leaching of the coating solution into the tablet, or local 
disintegration at the tablet surface. Over wetting may also result in poor adhesion of the 
film coat solution to the tablet surface and pore formation between the tablet core and 
the coat. In either case, avoidance of over wetting through improving drying would likely 
provide insight into the root of this problem and may result in a smooth coating-core 
interface. 
 
3.7.4 Discussion 
Stationary coating provides a novel technique to improve the mechanical characteristics 
of weak cores and could aid in the development of ODTs and solid dosage forms of 
poorly compressible and compactable drugs. The evidence here suggests that coating 
in this way may also improve the quality and uniformity of the film coating.  This method 
may also benefit from quicker coating times, thus saving time and reducing cost. There 
are of course limitations to this novel approach that demand attention, namely the 
requirement to manually flip the tablets during the coating process to coat both faces. 
Similarly, although tablet edges were coated the quality and consistency of this was not 
investigated here. To resolve both of these issues may require a radical new approach 
to provide even coating of stationary dosage forms; conversely, this may also be 
achieved through simply using tablets of a more rounded geometry, coupled with 
enhancing the spreadability of the coating polymer solution. Furthermore, problems likely 
resulting from over wetting would necessitate improved drying. With the potential various 
benefits and despite the limitations described here, as a proof of concept, stationary film 
coating was able to impart substantial mechanical strength onto weak tablet cores, a feat 
otherwise not possible with conventional coating methods due to the high tablet attrition 
they cause. 
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3.8 Conclusion 
The ability to improve the mechanical strength of tablets, including both crushing strength 
and friability, was demonstrated by application of an instant release film coating. The 
effect on disintegration time with incorporation of other excipients into the film coat, 
namely surfactants and disintegrants, in either a single layer or bilayer was inconclusive. 
Regardless of this however, it was shown that a coating could be applied to a tablet 
without hindering either disintegration or hardness, whilst offering the various 
advantages of a coating, significantly in this case, the reduction of tablet friability to a 
negligible level. The limitation of weak cores of poorly compactable drugs to lose 
substantial weight through the fluidised bed coating process was addressed by the 
development of a novel stationery coating technique. Modification of the existing fluidised 
bed apparatus through use of a vacuum system to hold the tablets in place and 
redirection of the air flow inside the coating chamber overcame the complications of 
tablet scattering and over-wetting, respectively. Furthermore, weak tablets containing 
poorly compactable drugs coated using this technique followed by a curing stage 
displayed enhanced hardness and a satisfactory finish and thus formed a proof of 
concept for this novel approach. Several limitations for this new technique were prevalent 
and require addressing, most importantly the ability to rotate the tablets automatically 
during the process to ensure complete and uniform coating and further improvement of 
the drying process. Despite these concerns, the potential to improve the mechanical 
properties of weak tablets by stationary coating is, prior to this work, unexplored and 
could open up new possibilities in solid oral dosage form development.  
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4.1 Introduction 
The atomisation of a liquid stream into a fine spray is utilised in a variety of industries for 
a range of applications, including the pharmaceutical industry, where it is most notably 
employed for tablet film coating [79, 259]. During the atomisation process individual 
droplets evolve from a liquid stream with a concurrent increase in surface area to mass 
ratio of the liquid [260]. In principle, for atomisation to occur it is necessary to generate 
a high relative velocity between the liquid stream and the surrounding air or gas [261, 
262]. The ratio of the flow rates of the atomising air and the liquid stream, known as the 
atomisation to liquid flow ratio (ALM), is considered an important parameter in 
determining droplet size [263, 264]. Various reports highlight the dependency of droplet 
size on both atomisation pressure and liquid flow rate (pump rate) [265, 266] and both 
have been recognised as critical process parameters (CPPs) for coating processes 
[267]. Viscosity is also known to significantly influence droplet size during atomisation 
[268, 269], with higher viscosity liquids forming larger droplets during atomisation.  
Twin-fluid atomisation is a complex and multivariable process that, despite significant 
efforts, is still not well understood and remains difficult to predict [268]. The general 
agreed mechanism involves an initial sheet formation of the liquid stream after exiting 
the nozzle, followed by a breakup into stretched liquid ligaments and then droplet 
formation [76, 77, 259, 270]. A more recent and complex two-stage instability mechanism 
comprises the formation of an initial shear instability forming waves on the liquid surface 
and then a Raleigh-Taylor instability at the wave crests, forming ligaments that stretch 
and further break up into droplets [268, 271-273]. Unfortunately for tablet film coating, 
few studies have been undertaken using non-Newtonian (viscous) fluids [274]. 
Production of a high quality tablet film coat depends upon multiple factors such as the 
formulation [275], equipment [276] and process parameters [277, 278]. The importance 
of droplet size on coating efficiency and quality has been reported, [270, 279, 280] with 
small droplets responsible for a more homogenous or even distribution of coating 
solution on the tablet surface [281, 282]. More rapid water evaporation due to the greater 
volume to surface area ratio of small droplets [283-285] leads to greater coating 
efficiency [286]. Over-wetting, which can result in defects such as poor adhesion of 
coating polymer to the tablet surface, peeling, twinning, picking and sticking and tablet 
erosion [79, 287], is thus less prevalent with smaller droplets. Tablet defects, particularly 
poor adhesion can harm film functionality and negatively impact on the mechanical 
properties provided by a film coat. Typical droplet sizes in fluidised bed coating range 
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between 20 and 100 µm, with coating efficiency reportedly being optimal below 10 µm, 
although this may run the risk of spray-drying of droplets before they reach the tablet 
surface [286, 288]. To date no studies have investigated the direct impact of droplet size 
on tablet film coat using micro scale imaging.  Revealing the micro scale morphology of 
the coat in this way could provide information on coat quality as well as the interaction 
of the coat with the tablet core. 
The aim of this study was to investigate and identify the differences in tablet film coats 
produced from either small or large droplets using micro imaging techniques. To produce 
droplets of a known size a design of experiments (DOE) approach was implemented to 
evaluate the impact of three CPPs: atomisation pressure, pump rate and polymer 
concentration on droplet size during atomisation of a film coat solution from a twin-fluid 
external mixing nozzle. The generated model was then exploited to reveal the process 
conditions required to achieve droplets of a desired size. The hypothesis that small 
droplets would create films that were more even and homogenous was then tested non-
invasively using confocal microscopy (CLSM) and X-ray microcomputed tomography 
(XµCT). CLSM has been used previously for imaging of film coatings [251, 289, 290] and 
XµCT has been used to study tablet microstructure [291], particle coating [292] and tablet 
coat visualisation [251, 293], although common radiopacifying agents to improve 
contrast have not previously been included. Both imaging techniques provided 
qualitative and quantitative information that revealed differences in coat characteristics 
depending on the droplet size used.  
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4.2 Materials and Methods 
4.2.1 Materials 
D-mannitol, D-sorbitol, magnesium stearate, bismuth(III) oxide and barium sulphate 
were purchased from Sigma –Aldrich (Poole, UK). Polyplasdone XL-10 (crospovidone) 
was obtained from ISP (Switzerland). Avicel PH102 (MCC) was obtained from FMC 
Biopolymer (Philadelphia, USA). Aerosil 200 Pharma (colloidal silicon dioxide) was 
obtained from Evonik Industries (Essen, Germany). A coating polymer Kollicoat IR 
(BASF, Germany) and a fluorescent dye riboflavin 5′-monophosphate sodium salt 
(Sigma-Aldrich, Pool, UK) were obtained for film coating work. 
 
4.2.2 Viscosity Measurements 
Viscosity measurements of Kollicoat IR solutions were performed on a Brookfield LVDV-
I+ viscometer (Massachusetts, USA) using spindle 1 (for concentrations of 12.5% w/w 
and below) and spindle 2 (for 20% w/w) at 100rpm, 25°C. 
 
4.2.3 Tablet Formation 
A formulation consisting of MCC (47% w/w), mannitol (23.5% w/w), sorbitol (23.5% w/w), 
crospovidone (4% w/w) and silicon dioxide (1% w/w) was blended for 5 mins followed by 
addition of magnesium stearate (1% w/w) and further blending for 1 min. Direct 
compression of tablets (500 mg) at a compaction force of 30 kN and 6 s dwell time was 
performed using an Atlas T8 automatic press SPECAC® (Slough, UK). A 13mm round, 
flat faced die was used for tablet production. All tablets were produced under ambient 
conditions.  
 
4.2.4 Film Coating and Apparatus 
Suspensions of Kollicoat IR (BASF. Germany) were prepared using ultrapure water. The 
suspensions were pumped and atomized using a Mini Coater Drier-2 (Caleva Process 
Solutions Ltd., Dorset, UK) comprising a 1/8 JJAU-SS air-actuated external mixing 
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atomising nozzle (Spraying Systems Co., Wheaton, IL, USA). Film coating conditions 
were determined from the results obtained from the DOE study to obtain desired droplet 
sizes. In all cases, fluidization air was provided at a velocity of 16 m/s and a temperature 
of 60°C. Assuming a linear correlation between coating time and film coat thickness for 
solutions of the same polymer concentration, large droplet coating was performed for 
2.5x longer to achieve a similar coating thickness between the two droplet sizes. 
 
4.2.5 Droplet Size Analysis 
Real-time measurement techniques offer the advantage of measuring droplet size 
ranges and droplet dimensions more accurately [251, 294]. Real-time droplet size 
measurements using laser diffraction was performed on a Spraytec System (Malvern 
Instruments Ltd, Malvern, UK), to record droplet size distribution under different 
conditions. In order for the laser to access the spray path the fluidisation chamber was 
removed and the spray gun was placed 8 cm above the path of the laser beam. The 
measuring distance to the nozzle was set at 8.5 cm. Each sample was measured in a 
continuous mode for one min, with particle size distribution measured once per s. 
Kollicoat IR solutions were used for droplet size analysis. 
 
4.2.6 Design of Experiments (DOE) 
4.2.6.1 CQA and CPP Selection 
Critical quality attribute (CQA) and CPP selections were based on reports from the 
literature concerning the importance of droplet size on coating quality and parameters 
effecting droplet size during atomisation, discussed earlier. CPP selection was also 
determined by the limitations of the experimental setup, namely removal of the coating 
chamber. Droplet volume median diameter (VMD) was selected as a CQA and a range 
of 20-100 µm chosen based on typical droplet size range during coating and the risk of 
spray drying at lower droplet sizes. Pump rate, atomisation pressure and 
viscosity/polymer concentration were chosen as CPPs. Appropriate CPP ranges were 
founded on the equipment ranges and preliminary work with the apparatus and coating 
polymer. The atomisation pressure range was set at 1-2 bar and pump rate at 1-4 rpm 
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(corresponding to a flow rate of 10-40 ml/hour). Kollicoat IR concentrations (w/w) were 
set at 5%, 12.5% and 20% corresponding to a viscosity of 0.99, 3.10 and 15.00 mPa.s 
respectively.  
 
4.2.6.2 Experimental Design 
Modelling of the atomisation process was performed using MODDE 10 software 
(Umetrics, Sweden). A quadratic process model using response surface modelling 
optimisation with a central composite face-centred design was chosen. This required 17 
runs, including 3 centre points. These ranges were used to set low, medium and high 
levels for each parameter, see Table 4.1. Medium levels were used for the centre point 
measurements and were run in triplicate. All experimental runs are shown in Table 4.2.  
 
  
Low Medium High 
Pump Rate (rpm) 1 2.5 4 
Atomisation Pressure (bar) 1 1.5 2 
Kollicoat IR Concentration (% w/w) 5 12.5 20 
 
  
Table 4.1 Low, medium and high levels for CPPs. The medium level for each CPP was 
used for centre point measurements.    
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Experiment 
Number 
Run Order 
Pump Rate 
(rpm) 
Pressure (bar) 
Concentration 
(% w/w) 
13 1 2.5 1.5 5 
16 2 2.5 1.5 12.5 
6 3 4 1 20 
11 4 2.5 1 12.5 
2 5 4 1 5 
8 6 4 2 20 
7 7 1 2 20 
3 8 1 2 5 
15 9 2.5 1.5 12.5 
1 10 1 1 5 
14 11 2.5 1.5 20 
12 12 2.5 2 12.5 
9 13 1 1.5 12.5 
5 14 1 1 20 
10 15 4 1.5 12.5 
17 16 2.5 1.5 12.5 
4 17 4 2 5 
 
 
4.2.7 Confocal Scanning Laser Microscopy (CLSM) 
Confocal microscopy was carried out on a CLSM TCS SP5 II System (Leica 
Microsystems GMBH, UK) using a 10x dry objective. Riboflavin monophosphate sodium 
was used as a fluorescent dye (0.5% w/w) in the film coat solution, as described by 
Ruotsalainen, Heinämäki [251] and scanned at a wavelength of 458 nm. Maximum 
projection images were used to analyse the surface morphology based on the intensity 
of the fluorescence of pixels within each plane. Maximum projection images were also 
rotated to provide a side view of the film coating to reveal film coat thickness, the 
morphology of the outer coating surface and also the tablet-core interface. 
Table 4.2 Randomised experimental runs for DOE study, including 3 centre points. 
Experiment number 14 (greyed out) was eventually removed from consideration 
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4.2.8 X-Ray Microcomputed Tomography (XµCT) 
XµCT was performed using a Skyscan 1172 high- resolution micro-CT (Bruker, Belgium). 
Samples were placed in a Perspex tube and separated by polystyrene spacers. Samples 
were scanned using an Al/Cu filter, at a pixel size of 6.79 μm, a source voltage of 89 kV, 
current of 112 μÅ and rotated through 360° at increments of 0.64°. Projections were 
reconstructed using NRecon software (Skyscan, Version 1.5.11) to produce non-
invasive cross-sections of the tablets at sequential z planes. 
 
4.2.9 Film Coat Water Content 
Film coat sections (around 5 mg) were analysed for water content by thermogravimetric 
analysis (TGA). A PerkinElmer Pyris 1 TGA (Massachusetts, USA) was used to heat 
samples from 50-150°C (holding for 5 min at 100°C) and % weight loss measured as film 
coat water content. 
 
4.2.10 Image Analysis 
Porosity measurements of XµCT reconstructions were performed using two separate 
methods. Bruker-MicroCT CT-Analyser (CTAn, Bruker, Belgium) was used to provide 
porosity measurements of the coating using the 5 outermost reconstructions in the z-
plane, calculating porosity using the porosity plug-in. ImageJ (National Institutes of 
Health, USA) was used to process the reconstructions by adjusting the image threshold 
by applying the Huang threshold and subsequent binarisation, followed by measuring 
the porous area fraction at a set ROI of the coating. Fluorescent coat porosity was 
measured in the same way as XµCT using the ImageJ method. Film coat thickness at 
the top and bottom tablet surface for fluorescent coats was performed using ImageJ, 
starting with image processing through initial contrast adjustment, followed by 
binarisation, hole filling and despeckling to produce one complete binary section. The 
local thickness plugin for ImageJ, based upon the algorithm developed by Hildebrand 
and Rüegsegger [295], was used to measure film coat thickness; this involves fitting 
spheres within the binary layer and the film coat thickness at any point measured as the 
diameter of the largest sphere at that point. Surface roughness of the coat was 
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represented by the root mean square (RMS) of the valleys and peaks of the coating, 
otherwise put as the standard deviation in individual film coat thickness values [296]. 
Heat maps were generated using the HeatMap From Stack ImageJ plugin by Samuel 
Péan [297]. 
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4.3 Results and Discussion 
A model of the atomisation process was generated from the droplet size data. Model 
optimisation revealed the parameters required to produce droplets of a given size and 
this informed the choice of process conditions for tablet coating. Before coating, 
however, the model required verification and validation. 
 
 
4.3.1 DOE 
4.3.1.1 Model Verification and Validation 
A residuals normality plot was used to identify any outliers, resulting in the exclusion of 
one of the data points from the total 17. The quadratic model generated was fitted against 
the data and the response is shown in the summary of fit plot (Figure 4.1), which provides 
information on the strength and robustness of the model. The R2 value of 0.977 signified 
a low variation in the response (droplet size) and strong fit between the data and the 
model. The Q2 value of 0.837, ideally >0.5, demonstrated a high predictive power, 
allowing for confident prediction of the effect of changing process parameters on droplet 
size and process optimisation. The model also demonstrated a strong score for validity 
of 0.736, far exceeding the required value of >0.25. Similarly the value obtained for 
reproducibility of 0.967 significantly surpassed the requisite value of 0.5, indicating good 
experimental control and low pure error.  
For further model validation a lack of fit plot and ANOVA were employed to compare the 
model error and pure error. In the lack of fit plot (Figure 4.1) the first bar shows standard 
deviation (SD) due to lack of fit or model error (SD-LoF) and the second bar shows the 
SD of the pure error (SD-pe). The final bar shows the SD of pure error * the critical F-
value (SD-pePsqrt(F(crit)), at the p = 0.05 level of significance. The SD-LoF is much 
lower than SD-pePsqrt(F(crit), indicating a good fit. The ANOVA shows a very low 
variance of P <0.00001 due to the regression model, whereas the variance due to 
residuals and replicate errors was insignificant at a P value of 0.348. The results obtained 
for both lack of fit and ANOVA validate the model by demonstrating low error due to the 
model and a low level of pure error in the experimental setup, indicating good control 
over the experiment.  
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4.3.1.2 Regression Model Equations and Factor Effects 
The regression model equation was based upon the correlation coefficients and their 
effect on droplet size. The values were determined from the effects plot (Figure 4.1), 
where the coefficient for each significant response was scaled and centred to allow for 
interpretation. Either a positive or negative effect on droplet size is judged significant if 
the confidence interval crosses the origin, with insignificant effects excluded from the 
model, giving the regression model equation: 
ଵܻ  =  31.89 +  11.05 ଵܺ –  10.28 ܺଶ  +  14.25 ܺଶଶ + 14.29 ܺଷଶ + 4.60 ܺଶܺଷ − 10.63 ଵܺଶ 
Where: ଵܻ = ܦݎ݋݌݈݁ݐ ݏ݅ݖ݁, ଵܺ = ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊, ܺଶ = ܲݎ݁ݏݏݑݎ݁, ܺଷ = ܲݑ݉݌ ܴܽݐ݁ 
 
 
Figure 4.1 Summary of fit plot showing model fit (R2), predictability (Q2), model validity 
and reproducibility. The model has been fitted using RSM. Lack of Fit plot showing 
standard deviation (SD) due to lack of fit (SD-LoF), SD of pure error (SD-pe) and SD 
of pure error * the critical F-value (SD-pePsqrt(F(crit)). Effects plot for the three 
factors: pump rate (Pum), concentration of Kollicoat IR suspension (Conc) and 
atomisation pressure (Pre). Factors are ordered in terms of impact on droplet size. 
Confidence interval bars are included for each factor. 
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The derived regression model equation describes a complex process with linear and/or 
quadratic relationships for all parameters with droplet size. The most significant factor 
that showed a linear effect on droplet size is concentration (X1), followed by the 
atomisation pressure (X2). When the concentration of Kollicoat IR is increased there is 
an increase in droplet size; conversely, an increase in atomisation pressure leads to a 
reduction in droplet size. No significant linear relationship between pump rate and droplet 
size was seen. All three factors also had a significant quadratic relationship with change 
in droplet size, with pump rate and atomisation pressure showing very similar values for 
their coefficients. An interaction between pump rate and pressure (ܺଶܺଷ) was also 
detected, a finding made possible by DOE.  
More detailed information on the effect that changes in each factor had on droplet size 
is shown in the Main Effects Plot, Figure 4.2. The plot for the interaction between pump 
rate and atomisation pressure is also shown in Figure 4.2. A clear trend can be seen 
with an increase in concentration causing an increase in droplet size and an increase in 
atomisation pressure causing a decrease in droplet size, with the effect of pump rate 
being more complex. All three plots show a characteristic curved quadratic shape. The 
increase in droplet size seen with increased Kollicoat IR concentration peaked around 
the 12.5% centre point, with little change seen at 20%. The relationship seen with 
increasing pump rate is complex, with the plot forming a clear U shape and the smallest 
droplets forming approximately between 2 and 3 rpm. The interaction plot between pump 
rate and atomisation pressure demonstrates finer droplet formation at high pressure. 
Notably, the difference in droplet size at low and high pump rates is different depending 
on the atomisation pressure; at low pressure there is a decrease in droplet size from 
around 77 to 65 µm, whereas at high pressure there is an increase in droplet size from 
around 47 to 54 µm. This behaviour of a decrease in droplet size with increased flow 
rate at low pressure and an increase in droplet size with increased flow rate at high 
pressure is in line with that described for external mix twin-fluid atomisers by Suyari and 
Lefebvre [294]. They attributed this behaviour to the fact that at low pressure the 
atomisation equipment operates in a simplex pressure-swirl mode, whereas at high 
pressure it operates in a simplex-airblast mode. In pressure-swirl mode the increase in 
liquid flow rate is analogous to an increase in liquid injection pressure; in simplex-airblast 
mode, due to the high air pressure the increase in flow rate lowers the ALM, thus 
lessening the atomisation ability. The increase in droplet size seen at the lowest flow rate 
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may similarly be explained by the low flow rate being equivalent to a low liquid injection 
pressure, resulting in a liquid sheet at the nozzle exit that is more stable and resistant to 
breakup. 
 
 
 
The response contour plots, Figure 4.3, give a visual representation of changes in droplet 
size over the parameter ranges, allowing for optimisation of the process conditions. The 
plots indicate that in order for very fine droplet formation the major limiting factor is the 
polymer concentration, since at the mid and high polymer concentrations droplet sizes 
do not fall below 30 µm unlike at the low polymer concentration.  
 
 
Figure 4.2 Main Effect Plots for concentration, atomisation pressure and pump rate 
on droplet size. Bottom right, Interaction Plot for the interaction between pump rate 
and atomisation pressure. The two lines show atomisation pressure at the low level 
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4.3.2 Film Coating 
The DOE atomisation model allowed for coating of tablets with either large or small 
droplets. A small droplet VMD of 20 µm and a large droplet VMD of 70 µm were chosen 
to show the effect of droplet size on the film coat. The conditions to produce droplet sizes 
as close to these as possible were determined by optimisation of the model using 
 
Figure 4.3 Response contour plot with respect to fixed levels of atomisation pressure, 
pump rate and polymer concentration. 
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MODDE software. Polymer concentration was set at 8.49% (w/w) (corresponding to a 
viscosity of 1.73 mPa.s) for both droplet sizes in order for droplet properties to remain 
consistent, with the exception of VMD. The predicted droplet sizes and the process 
conditions required to achieve these are shown in Table 4.3.  
 
Predicted 
droplet VMD 
(µm) 
Pump rate 
(rpm) 
Atomisation 
pressure (bar) 
Polymer 
concentration 
(% w/w) 
Coating time 
(min) 
21.0 2.56 1.68 8.49 80 
69.3 1 1 8.49 200 
 
4.3.3 Film Coat Imaging 
Qualitative analysis of the tablet coatings was performed non-invasively using XµCT and 
CLSM, to examine the effect of droplet size. Processing of the images yielded 
quantitative information for film coat thickness and porosity, providing a greater 
comparison between large and small droplet coating quality. 
 
4.3.3.1 Confocal Microscopy 
Maximum projection images of the film coated tablets at different droplet sizes are shown 
in Figure 4.4. A marked difference can be seen between the two batches. The film 
coatings of 20 µm droplets are clearly more uniform and complete when compared to 
the 70 µm droplet coatings. Dark spots in these images indicate areas of low or no 
coating (pores); the smaller droplet size coated tablets (1 A and 1 B) appear to have a 
much more complete coating, with fewer dark spots visible when compared to the larger 
droplet size. Furthermore, the smaller droplet coated tablets display a more consistent 
texture and colour, with the larger droplets forming patches of increased intensity of 
fluorescence indicating poor homogeneity. Unlike the small droplet coatings, in the large 
droplet coatings droplet outlines are visible, most apparent in the 25x magnification (2 
B). This would suggest a greater water content for the large droplet coats through 
Table 4.3 Processing conditions for production of small and large droplets   
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insufficient water evaporation, however TGA analysis showed no significant difference 
(P=0.31) in water content between small and large droplet coatings, with values of 
2.68±0.03% and 2.51±0.14% respectively. 
 
 
Pixel fluorescence intensity of images at sequential planes was used to generate a 3D 
projection (Figure 4.5) of the coating to provide a representation of the surface 
roughness. These images indicate a thicker coating with large droplets and complement 
the maximum projection images by showing a rougher surface for the tablets coated with 
 
Figure 4.4 Maximum projection images of the film coat surface, providing a visual 
representation of surface morphology and film coat uniformity. Aqueous film coat 
consisting of Kollicoat IR 20% w/w and riboflavin 5’-monophosphate sodium 0.5% w/w 
as a fluorescent dye. Tablets coated by fluidised bed coating method at defined 
droplet sizes: 20µm (1) and 70 µm (2). Images were taken at 10x (A) and 25x (B) 
magnification. 
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large droplets (2). A transverse view of the maximum projection images can be seen in 
Figure 4.6 and gives a non-invasive cross-section of the film coat and the coat-core 
interface. Since film coat thickness was assumed to be largely dependent on the solid 
content of the film coat and this was corrected for by coating time, no difference in coating 
thickness was expected between large and small droplet coatings. Small droplet 
coatings however are much thinner when compared to the large droplet coatings, with 
the differences actually being in a similar magnitude as the difference in coating time 
(2.5x). This may be due to a higher porosity seen with the large droplet coatings.  
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Figure 4.5 3D CLSM image showing fluorescence intensity at each image layer, 
providing a visual representation of surface morphology. Film coat consisting of 
Kollicoat IR 20% w/w and riboflavin 5’-monophosphate sodium 0.5% w/w as a 
fluorescent dye. Tablets coated by fluidised bed coating method at defined droplet 
sizes: 20µm (1) and 70 µm (2). Images were taken at 10x (A) and 25x (B) 
magnification. 
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The images obtained by CLSM suggest that small droplets have produced a thinner, 
more compact coat that is more homogenous, complete and smooth. This can be 
attributed to the more efficient evaporation of small droplets due to their greater surface 
area to volume ratio. These findings are significant since the differences seen between 
the coats may impact upon the overall tablet properties.  
 
4.3.3.2 Micro-CT 
XµCT was used to complement confocal data to assess film coat quality and 
characteristics. Imaging of the tablet core alone was not possible due to low radiopacity 
shown by the tablet core excipients and Kollicoat IR, as measured using an aluminium 
step wedge to compare against aluminium standards. Barium sulphate (BaSO4) and 
bismuth(III) oxide (Bi2O3) were tested as contrast materials for incorporation into both 
 
Figure 4.6 Transverse view of maximum projection images showing the film coat 
thickness and morphology. Film coat consisting of Kollicoat IR 20% w/w and riboflavin 
5’-monophosphate sodium 0.5% w/w as a fluorescent dye. Tablets coated by fluidised 
bed coating method at defined droplet sizes: 20µm (1) and 70 µm (2). Images were 
taken at 10x (A) and 25x (B) magnification. 
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the tablet core and the polymer coating to increase radiopacity. BaSO4 has been used 
extensively in orthopaedic surgery as a radiopacifier in bone cement to monitor the 
healing process after fixation of artificial joints [298]. Bi2O3 is similarly considerably used 
as a radiopacifier component of dental cement for peri-/postoperative assessment [299]. 
XµCT reconstructions in Figure 4.7 and Figure 4.8 show transverse views of the entire 
tablets. Addition of either contrast material increased radiopacity enough for successful 
imaging. The distribution of the contrast material within the tablet core was initially not 
homogenous, with clumps visible in the reconstructions where contrast material had 
been blended with the rest of the formulation. Co-processing of the contrast material with 
the formulation by milling then vastly improved homogeneity of the tablet core. Contrast 
material inclusion in the coat similarly increased radiopacity for successful imaging. 
Increasing contrast material concentration in the film coat produced sharper, more 
defined images, as shown in Figure 4.8, B and D.  
 
 
 
 
Figure 4.7 Transverse view of XµCT reconstruction of placebo tablets (13mm) 
containing contrast material in the core. Contrast material Bi2O3 is included at 5% w/w 
and 10% w/w (milled), A and B respectively. BaSO4 is included at 10% w/w and 20% 
w/w (milled), C and D respectively. 
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To determine the effect of droplet size on film coat Bi2O3 (2.5% w/w) was added to the 
coating solution. Bi2O3 was chosen as contrast material since BaSO4 demonstrated 
similar radiopacity but at a higher concentration. The parameters for obtaining the 
defined droplet sizes caused issues with effective coating with contrast material. At the 
higher pump rate of 2.56 rpm, Bi2O3 was readily pumped and atomised. The lower pump 
rate of 1 rpm necessary for large droplet production proved more challenging and 
required reduction in the coating solution pumping length, due to the increased transit 
time of the insoluble bismuth oxide. 
Figure 4.9 shows the XµCT maximum projections of the top tablet surface, coated with 
either large or small droplets. The surface images for the small droplet coating 
complement the confocal data by showing a homogeneous, uniform coating. Similarly, 
the surface of the large droplet coating shows large droplet artefacts on the coating 
surface and poor homogeneity. These differences are particularly clear in the heat map 
images. 
 
 
Figure 4.8 Transverse view of XµCT reconstruction of placebo tablets (13mm) 
containing contrast material in the coat. Contrast material Bi2O3 is included at 1% w/w 
and 2.5% w/w, A and B respectively. BaSO4 is included at 2% w/w and 5% w/w, C 
and D respectively. 
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4.3.3.3 Film Coat Thickness and Porosity 
Analyses of film coat porosity for XµCT reconstructions were performed using two 
different techniques. Film coat porosity, thickness and roughness analysis was also 
performed for fluorescent coatings. Porosity measurements were used as an indication 
of film coat uniformity, with lower porosity representing a more concise coating. The 
results for the XµCT reconstructions are shown in Table 4.4. Both techniques for film 
coat porosity assessment show similar results and similar deviation. Large droplet 
coated tablets showed approximately double the coating porosity of 44.3±7.1% and 
 
Figure 4.9 Maximum projection and heat map images of the tablet surface of XµCT 
reconstructed film coated tablets of either large or small droplet size. Placebo tablets 
were coated with Kollicoat IR and bismuth oxide (2.5% w/w). Droplet size coatings of 
20µm (1) and 70 µm (2) are shown in maximum projections (A) and heat maps (B). 
Heat maps demonstrate coat uniformity, with blue areas and red areas representing 
high and low intensity of radiopacity, respectively. 
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32.8±6.7% compared to the small droplet coating porosity values of 21.4±4.1% and 
16.4±3.3% respectively, using each technique.  
The results for the fluorescent coatings, shown in Table 4.5, show a similar trend, with 
large droplet coatings having double the porosity of small droplet coatings at 30.0±6.0% 
and 15.1±3.2% respectively and showing comparable values with the XµCT 
reconstructions. The film coat thickness measurements show that large droplet coatings 
are substantially thicker at 114.2±18.1µm compared to small droplet coatings at 
48.4±8.1µm, as was visible from the transverse views of the maximum projection 
images. The greater surface roughness values for the large droplet coated tablets were 
not deemed significant (P > 0.05).  
 
Coating Porosity of XµCT Scans by Two Methods 
 Droplet Size Mean (%) 
CTAn 
Small (20 µm) 21.4 ± 4.1 
Large (70 µm) 44.3 ± 7.1 
ImageJ 
Small (20 µm) 16.4 ± 3.3 
Large (µm) 32.8 ± 6.7 
 
Film Coat Thickness and Porosity Measurements for Fluorescent Coatings 
 
Porosity (%) Thickness (μm) Roughness - RMS (μm) 
Small 15.1 ± 3.2 48.4 ± 8.1 6.6 ± 2.4 
Large 30.0 ± 6.0 114.2 ± 18.1 12.8 ± 6.2 
Table 4.4 Surface porosity measurements of film coatings analysed by XµCT. Porosity 
has been measured using either the CTAn or ImageJ technique.    
Table 4.5 Porosity, thickness and roughness measurements of fluorescent coatings. 
Maximum projection images were analysed using ImageJ. Coatings produced by large 
and small droplets are compared.  
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4.4 Conclusion 
DOE successfully generated a robust model capable of predicting the impact that altering 
process parameters had on droplet size. All three CPPs under investigation were verified 
as having a significant impact on droplet size contributing to a complex atomisation 
process. This approach provided a wealth of information and insight into the process in 
a short time and allowed for droplet size optimisation that would not have been easily 
achieved otherwise.  
Film coat characterisation by CLSM and XµCT provided complementary qualitative and 
quantitative information. Small droplets were shown to produce a more complete and 
concise film coating, and are expected to benefit from enhanced stability as a result of 
lower porosity and be less at risk to detrimental over-wetting. The increased thickness 
of large droplet coatings may be as a result of greater porosity of these coatings. The 
incorporation of a commonly used radiopaque contrast material for XµCT imaging of a 
film coat was designed to overcome a major limitation of XµCT, that is poor contrast 
between tablet and coating materials [293]. The wider implications could extend beyond 
coating, for example with inclusion of contrast materials into tablet cores for non-invasive 
analysis of internal tablet structure by XµCT. Another application could be to study 
homogeneity, not only within tablet cores but also powders. 
 
Chapter 5 – Fixed Dose Combination ODTs to Treat Tuberculosis: Physiologically 
Based Pharmacokinetic Modelling to Assess Bioavailability 
199 
 
 
 
 
 
Chapter 5 
Fixed Dose Combination Orally Disintegrating Tablets to 
Treat Tuberculosis: Physiologically Based Pharmacokinetic 
Modelling to Assess Bioavailability 
 
Chapter 5 - Fixed Dose Combination Orally Disintegrating 
Tablets to Treat Tuberculosis: Physiologically Based 
Pharmacokinetic Modelling to Assess Bioavailability 
 
5  
 
 
  
Chapter 5 – Fixed Dose Combination ODTs to Treat Tuberculosis: Physiologically 
Based Pharmacokinetic Modelling to Assess Bioavailability 
200 
5.1 Introduction 
Recognised as one of humankind’s oldest diseases, with evidence of cases dating back 
more than 5000 years [300], tuberculosis (TB) remains a major cause of morbidity and 
mortality. Today there are an estimated 9.6 million TB cases worldwide, with the disease 
claiming 1.5 million deaths in 2014 alone [301]. Since 2000 the incidence of TB has fallen 
by 18%, at an average rate of 1.5% per year, with effective treatment within this time 
frame saving an estimated 43 million lives [301]. 
TB is an infectious disease caused by the aerobic bacterium Mycobacterium tuberculosis 
(MTB) [302]. Transmission occurs through aerosolisation of the bacterium into droplet 
nuclei by coughing, sneezing or talking [303]. Inhalation of the organism into the alveoli 
leads to respiratory infection that, if spreads, causes extrapulmonary tuberculosis, which 
can involve any organ system in the body [304]. Pulmonary tuberculosis, the most 
common presentation, is avoided in most cases of exposure through mucociliary 
clearance [305], or failing that through the successful activity of phagocytic alveolar 
macrophages, resulting in symptomless latent tuberculosis [306]. Around 5% of TB 
infections progress to the active form of the disease within two years, with about 10% of 
latent cases reactivating at some point later in life [303, 307-309].  TB outcome is 
dependent on a multitude of factors, most prominent of which is the immunocompetence 
of the individual [310], itself dependent on various intrinsic and extrinsic factors such as 
the hosts genetics and nutritional state, respectively [311, 312].  
Clinical manifestation of TB depends on the site of infection. Pulmonary TB, historically 
referred to as consumption or pthisis, classically manifests as severe wasting [312], as 
well as cough, haemoptysis, chest pain, dyspnoea, malaise, fatigue, low-level fever and 
night sweats [313, 314].  Extrapulmonary TB can include the same symptoms as 
pulmonary TB, with a wide range of additional symptoms based upon the site of infection, 
such as meningitis (CNS), lymphadenitis (lymphatic), arthritis (skeletal) and haematuria 
(renal) [315, 316].  
Various social, environmental and biological risk factors determine the risk of TB 
contraction [317]. Risks for infection and progression to disease are distinctly different; 
infection risk involves extrinsic factors including social and behavioural risks (alcohol, 
smoking and pollution), source infectiousness and proximity (including overcrowding and 
length of exposure), whereas risk of progression to disease is endogenous to the host 
[318]. Immunosuppressive conditions accelerate progression to active disease, with HIV 
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being especially potent [319, 320]. Impaired immune response as a result of malnutrition 
is also known to increase the risk of TB [321, 322], whilst a strong socioeconomic 
association with the disease exists, with the poorest experiencing the greatest risk [323]. 
Children also present an increased susceptibility to TB development, which is greater 
still before the age of 2 and after age 10 [324]. Other risk factors for progression to 
disease include diabetes, alcohol, smoking and indoor air pollution [318].  
Isoniazid and rifampicin form the basis of front-line treatment for TB [301], with both 
drugs included in the WHO Model List of Essential Medicines [325] and Essential 
Medicines for Children [326]. Isoniazid (Biopharmaceutics Classification System (BCS) 
class I/III [327, 328]) is a pro-drug that requires activation by catalase-peroxidase 
enzyme (KatG), which is endogenous to MTB [329]. The drug inhibits the synthesis of 
mycolic acids, essential components of the bacterial cell wall [330, 331] and at 
therapeutic doses is bactericidal against actively growing intra and extra cellular MTB 
[332]. Rifampicin (BCS class II [333, 334]) also displays a bactericidal effect on MTB, by 
inhibition of transcription through high-affinity binding to the β-subunit of bacterial DNA-
dependent RNA polymerase [75, 335]. Rifampicin is highly effective against TBM 
through its ability to readily diffuse into tissues, cells and bacteria [336]. The tendency of 
rifampicin to degrade substantially when combined with isoniazid in acidic media is a 
well-recognised complication when considering combination of the two drugs in solid 
oral-dosage forms [337-339] 
The first-line recommended oral drug regimen for treatment of drug susceptible TB 
involves isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months, followed by 
isoniazid and rifampicin for 4 months, with the regimen altering due to drug or multi-drug 
resistance [340]. Treatment for extrapulmonary TB does not differ, except in some cases 
where duration of therapy is extended [341]. Recommended doses for treatment of 
children differ compared to adults [342]. Fixed dose combinations (FDCs) are 
recommended for TB treatment of both adults and children [340, 342], however FDCs 
currently on the market do not correspond to appropriate doses for children [341]. FDCs 
for TB treatment have not been shown to alter efficacy, drug resistance or adverse 
effects or events when compared to single-dose [341]. Furthermore, whilst FDCs have 
not provided evidence for improvement of treatment outcomes, their use simplifies TB 
therapy, with some evidence for an increase in patient satisfaction [343].  
In order for a new generic formulation to be approved it needs to demonstrate 
bioequivalence with a reference branded product. A bioequivalent drug will display 
Chapter 5 – Fixed Dose Combination ODTs to Treat Tuberculosis: Physiologically 
Based Pharmacokinetic Modelling to Assess Bioavailability 
202 
comparable bioavailability and thus in vivo performance (efficacy and safety) [344]. 
Bioequivalence can be assumed in the absence of clinical trials, if there is no significant 
difference in the rate and extent to which the active pharmaceutical ingredient (API) 
becomes available within the systemic circulation, when compared with the reference 
product [345].  Bioequivalence testing may also be applied in the assessment of FDCs 
[344]. For immediate release formulations bioequivalence can be determined by 
comparison of in vitro dissolution profiles using FDA recommended difference factor (f1) 
and similarity factor (f2) testing, for biowaiver applications [345, 346]. Comparison testing 
is not deemed necessary if test products display greater than 85% dissolution within 15 
min, given that the API falls within BCS class I or III (although class III carries stricter 
requirements) [344]. The extension of biowaivers to BCS class II compounds is topic of 
much discussion [347-349]. 
Pharmacokinetic modelling and simulation has become an established tool over the past 
20 years to predict drug pharmacokinetics in humans and assess the effect of intrinsic 
and extrinsic factors on drug exposure. Physiologically based pharmacokinetic (PBPK) 
models define tissues and organs as compartments, with parameters based upon 
decades of knowledge of body fluid dynamics [350, 351]. PBPK models consider ADME 
processes throughout all compartments to estimate the pharmacokinetic profile of a drug 
at a target tissue or organ [351, 352]. As such, PBPK models have become a powerful 
tool for prediction of oral drug absorption (to the systemic circulation) through integration 
of common in-vitro drug-specific information, with systems based data [138, 148]. PBPK 
modelling is often exploited for prediction of oral drug absorption, to study formulation 
changes [353, 354] or FDCs [355] whilst there is a significant effort to apply PBPK 
modelling to investigations into bioequivalence [356-358]. 
An FDC ODT for isoniazid and rifampicin could potentially increase patient compliance 
and be particularly beneficial in developing areas with little to no access to water. The 
use of a paediatric relevant dose would be valuable given the current lack of support and 
the widely reported and supported applicability of ODTs to enhance compliance in 
paediatric populations [33, 250, 359, 360], including patients as young as 6 months old 
[361]. Similarly, improved clinical outcomes from FDCs, due primarily to improved 
adherence as a result of reduced pill burden, are well documented [362-364].  
This work describes the development and characterisation of an isoniazid and rifampicin 
FDC ODT targeted at paediatrics. Single dose and fixed dose drug dissolution from 
ODTs in biorelevant media and permeability data from in-vitro Caco2 cell monolayers 
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was used to predict drug pharmacokinetics through simulated clinical trials. This allowed 
for comparison of bioavailability of each API from single and combination formulations. 
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5.2 Materials and Methods 
5.2.1 Materials 
Isoniazid and rifampicin was purchased from Molekula Ltd (UK). PEARLITOL® Flash 
(mannitol-starch copolymer) was obtained from Roquette Pharma (France), with Avicel 
PH-102 micro-crystalline cellulose (MCC) and sodium stearyl fumerate (SSF) supplied 
by FMC BioPolymer (USA).  
Biorelevant FaSSIF/FeSSIF/FaSSGF Instant Powder was purchased from 
biorelevant.com (UK). Sodium hydroxide, sodium chloride, sodium phosphate and 
glacial acetic acid for biorelevant media were obtained from Sigma-Aldrich (UK). 
Acetonitrile (ACN) and methanol (HPLC-grade) were obtained from Fisher Scientific 
(UK). 
For cell culture media DMEM was purchased from Lonza (UK), fetal bovine serum (FBS), 
gentamicin (10 mg/ml), Fungizone (amphotericin B 250 μg/ml), HBSS and 
penicillin/streptomycin (10,000 U/ml) were all purchased from Gibco (Thermo Fischer 
Scientific, UK). Trypsin-EDTA solution (0.25%) was procured from Sigma-Aldrich (UK). 
 
5.2.2 HPLC 
HPLC was performed on an Agilent 1260 series (Agilent Technologies, USA), comprising 
a quarternary pump, Infinity VWD and autosampler. Analysis was conducted on a 
reversed-phase Gemini C18, 150 x 4.6 mm, 110Å, 5μm column (Phenomenex, UK). 
Protocols were developed, calibrated and validated for both isoniazid and rifampicin 
alone and in combination. 
Separations were achieved using either deionised H2O, 0.1% (v/v) TEA, 0.1% (v/v) TFA 
or ACN at different ratios as the mobile phase. Ascorbic acid (0.5 mg/ml) was included 
as an antioxidant to prevent the degradation of rifampicin [365]  Isoniazid separation was 
performed with an isocratic mobile phase of H2O: ACN (90:10 v/v), a flow rate of 1 ml/min 
and a wavelength of 254 nm. Rifampicin separation was achieved using an isocratic 
mobile phase of TFA: ACN (45:55 v/v), a flow rate of 1 ml/min and a wavelength of 254 
nm. Separation of isoniazid and rifampicin in combination required a mobile phase of 
TEA: ACN delivered at a gradient (95:5 to 20:80 v/v), with a flow rate of 1 ml/min and a 
wavelength of 254 nm. An injection volume of 20 μl was used throughout. 
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HPLC method validation followed ICH guidelines [366] and involved assessment of 
precision through intra-day variation, accuracy by multilevel recovery studies, instrument 
precision, linearity and limit of detection and quantification (LOD and LOQ). Stock 
solutions (1 mg/ml) of each drug were prepared in mobile phase from which dilutions and 
subsequently two-fold serial dilutions were prepared to form a calibration curve. 
 
5.2.3 Tablet Production 
Direct compression of tablets (500 mg) at a compaction force of 22 kN (2.2 ton) was 
performed on an Atlas T8 automatic press (SPECAC, UK), using a 13mm round, flat 
faced die. Tablets were produced under ambient conditions. 
 
5.2.4 Friability 
Tablet friability was determined on 6 tablets using an F2 friability tester (Sotax, 
Switzerland). Tablets were placed inside the drum and rotated at 25 rpm for a total of 
100 revolutions. Dust was removed pre and post testing to remove excess powder that 
would contribute to tablet mass. Friability was calculated and expressed as % tablet 
weight loss from initial tablet weight. 
 
 
5.2.5 Tablet Hardness 
A Tablet Hardness Tester TBF1000 (Copley Scientific, UK) was used to measure the 
radial crushing strength (hardness) of tablets in triplicate.  
 
5.2.6 Dissolution Testing 
API dissolution from ODTs in 900 ml biorelevant media was tested in both fasted state 
simulated intestinal fluid (FaSSIF) and fed state simulated intestinal fluid (FeSSIF), at 
pH 6.5 and 5 respectively and maintained at 37°C. An ERWEKA DT 600 USP 2 paddle 
apparatus (Germany) was used at a paddle speed of 50 rpm [367]. 5ml samples were 
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taken over 2 h, replacing with 5 ml fresh media to simulate sink conditions. API 
dissolution was measured using HPLC and corrected for % dose dissolved.  
 
5.2.7 Cell Culture 
Prior to seeding, cells were trypsinised (2.5 ml) from 75-cm2 cell culture flasks (Corning, 
USA) on which they had been grown (80% confluence), after washing with HBSS. Caco-
2 cells (passage 54-58) were seeded onto Transwell (Corning, USA) semi-permeable 
membrane supports (12-well, 1.12 cm2, 0.4 μm pore size) at a density of 8x104 cells/cm2. 
Cells were maintained in DMEM containing L-glutamine (4 mM) and glucose (4.5 mg/ml) 
supplemented with (v/v) 10% FBS, 1% penicillin/streptomycin, 1% NEAA, amphotericin 
B (0.5 μg/ml) and gentamicin (20 μg/ml).  Media was changed every 2-3 days and 
transwells cultured at 37°C, 5% CO2 for 21 days, after which transport studies were 
performed.  
 
5.2.8 Transepithelial Electrical Resistance (TEER) Measurements 
TEER value measurements were performed to monitor monolayer integrity using an 
EVOM meter (World Precision Instruments, USA). TEER values are expressed using the 
equation: 
ܶܧܧܴ (ߗ/ܿ݉2)  =  (ݎ݁ݏ݅ݏݐܽ݊ܿ݁ –  ܾ݈ܽ݊݇ ݎ݁ݏ݅ݏݐܽ݊ܿ݁) ݔ ܾ݉݁݉ݎܽ݊݁ ݏݑݎ݂ܽܿ݁ ܽݎ݁ܽ 
 
5.2.9 Caco-2 Transport Studies 
Caco-2 monolayers were used for transport studies between 21 and 24 days post-
seeding. Drug absorption through Caco-2 monolayers was measured for isoniazid and 
rifampicin alone and in combination in both the apical to basolateral (A-B) and basolateral 
to apical (B-A) directions (n=3). Transport studies were carried out in DMEM (37°C) 
containing 10 mM HEPES (pH 7.4), with 0.5 ml and 1.5 ml in the A and B compartments, 
respectively. Samples of 100 μl were removed from the A side and 200 μl from the B 
side at time points over 2 h, replacing with fresh pre-warmed media (37°C) to mimic sink 
conditions. For mass balance, samples were taken from the donor compartments at t=0 
and t=120 min.  
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Isoniazid was administered at a concentration of 20 μg/ml and rifampicin at a 
concentration of 30 μg/ml. Concentrations used were comfortably within or below 
previously reported well tolerated concentration ranges for both isoniazid [368, 369] and 
rifampicin [368, 370]. Cultures were maintained at 37°C and 5% CO2 throughout the 
experiment. Samples were analysed by HPLC and apparent permeability (Papp) values 
were calculated using equation: 
ܲܽ݌݌ =  (݀ܳ/݀ݐ)/(ܥ଴ ݔ ܣ) 
Where dQ/dt is the mass transfer rate of the compound from the donor to the receiver 
compartment, C0 is the initial concentration in the donor chamber and A is the monolayer 
surface area (cm2).  
 
5.2.10 Clinical Trials Simulation 
The population-based clinical trials simulator Simcyp (V14) (Certara, USA) was used to 
simulate the plasma concentration of isoniazid and rifampicin from single API and FDC 
formulations. Default parameter values for creating a North European Caucasian 
population were selected [371].  
 
5.2.11 Compound Data 
Physicochemical information for each API was collated from the literature used to 
develop compound files (Table 5.1).  Simulations were performed using a minimal-PBPK 
model. Where uncertainty arose regarding the precise value of compound data 
parameters, parameter estimation was conducted using the Parameter Estimation 
Module to optimize parameter values. The ADAM model [372] was assumed for all 
simulations and the dissolution profile for each formulation (single and FDC) in FaSSIF 
and FeSSIF were utilized. 
 
5.2.12 Clinical Studies 
The optimization and validation of the PBPK model was conducted using clinical study 
results reported in healthy adult subjects.  For isoniazid: study 1 included a total dose of 
Chapter 5 – Fixed Dose Combination ODTs to Treat Tuberculosis: Physiologically 
Based Pharmacokinetic Modelling to Assess Bioavailability 
208 
300 mg dosed to 18 healthy volunteers (18-55 years old) [373];  study 2 included a total 
dose of 300 mg dosed to 22 healthy volunteers [374]; study 3 included a total dose of 
300 mg dosed to 20 healthy volunteers (23 ± 1.8 years old) [375]; study 4 included a 
total dose of 300 mg dosed to 18 healthy volunteers (36.4 ± 10.6 years old) [376]. Studies 
1 and 2 were used for model development and studies 3 and 4 utilized for validation. 
For rifampicin:  study 1 included a total dose of 600 mg dosed to 18 healthy volunteers 
(18-55 years old) [373]; study 2 included a total dose of 600 mg dosed to 20 healthy 
volunteers (23 ± 1.8 years old) [375]; study 3 included a total dose of 600 mg dosed to 
18 healthy volunteers (36.4 ± 10.6 years old) [376]; study 4 included a total dose of 600 
mg dosed to 22 healthy volunteers [374]. Studies 1 and 2 were used for model 
development and studies 3 and 4 utilized for validation. 
Raw data from published human trial plasma concentration profiles was extracted using 
WebPlotDigitizer 3.10 [377] and, where necessary, parameter estimation was conducted 
using the validation clinical datasets.  
Predictions of API plasma pharmacokinetic profiles were simulated following the oral 
administration of a single immediate release solid dosage form of 50mg (isoniazid) and 
75 mg (rifampicin) dose over a 24 hr period. 
 
 
 
Parameter Isoniazid Rifampicin 
Type Monoprotic base Ampholyte 
MW 137.1 823 
LogP -0.7 4.01 
pKa 1.82 1.7,7.9 
fu 0.95 0.113 
 Table 5.1 Input parameter values and predicted PBPK values for simulation of 
pharmacokinetics of isoniazid and rifampicin. 
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Vss (L/kg)a Predicted PBPK/PE 0.42 (Full PBPK) 
B:P ratio 0.825 0.9 
CLpo (L/min) 12 8.75 
Peff (cm/s) PE 2.15 
MW: molecular weight; fu: plasma unbound fraction; Vss: steady-state volume of 
distribution; B:P ratio: blood-to-plasma ratio; Peff: human effective permeability; CLpo: 
oral clearance; PE: parameter estimation. a Vss was determined from calculation of 
tissue partitions coefficients within Simcyp or parameter estimated.  
 
 
5.2.13 Statistical Analysis 
GraphPad PRISM software version 6.01 (USA) was used for data analysis. Ordinary 
one-way ANOVA was used with Tukey’s multiple comparisons test to analyze data for 
tablet characterization. Unpaired two-tailed t-test was used to determine statistical 
differences between data sets for pharmacokinetic parameters.  
Differences between dissolution profiles of APIs in single dose (reference) and 
combination (test) were assessed using f1 and f2 difference and similarity factor testing, 
using the equations [346]: 
 
ଵ݂ = ([෍ |ܴ௧ − ௧ܶ|]/[෍ ܴ௧]) ∗ 100
௡
௧ୀଵ
௡
௧ୀଵ
 
ଶ݂ = 50 ∗ log ([1 + (1/݊) ෍(ܴ௧ − ௧ܶ)ଶ]ି଴.ହ ∗ 100)
௡
௧ୀଵ
 
Where Rt and Tt are the % drug dissolved value at each time point for the reference and 
test product respectively and n is the number of time points. 
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5.3 Results and Discussion 
5.3.1 ODT Development 
An ODT formulation for rifampicin and isoniazid both alone and in combination was 
developed, with the requirement that tablets were mechanically robust whilst maintaining 
rapid disintegration. Round flat faced tablets (500 mg) were produced by direct 
compression. In order to isolate the effect of combination of APIs, the number of 
excipients used was kept at a minimum. The formulation consisted of API alongside Na 
stearyl fumerate (SSF, 0.5% w/w) as a lubricant and Pearlitol as a diluent. Compaction 
forces were applied at a range of 1-2 ton and the effect on ODT properties shown in 
Table 5.2. Hardness values were acceptable from a compaction force of 1.2 ton and 
above. Friability values at all compaction forces were high (1%), with tablets compressed 
at and below 1.2 ton not withstanding friability testing. Disintegration times at all 
compaction forces were within 30 s, as recommended by the FDA for ODTs [378]  with 
no significant effect (p>0.05) on disintegration with changes in compaction force.  
Different concentrations of SSF or Mg stearate (MS) as lubricants were assessed for 
their effect on ODT properties (Table 5.3). No significant difference in tablet hardness 
was demonstrated when SSF concentration was altered. SSF ODT’s displayed greater 
hardness values than MS, with the exception of SSF at 1% w/w that was not deemed 
significant. Increasing SSF to 1.5% w/w ensured improved lubricant ability whilst 
maintaining high hardness and a low disintegration time. Inclusion of MS at 1% w/w 
slowed disintegration when compared to all other ODTs, above the 30 s requirement 
(p>0.01).  
To combat high friability (>1%) MCC was included as a binder [160]. Addition of MCC up 
to 15% w/w (Table 5.4) improved hardness (p>0.01) compared to other concentrations 
whilst lowering friability and maintaining rapid disintegration. MCC has excellent binding 
properties due to its plastic deformation, maximising interparticulate bonding [160] and 
hydrogen bond formation between adjacent molecules [162, 379], whilst mechanical 
interlocking has also been proposed as a mechanism [165, 380]. The high intraparticle 
porosity of MCC promotes rapid penetration of water through capillary action and is 
responsible for its ability to enhance disintegration [160, 381, 382]. Raising compaction 
force to 2.2 T lowered friability <1% (0.74%), maintained a low disintegration time of 
22.67 ± 2.52 sec and raised hardness to 137.63 ± 2.91 N (data not shown). Formulation 
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composition is shown in Table 5.5 and characterisation of formulations is shown in Table 
5.6.  
 
Compaction Force (T) Hardness (N) Disintegration Time (s) Friability (% loss) 
1 51.40 ± 0.26 19.33 ± 1.53 
 
1.2 68.27 ± 5.56 20.67 ± 4.16 
 
1.4 78.23 ± 2.96 18.33 ± 2.52 3.97 
1.6 99.37 ± 5.28 21.33 ± 0.58 2.46 
1.8 99.83 ± 13.67 19.67 ± 1.15 2.29 
2 100.17 ± 7.97 20.33 ± 0.58 1.97 
 
  
Table 5.2 ODTs of rifampicin and isoniazid (15% and 10% w/w respectively), containing 
SSF (0.5% w/w) and Pearlitol Flash as a diluent. The effect on tablet properties of altering 
compaction force is shown (mean ± SD, n=3) 
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Lubricant Hardness (N) Disintegration Time (s) Friability (%) 
SSF 0.5% w/w 100.17 ± 7.97 20.33 ± 0.58 1.97 
SSF 1% w/w 96.27 ± 6.87 18.67 ± 1.15 1.62 
SSF 1.5% w/w 101.03 ± 2.35 21.67 ± 0.58 1.71 
MS 0.5% w/w 82.07 ± 7.72 25.33 ± 2.52 1.61 
MS 1% w/w 61.90 ± 2.55 43.67 ± 9.71 2.83 
 
MCC Hardness (N) Disintegration Time (s) Friability (%) 
5% MCC w/w 102.03 ± 1.62 19.33 ± 1.15 1.67 
10% MCC w/w 106.00 ± 3.68 20.67 ± 1.15 1.48 
15% MCC w/w 119.50 ± 3.90 20.33 ± 1.15 1.04 
 
  
Table 5.3 FDC ODTs of rifampicin and isoniazid (15% and 10% w/w respectively), 
containing either MS or SSF as lubricants. The effect that changing lubricant and 
lubricant concentration has on ODT properties is shown (mean ± SD, n=3). 
Table 5.4 Inclusion of MCC as a binder and disintegrant in the ODTs containing both 
rifampicin and isoniazid (15% and 10% w/w respectively), SSF (1.5% w/w) and Pearlitol 
diluent. MCC concentrations are given as % w/w (mean ± SD, n=3). 
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 Isoniazid (10%) Rifampicin (15%) 
Isoniazid + 
Rifampicin (10% + 
15%) 
 f1 f2 f3 
Isoniazid 50  50 
Rifampicin  75 75 
Pearlitol 
Flash 367.5 342.5 292.5 
SSF (1.5%) 7.5 7.5 7.5 
MCC (15%) 75 75 75 
 
 Hardness (N) Porosity Disintegration Time (s) Friability (%) 
f1 95.50 ± 1.15 0.26 ± 0.01 22.67 ± 1.53 1.10 
f2 143.90 ±15.47 0.25 ± 0.01 22.67 ± 1.15 0.86 
f3 151.17 ± 4.48 0.23 ± 0.01 26.67 ± 2.52 0.85 
 
5.3.2 HPLC Protocol Validation 
Linearity test solutions were prepared from stocks at six concentrations ranging from 100 
to 1.5625 μg/ml. Calibration curves for both drugs alone and in combination are shown 
in Figure 5.5 to Figure 5.8. Validation of protocols by intraday studies for isoniazid, 
rifampicin and isoniazid/rifampicin combination (Table 5.7 to Table 5.9), show good 
method accuracy and precision. Method accuracy is demonstrated by multilevel 
recovery, ranging from 100 μg/ml to 6.25 μg/ml. Accurate recovery was exhibited in all 
Table 5.5 ODT formulations for individual dose and FDC ODTs. Values for APIs and 
excipients are given as % w/w for 500mg tablets.  All formulations underwent compaction 
at 2.2 T with a 6 s dwell time 
Table 5.6 Individual and FDC ODT properties. All formulations underwent compaction at 
2.2 T with a 6 s dwell time (mean ± SD, n=3) 
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instances, ranging from 98.03 to 101.98 %. Relative standard deviation (RSD) values 
representing intraday precision for isoniazid, rifampicin and isoniazid/rifampicin were 
low, ranging from 0.51 to 2.40 %. Instrument precision, tested for by six consecutive 
injections of the same sample (100 μg/ml), was high, with RSD values of 0.01% in all 
cases. LOQ and LOD values for isoniazid and rifampicin alone were at or below 0.80 
and 0.24 μg/ml, respectively. LOQ and LOD values for isoniazid in combination were 
even lower, whilst rifampicin in combination rifampicin showed the highest LOQ and LOD 
of 1.18 and 0.36 μg/ml, respectively. 
 
 
 
 
 
Figure 5.1 HPLC calibration curve for isoniazid, linear over a concentration range of 
100 to 1.6 μg/ml (mean ± SD, n=3) 
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Figure 5.3 HPLC calibration curve for rifampicin, linear over a concentration range of 
100 to 1.6 μg/ml (mean ± SD, n=3) 
 
Figure 5.2 HPLC calibration curve for detection of isoniazid (50 mg) in combination 
with rifampicin, linear over a concentration range of 25 to 0.78 μg/ml (mean ± SD, 
n=3) 
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Figure 5.4 HPLC calibration curve for detection of rifampicin (75 mg) in combination 
with isoniazid, linear over a concentration range of 25 to 0.78 μg/ml (mean ± SD, n=3) 
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Isoniazid conc. actual 
(µg/ml) 
Isoniazid conc. 
calculated (µg/ml) RSD (%) Recovery (%) 
100 100.15 ± 0.94 0.94 100.15 ± 0.94 
50 49.87 ± 0.35 0.70 99.74 ± 0.70 
25 24.69 ± 0.31 1.25 98.78 ± 1.25 
12.5 12.38 ± 0.10 0.83 99.03 ± 0.83 
6.25 6.25 ± 0.04 0.71 99.96 ± 0.71 
Instrument precision (% RSD)  =  0.08 
Mean % recovery  =  99.53 ± 0.60 
RSD % recovery  =  0.01 
LOD = 0.24 µg /ml 
LOQ = 0.80 µg /ml 
Correlation coefficient  0.99997 
 
 
 
 
 
 
 
 
Table 5.7 HPLC method validation for detection of isoniazid. Data for linearity (correlation 
coefficient), instrument precision, accuracy (recovery), precision (% RSD), LOD and 
LOQ are displayed (mean ± SD, n=3) 
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Rifampicin conc. 
actual (µg/ml) 
Rifampicin conc. 
calculated (µg/ml) RSD (%) Recovery (%) 
100 100.26 ± 2.40 2.40 100.26 ± 2.40 
50 49.39 ± 1.12 2.24 98.78 ± 2.24 
25 25.10 ± 0.53 2.11 100.42 ± 2.11 
12.5 12.53 ± 0.16 1.31 100.22 ± 1.31 
6.25 6.37 ± 0.15 2.32 101.98 ± 2.32 
Instrument precision (% RSD)  =  0.13 
Mean % recovery  =  100.33 ± 1.13 
RSD % recovery  =  0.01 
LOD = 0.14 µg /ml 
LOQ = 0.46 µg /ml 
Correlation coefficient  0.99994 
 
  
Table 5.8 HPLC method validation for detection of rifampicin. Data for linearity 
(correlation coefficient), instrument precision, accuracy (recovery), precision (% RSD), 
LOD and LOQ are displayed (mean ± SD, n=3) 
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Conc. actual (µg/ml) Conc. calculated (µg/ml) RSD (%) Recovery (%) 
Isoniazid    
100 99.78 ± 1.89 1.89 99.78 ± 1.89 
50 50.51 ± 0.90 1.81 101.02 ± 1.81 
25 24.94 ± 0.20 0.80 99.75 ± 0.80 
12.5 12.45 ± 0.15 1.19 99.61 ± 1.19 
6.25 6.13 ± 0.11 1.69 98.03 ± 1.69 
Instrument precision (% RSD)  =  0.27 
Mean % recovery  =  99.64 ± 1.06 
RSD % recovery  =  0.01 
LOD = 0.15 µg /ml 
LOQ = 0.51 µg /ml 
Correlation coefficient  0.99996 
Rifampicin    
100 99.59 ± 1.78 1.78 99.59 ± 1.78 
50 50.65 ± 0.62 1.23 101.30 ± 1.23 
25 25.34 ± 0.13 0.51 101.36 ± 0.51 
12.5 12.69 ± 0.14 1.13 101.52 ± 1.13 
6.25 6.17 ± 0.08 1.35 98.69 ± 1.35 
Instrument precision (% RSD)  =  0.02 
Mean % recovery  =  100.49 ± 1.28 
RSD % recovery  =  0.01 
LOD = 0.36 µg /ml 
LOQ = 1.18 µg /ml 
Correlation coefficient  0.99987 
 
Table 5.9 HPLC method validation for simultaneous detection of isoniazid and rifampicin. 
Data for linearity (correlation coefficient), instrument precision, accuracy (recovery), 
precision (% RSD), LOD and LOQ are displayed (mean ± SD, n=3) 
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5.3.3 Dissolution 
Dissolution of API from single and FDC ODTs was tested in FaSSIF and FeSSIF media 
(Figure 5.5 to Figure 5.8) and profiles were compared by f1 and f2 testing (Table 5.10). 
Rapid and complete isoniazid dissolution from single dose (99.2%) and FDC (100.6%) 
in FaSSIF was observed. Difference testing showed dissolution profiles were equivalent 
(f1=14.17), however similarity testing indicated difference between both profiles 
(f2=32.79). Despite this isoniazid dissolution exceeded 85% within 15 min. In FeSSIF, 
similar drug release profiles for isoniazid are again seen from both single dose and FDC 
formulations. Rapid dissolution, peaking at 100.12% and 101.52%, was observed in 
single and FDC respectively, with both formulations exceeding 85% dissolution by 5 min. 
Values for f1 and f2 testing support the similarity between single and FDC, showing no 
difference between the two dissolution profiles. 
Rifampicin dissolution from single and FDC formulations in FaSSIF was comparable 
based on f1 and f2 testing, with complete dissolution of 100.6% from single dose, whilst 
dissolution from FDC peaked at 91.5%. Dissolution profiles for rifampicin from single and 
FDC in FeSSIF were deemed different, failing f1 and f2 testing.  Rifampicin from single 
dose was rapidly released, showing >85% dissolution by 5 min, peaking at 98.26%, 
however in combination rifampicin release was retarded, with a maximum dissolution 
after 1 h of 85.32%.  
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Figure 5.5 Isoniazid (50 mg) dissolution profiles of single and FDC formulations in 
fasted state biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution 
performed using USP 2 paddle apparatus (mean ± SD, n=3) 
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Figure 5.6 Isoniazid (50 mg) dissolution profiles of single and FDC formulations in fed 
state biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution performed 
using USP 2 paddle apparatus (mean ± SD, n=3) 
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Figure 5.7 Rifampicin (75 mg) dissolution profiles of single and FDC formulations in 
fasted state biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution 
performed using USP 2 paddle apparatus (mean ± SD, n=3) 
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Figure 5.8 Rifampicin (75 mg) dissolution profiles of single and FDC formulations in 
fed state biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution performed 
using USP 2 paddle apparatus (mean ± SD, n=3) 
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Compound Media >85% Dissolution ≤15 min f1 f2 Result 
Isoniazid 
FaSSIF Yes 14.17 32.79 Pass 
FeSSIF Yes 3.78 65.30 Pass 
Rifampicin 
FaSSIF No 9.30 55.76 Pass 
FeSSIF No 15.55 44.82 Fail 
 
5.3.4 Permeability Studies 
TEER values for Caco-2 cells over 21 days (Figure 5.9) plateau from day 18, showing a 
resistance of 1351.1 ± 88.6 Ω·cm2 by day 21 post-seeding. Isoniazid and rifampicin 
transport across Caco-2 monolayers alone and in combination was measured in A-B and 
B-A directions. Drug transport is shown for isoniazid (Figure 5.10), rifampicin (Figure 
5.11), isoniazid combination (Figure 5.12) and rifampicin combination (Figure 5.13). 
Papp values were calculated using the gradient of the linear portion of the curve and are 
summarised in Table 5.11.  
Isoniazid was readily absorbed across Caco-2 monolayers from both A-B and B-A 
directions, exhibiting an efflux ratio of 1.18 indicating passive diffusion. Similar 
permeability was displayed for isoniazid in combination with rifampicin, with an efflux 
ratio of 1.19. Rifampicin Papp values suggested active efflux of the compound, with efflux 
ratio values of 4.33 and 2.61 from single and combination respectively. Active efflux of 
rifampicin across Caco 2 monolayers has previously been indicated [383]. 
 
 
Table 5.10 Comparison of dissolution profiles for each compound from single and FDC 
formulations in FaSSIF and FeSSIF media, by difference factor f1 and similarity factor f2 
testing. Dissolution profiles are considered similar if the f1 value is below 15 and the f2 
value is above 50.   
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Figure 5.10 Cumulative mass transfer of isoniazid alone (20 μg/ml) across Caco-2 
monolayers (pH 7.4). Papp values calculated using the gradient of the linear portion 
of the curve (mean ± SD, n=3) 
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Figure 5.9 TEER values for Caco-2 monolayers grown on 12 mm Transwell inserts 
from days 0-21 post-seeding. Cells were seeded at a density of 8x104 cells/cm2 and 
maintained in DMEM at 37°C and 5% CO2 (mean ± SD, n=12) 
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Figure 5.11 Cumulative mass transfer of rifampicin alone (20 μg/ml) across Caco-2 
monolayers (pH 7.4). Papp values calculated using the gradient of the linear portion 
of the curve (mean ± SD, n=3) 
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Figure 5.12 Cumulative mass transfer of isoniazid (20 μg/ml) whilst in combination 
with rifampicin across Caco-2 monolayers (pH 7.4). Papp values calculated using the 
gradient of the linear portion of the curve (mean ± SD, n=3) 
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Compound Papp 10-6 cm s-1 Efflux Ratio 
 A-B B-A  
Isoniazid 16.37 ± 0.48 19.27 ± 0.32 1.18 
Rifampicin 1.37 ± 0.12 5.95 ± 0.42 4.33 
Isoniazid Combination 22.69 ± 1.21 26.98 ± 0.26 1.19 
Rifampicin Combination 2.14 ± 0.19 5.58 ± 0.50 2.61 
 
  
Table 5.11 Papp vales for isoniazid and rifampicin alone and in combination in A-B and 
B-A directions across Caco-2 monolayers at pH 7.4 in both compartments (mean ± SD, 
n=3) 
 
Figure 5.13 Cumulative mass transfer of rifampicin (20 μg/ml) whilst in combination 
with isoniazid across Caco-2 monolayers (pH 7.4). Papp values calculated using the 
gradient of the linear portion of the curve (mean ± SD, n=3) 
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5.3.5 Clinical Trials Simulation 
The initial simulation of the kinetics of isoniazid (derived from data presented in Table 
5.1) were used to optimize the effective permeability (Peff) and steady-state volume of 
distribution (Vss) from clinical data sets 1 and 2 for each API.  Optimized Peff and Vss were 
estimated as 10.23 x10-4 cm/s and 0.63 L/kg. Default (Simcyp validated) parameters (as 
presented in Table 5.1) were used to simulate rifampicin kinetics. 
Subsequent validation of isoniazid and rifampicin using validation data sets 3 and 4 for 
each API was successful and generally centred around the mean simulated profiles and 
within the 5th and 95th percentiles of the simulated profiles (see Figure 5.14 and Figure 
5.15). 
 
 
 
 
Figure 5.14 Simulated mean plasma profile after a 300 mg oral dose of isoniazid (solid 
black line). The corresponding observed data points are shown by red open circles. 
The grey lines represent the 5th and 95th percentiles for the predicted values. All 
simulations were performed using the minimal PBPK model. 
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Simulations to predict the in vivo performance of ODTs in healthy volunteers were used 
to compare the bioavailability between single and FDC formulations under fasted and 
fed conditions using dissolution data determined in section 5.3.3. For isoniazid the 
formulation state (single or combined) or dosing state (fasted or fed) had no statistically 
significant impact on pharmacokinetics (A and B). Isoniazid plasma concentrations 
reached a geometric mean Cmax of 0.70-0.74 ng/ml in all conditions (Table 5.12), yielding 
a median AUC in the range of 4-4.25 ng/ml.h. 
At the level of the small-intestine, predicted mean fraction dose absorbed (Fa) for 
isoniazid correlated with dissolution profiles, showing no significant differences between 
single and combination formulations, 0.98 ± 0.02 and 0.97 ± 0.03 (fasted) and 0.99 ± 
0.04 and 0.96 ± 0.05 (fed), respectively.  
 
 
 
 
Figure 5.15 Simulated mean plasma profile after a 600 mg oral dose of rifampicin 
(solid black line). The corresponding observed data points are shown by red (set 3) 
or green (set 4) open circles. The grey lines represent the 5th and 95th percentiles 
for the predicted values. All simulations were performed using the minimal PBPK 
model. 
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Fa values for rifampicin were equivalent between single and combination doses at 0.94 
in fasted subjects; likewise, no difference was seen in Fa for fed subjects, with values of 
0.94 for both single and combination doses. Rifampicin plasma profiles similarly showed 
no statistically significant difference (p>0.05) in pharmacokinetic parameters between 
single and combination doses in fasted subjects (Figure 12C). Rifampicin plasma 
concentrations in combined formulations (irrespective of fasted/fed state) demonstrated 
higher AUCs (9.26 ng/ml.h) compared to single formulation (8.80 ng/ml.h). Furthermore, 
geometric mean Cmax was generally consistent across all formulations and conditions 
(1.22-1.24 ng/ml) (Table 5.13) with a tmax of 2.56-2.38 h. 
Bioavailability (F) for isoniazid in all cases was approximately 1, whilst F values for 
rifampicin were 0.91. This may be related to the high Fa seen with both APIs. 
Bioavailability for rifampicin correlates well with reported values. Rifampicin is a CYP3A4 
 
Figure 5.16 Simulated mean plasma profile after a 50 mg oral dose of isoniazid (A 
and B) and 75 mg oral dose of rifampicin (C and D) under fasted and fed conditions. 
Single API formulations indicated in black and fixed dose combination in red. Solid 
lines represent trial mean and dashed lines represent the 5th and 95th percentiles for 
the predicted values. 
Chapter 5 – Fixed Dose Combination ODTs to Treat Tuberculosis: Physiologically 
Based Pharmacokinetic Modelling to Assess Bioavailability 
230 
inducer and it is likely that over a longer study period (i.e. multidose over a few weeks) 
F would drop to around 65-70%, as a result of increased metabolism [384].  
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  Isoniazid Fasted Isoniazid Fed 
Parameters Single Combined Single Combined 
AUC (ng/ml.h) 4.05 (3.14-7.10) 4.24 (3.13-7.41) 4.05 (3.14-7.10) 4.24 (3.13-7.42) 
Cmax (ng/ml) 0.74 (0.13) 0.70 (0.12) 0.74 (0.13) 0.70 (0.12) 
tmax (h) 1.48 (1.14-1.92) 1.49 (1.21-1.96) 1.48 (1.14-1.92) 1.49 (1.12-1.91) 
 
  Rifampicin Fasted Rifampicin Fed 
Parameters Single Combined Single Combined 
AUC (ng/ml.h) 8.80 (6.63-13.63) 9.26 (6.61-13.50) 8.80 (6.63-13.63) 9.26 (6.61-13.50) 
Cmax (ng/ml) 1.24 (0.18) 1.22 (0.30) 1.24 (0.18) 1.22 (0.30) 
tmax (h) 2.38 (1.51-2.80) 2.38 (1.80-2.85) 2.38 (1.51-2.80) 2.36 (1.80-2.86) 
Table 5.12 Summary of pharmacokinetic parameters for isoniazid (50 mg) under fasted and fed conditions. Geometric mean (SD) reported for
Cmax and median (range) for AUC and tmax 
Table 5.13 Summary of pharmacokinetic parameters for rifampicin (75 mg) under fasted and fed conditions. Geometric mean (SD) reported for 
Cmax and median (range) for AUC and tmax  
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5.4 Conclusion 
ODTs demonstrated satisfactory performance for hardness, friability and disintegration. 
Dissolution profile assessment and comparison between single and FDC formulations of 
isoniazid indicated bioequivalence and this was reinforced through PBPK modelling, with 
no difference between pharmacokinetic parameters. Comparable bioequivalence was 
not assumed for rifampicin from dissolution comparison in FeSSIF, with release falling 
by around 15%. This observed drop in dissolution is most likely instead a result of 
degradation, given the complete release seen from single dose formulations and the well 
documented enhanced degradation of rifampicin seen in the presence of isoniazid under 
acidic conditions. In the absence of ascorbic acid, a perceived drop in rifampicin 
dissolution, due to degradation, would be seen for all rifampicin containing formulations 
in fact, however this is only significantly pronounced in combination with isoniazid in the 
more acidic FeSSIF media (pH 5).  
Clinical trial simulations reported no difference in the bioavailability of isoniazid from the 
combination dose compared to the single dose, as predicted through dissolution profile 
assessment and comparison. Additionally, no food effect was seen. Interestingly, despite 
the retarded dissolution (degradation) from FDCs in FeSSIF, this did not result in a 
reduced bioavailability, with performance of FDCs in FaSSIF similarly showing 
bioequivalence with the single dose formulation. Furthermore, no difference in Fa values 
for rifampicin formulations was seen, implying that permeation across the intestinal 
epithelial membrane was a rate limiting factor; indeed, reclassification of rifampicin as a 
BCS class IV compound due to low intestinal permeability has been suggested [385], 
whilst the Papp values reported here indicate moderate to low permeability. Significantly, 
this result highlights a failure in f1 and f2 factor testing in this instance to predict 
bioequivalence, since bioavailability was not altered despite dissolution profiles being 
different. 
For rifampicin, due to the inclusion of ascorbic acid as an antioxidant and since 
dissolution and degradation was not tested in simulated gastric fluid (at a lower pH), 
actual bioavailability values in vivo may differ. Regardless of this however, PBPK 
modelling demonstrated that the bioavailability of either drug was unaltered as a result 
of combination with the other, in these formulations. Rapid release isoniazid and 
rifampicin FDC ODTs thus may be a viable and attractive formulation prospect, whilst 
the framework used here could be employed in the development of more complex 
formulations. It should be noted that the focus for these investigations was on 
Chapter 5 – Fixed Dose Combination ODTs to Treat Tuberculosis: Physiologically 
Based Pharmacokinetic Modelling to Assess Bioavailability 
233 
preformulation and initial dosage form development and therefore stability studies were 
not carried out. 
Chapter 6 – Fixed Dose Combination ODTs to Treat Cardiovascular Disease: 
Physiologically Based Pharmacokinetic Modelling to Assess Bioavailability 
234 
 
 
 
 
 
Chapter 6 
Fixed Dose Combination Orally Disintegrating Tablets to 
Treat Cardiovascular Disease: Physiologically Based 
Pharmacokinetic Modelling to Assess Bioavailability 
 
Chapter 6 - Fixed Dose Combination Orally Disintegrating 
Tablets to Treat Cardiovascular Disease: Physiologically 
Based Pharmacokinetic Modelling to Assess Bioavailability 
 
6  
 
 
  
Chapter 6 – Fixed Dose Combination ODTs to Treat Cardiovascular Disease: 
Physiologically Based Pharmacokinetic Modelling to Assess Bioavailability 
235 
6.1 Introduction 
Cardiovascular disease (CVD) is the leading cause of death worldwide, claiming an 
estimated 17.3 million lives per year, a death toll that is expected to rise to in excess of 
23.6 million by 2030. Deaths from CVD accounted for 30% of global deaths in 2008, 
more than all forms of cancer combined [386].  
CVD is multifactorial, with risk factors such as hypertension, dyslipidaemia, diabetes 
mellitus, smoking and obesity frequently co-existing [387]. One of the most common risk 
factor combinations is dyslipidaemia (elevated levels of low-density lipoprotein (LDL) and 
triglyceride (TG) and low levels of high-density lipoprotein (HDL)) and hypertension 
[388]. Studies have demonstrated the link between hypertension and metabolically 
associated risk factors [389]; in a retrospective study of US veterans, for example, the 
prevalence of CVD was commonly double that in patients exhibiting both hypertension 
and dyslipidaemia when compared to those with either condition alone [390]. In the UK, 
a 2004 analysis of the medical records of over 600,000 patients revealed a 14.7% 
incidence of subjects with both hypertension and dyslipidaemia  [391]. 
Amlodipine (BCS class I [392]) is a 3rd generation dihydropyridine calcium channel 
blocker, a class of drug that works to lower blood pressure in hypertensive patients 
through relaxation of vascular smooth muscle and vessel dilation [393]. It acts by 
inhibiting ‘slow’ influx of extracellular calcium into cardiac and vascular cells via blockade 
of voltage-gated L-type calcium channels [394, 395]. Amlodipine’s slow onset of action 
is responsible for a low incidence of reflex tachycardia and other vasodilator side effects 
when compared to other dihydropyridines, whilst its slow elimination and resultant long 
duration of action grants the convenience of a once-daily dosage regime [396].  
Atorvastatin (BCS class II [397]), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitor, is used extensively in the treatment of dyslipidaemia [398]. HMG-
CoA reductase catalyses the conversion of HMG-CoA to mevalonate. Its inhibition 
reduces hepatocyte cholesterol levels, leading to upregulation of LDL cholesterol (LDL-
C) cell surface receptors and resulting in increased clearance of LDL-C from plasma 
[399, 400]. Atorvastatin reportedly reduces LDL-C in hypercholesterolaemic patients by 
41-61% [401], as well as reducing total cholesterol and plasma triglycerides alongside a 
modest increase in HDL cholesterol (HDL-C) levels [402]. 
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Despite the substantial risk to patients suffering both dyslipidaemia and hypertension, 
successful treatment falls short [403]. A major reason for this is poor patient compliance, 
for reasons including cost, treatment regime complexity, extent of concomitant treatment 
and side effects [401, 404, 405]. Several clinical studies have examined the efficacy and 
safety of amlodipine and atorvastatin combination therapy in patients with concurrent 
hypertension and dyslipidaemia. Combination therapy has been shown to achieve blood 
pressure and LDL goals [406, 407]. The RESPOND study, which compared combination 
therapy with amlodipine or atorvastatin alone showed no difference in efficacy [408], 
whereas the AVALON study reported an increased efficacy with combination therapy 
over either drug alone [409]. Furthermore, when amlodipine and atorvastatin are 
administered in a fixed dose combination (FDC) there is no significant difference in 
bioavailability (based on tmax, Cmax and AUC) compared to coadministered matching 
doses of individual amlodipine and atorvastatin tablets [410].  
An amlodipine and atorvastatin FDC is therefore an attractive prospect with the view of 
improving patient compliance. In addition to demonstrating bioequivalence in vivo, in 
combination both amlodipine and atorvastatin allow for once-daily dosing and have no 
issues with tolerability [401]. Indeed, an amlodipine and atorvastatin FDC (Caduet®) was 
approved in 2004 as the first fixed-dose combination to treat two cardiovascular disease 
categories [411].  
The potential to enhance therapy for patients suffering both dyslipidaemia and 
hypertension with an orally disintegrating FDC for amlodipine and atorvastatin is 
substantial. Since no change in bioavailability for amlodipine and atorvastatin from FDCs 
has been reported, it is expected that FDC ODTs, given their immediate disintegration 
and therefore rapid drug release, should show similar findings. Furthermore, the ability 
of ODTs to increase patient compliance due to their convenience as a dosage form, 
would likely enhance CVD therapy. In this work an FDC ODT for amlodipine and 
atorvastatin was developed and characterised. Single dose and fixed dose drug 
dissolution from ODTs was tested in biorelevant media, whilst drug permeability across 
Caco2 cell monolayers was measured for prediction of in vivo pharmacokinetics and 
bioequivalence of FDCs compared to single dose formulations, through PBPK 
computational modelling.  
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6.2 Materials and Methods 
6.2.1 Materials 
Amlodipine besylate (herein referred to as amlodipine) was purchased from Molekula 
Ltd (UK) and atorvastatin calcium (herein referred to as atorvastatin) from Chemical 
Point (Germany). Pearlitol Flash (mannitol-starch copolymer) was obtained from 
Roquette Pharma (France), with Avicel PH-102 micro-crystalline cellulose (MCC) and 
sodium stearyl fumerate (SSF) supplied by FMC BioPolymer (USA).  
Biorelevant FaSSIF/FeSSIF/FaSSGF Instant Powder was purchased from 
biorelevant.com (UK). Sodium hydroxide, sodium chloride, sodium phosphate and 
glacial acetic acid for biorelevant media were obtained from Sigma-Aldrich (UK). 
Acetonitrile (ACN) and methanol (HPLC-grade) were obtained from Fisher Scientific 
(UK). 
For cell culture media DMEM was purchased from Lonza (UK), fetal bovine serum (FBS), 
gentamicin (10 mg/ml), Fungizone (amphotericin B 250 μg/ml), HBSS and 
penicillin/streptomycin (10,000 U/ml) were all purchased from Gibco (Thermo Fischer 
Scientific, UK). Trypsin-EDTA solution (0.25%) was procured from Sigma-Aldrich (UK). 
 
6.2.2 HPLC 
HPLC was performed on an Agilent 1260 series (Agilent Technologies, USA), comprising 
a quarternary pump, Infinity VWD and autosampler. Analysis was conducted on a 
reversed-phase Gemini C18, 150 x 4.6 mm, 110Å, 5μm column (Phenomenex, UK). 
Protocols were developed, calibrated and validated for both amlodipine and atorvastatin 
alone and in combination. 
Separations were achieved using 0.1% (v/v) TFA and ACN at different ratios as the 
mobile phase. Amlodipine separation was performed with an isocratic mobile phase of 
TFA: ACN (57.5:42.5 v/v), a flow rate of 1 ml/min and a wavelength of 360 nm. 
Atorvastatin separation was achieved using an isocratic mobile phase of TFA: ACN 
(50:50 v/v), a flow rate of 1.2 ml/min and a wavelength of 246 nm. Separation of 
amlodipine and atorvastatin in combination required a mobile phase of TFA: ACN 
delivered at a gradient (65:35 to 35:65 v/v), with a flow rate of 1.5 ml/min and a 
wavelength of 240 nm. An injection volume of 20 μl was used throughout. 
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HPLC method validation involved assessment of precision through intra-day variation, 
accuracy by multilevel recovery studies, instrument precision, linearity and limit of 
detection and quantification (LOD and LOQ). Stock solutions (1 mg/ml) of each drug 
were prepared (using ACN and methanol as solvents for amlodipine and atorvastatin, 
respectively) from which dilutions and subsequently two-fold serial dilutions were 
prepared to form a calibration curve. 
 
6.2.3 Tablet Production 
Direct compression of tablets (500 mg) was performed on an Atlas T8 automatic press 
(SPECAC, UK), using a 13mm round, flat faced die. Tablets were produced under 
ambient conditions. 
 
6.2.4 Friability 
Tablet friability was determined on 6 tablets using an F2 friability tester (Sotax, 
Switzerland). Tablets were placed inside the drum and rotated at 25 rpm for a total of 
100 revolutions. Dust was removed pre and post testing to remove excess powder that 
would contribute to tablet mass. Friability was calculated and expressed as % tablet 
weight loss from initial tablet weight. 
 
6.2.5 Tablet Hardness 
A Tablet Hardness Tester TBF1000 (Copley Scientific, UK) was used to measure the 
radial crushing strength (hardness) of tablets in triplicate.  
 
6.2.6 Dissolution Testing 
API dissolution from ODTs in 900 ml biorelevant media was tested in both fasted state 
simulated intestinal fluid (FaSSIF) and fed state simulated intestinal fluid (FeSSIF), at 
pH 6.5 and 5 respectively and maintained at 37°C. An ERWEKA DT 600 USP 2 paddle 
apparatus (Germany) was used at a paddle speed of 50 rpm [367]. 5ml samples were 
Chapter 6 – Fixed Dose Combination ODTs to Treat Cardiovascular Disease: 
Physiologically Based Pharmacokinetic Modelling to Assess Bioavailability 
239 
taken over 2 h, replacing with 5 ml fresh media to simulate sink conditions. API 
dissolution was measured using HPLC and corrected for % dose dissolved.  
 
6.2.7 Cell Culture 
Prior to seeding, cells were trypsinised (2.5 ml) from 75-cm2 cell culture flasks (Corning, 
USA) on which they had been grown (80% confluence), after washing with HBSS. Caco-
2 cells (passage 54-58) were seeded onto Transwell (Corning, USA) semi-permeable 
membrane supports (12-well, 1.12 cm2, 0.4 μm pore size) at a density of 8x104 cells/cm2. 
Cells were maintained in DMEM containing L-glutamine (4 mM) and glucose (4.5 mg/ml) 
supplemented with (v/v) 10% FBS, 1% penicillin/streptomycin, 1% NEAA, amphotericin 
B (0.5 μg/ml) and gentamicin (20 μg/ml).  Media was changed every 2-3 days and 
transwells cultured at 37°C, 5% CO2 for 21 days, after which transport studies were 
performed.  
 
6.2.8 Transepithelial Electrical Resistance (TEER) Measurements 
TEER value measurements were performed to monitor monolayer integrity using an 
EVOM meter (World Precision Instruments, USA). TEER values are expressed using the 
equation: 
ܶܧܧܴ (Ω · ܿ݉2)  =  (ݎ݁ݏ݅ݏݐܽ݊ܿ݁ –  ܾ݈ܽ݊݇ ݎ݁ݏ݅ݏݐܽ݊ܿ݁) ݔ ܾ݉݁݉ݎܽ݊݁ ݏݑݎ݂ܽܿ݁ ܽݎ݁ܽ (ܿ݉2) 
 
6.2.9 Caco-2 Transport Studies 
Caco-2 monolayers were used for transport studies between 21 and 24 days post-
seeding. Drug absorption through Caco-2 monolayers was measured for amlodipine and 
atorvastatin alone and in combination in both the apical to basolateral (A-B) and 
basolateral to apical (B-A) directions (n=3). Transport studies were carried out in DMEM 
(37°C) containing 10 mM HEPES (pH 7.4), with 0.5 ml and 1.5 ml in the A and B 
compartments, respectively. Samples of 100 μl were removed from the A side and 200 
μl from the B side at time points over 2 h, replacing with fresh pre-warmed media (37°C) 
to mimic sink conditions. For mass balance, samples were taken from the donor 
compartments at t=0 and t=120 min.  
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Amlodipine was administered at a concentration equivalent to 20 μg/ml (representing a 
dose of 5 mg in 250 ml) and atorvastatin at a concentration equivalent to 40 μg/ml 
(representing a dose of 10 mg in 250 ml). Cultures were maintained at 37°C and 5% CO2 
throughout the experiment. Samples were analysed by HPLC and apparent permeability 
(Papp) values were calculated using equation: 
ܲܽ݌݌ =  (݀ܳ/݀ݐ)/(ܥ଴ ݔ ܣ) 
Where dQ/dt is the mass transfer rate of the compound from the donor to the receiver 
compartment, C0 is the initial concentration in the donor chamber and A is the monolayer 
surface area (cm2).  
 
6.2.10 Clinical Trials Simulation 
The population-based clinical trials simulator Simcyp (V14) (Certara, USA) was used to 
simulate the plasma concentration of atorvastatin and amlodipine from single API and 
FDC formulations.  Default parameter values for creating a North European Caucasian 
population were selected [371].  
 
6.2.11 Compound Data 
Physicochemical information for each API was collated from the literature used to 
develop compound files (Table 6.1).  Simulations were performed using a minimal-PBPK 
model. Where uncertainty arose regarding the precise value of compound data 
parameters, parameter estimation was conducted using the Parameter Estimation 
Module to optimise parameter values. The ADAM model [372] was assumed for all 
simulations and the dissolution profile for each formulation (single and FDC) in FaSSIF 
and FeSSIF were utilised. 
 
6.2.12 Clinical Studies 
The optimisation and validation of the PBPK model was conducted using clinical study 
results reported in healthy adult subjects. For atorvastatin: study 1 included 20 mg tablet 
dosed to 36 healthy volunteers (18-45 years old) [412]; study 2 included a 20 mg tablet 
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dosed to 24 healthy [413]; study 3 included an 80mg capsule dosed to 36 healthy 
subjects (20-50 years old) [414];  study 4 included 10 mg tablet dosed to 50 healthy 
volunteers[415]. Studies 1 and 2 were used for model development and studies 3 and 4 
utilised for validation. 
For amlodipine: study 1 included a 5 mg tablet dosed to 24 healthy [413]; study 2 
included a 5 mg tablet dosed to 28 healthy volunteers (35.48 ± 9.52 years old) [416]; 
study 3 included a 10 mg tablet dosed to 24 healthy volunteers (21-29 years old) [417]; 
study 4 included a 10 mg tablet dosed to 35 subjects (18-46 years old) [418]. Studies 1 
and 2 were used for model development and studies 3 and 4 utilised for validation. 
Raw data from published human trial plasma concentration profiles was extracted using 
WebPlotDigitizer 3.10 [377] and, where necessary, parameter estimation was conducted 
using the validation clinical datasets.  
Predictions of API plasma pharmacokinetic profiles were simulated following the oral 
administration of a single immediate release solid dosage form of 10mg (atorvastatin) 
and 5 mg (amlodipine) dose over a 24 hr period. 
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Parameter Amlodipine Atorvastatin 
Type Diprotic base Monoprotic acid 
MW 408.88 588.2 
LogP 3.43 [419] 5.7 
pKa 9.4,1.90 [419] 4.46 
fu 0.07 [420] 0.051 
Vss (L/kg)a Predicted PBPK/PE Predicted PBPK/PE 
B:P ratio 1 0.61 
CLpo (L/min) 24.8 949 
CLint3A4b - 8.28 
Peff (cm/s) PE PE 
Jmax,P-gp 
(pmol/cm2/min) - 151 [421] 
Km,P-gp (µM) - 115 [421] 
RAFP-gp - PE 
   
MW: molecular weight; fu: plasma unbound fraction; Vss: steady-state volume of 
distribution; B:P ratio: blood-to-plasma ratio; Peff: human effective permeability; CLpo: 
oral clearance; PE: parameter estimation; RAF; relative activity factor. a Vss was 
determined from calculation of tissue partitions coefficients within Simcyp or parameter 
estimated. b In vitro intrinsic metabolic clearance (Clint) was calculated using Simcyp 
Retrograde Calculator from in vivo oral clearance and assuming fa=1, fg=0.24 [422] with 
CYP3A4 being the predominant metabolic pathway [423]. 
 
 
 
Table 6.1 Input parameter values and predicted PBPK values for simulation of 
pharmacokinetics of amlodipine and atorvastatin. 
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6.2.13 Statistical Analysis 
GraphPad PRISM software version 6.01 (USA) was used for data analysis. Ordinary 
one-way ANOVA was used with Tukey’s multiple comparisons test to analyse data for 
tablet characterization. Unpaired two-tailed t-test was used to determine statistical 
differences between data sets for pharmacokinetic parameters.  
Differences between dissolution profiles of APIs in single dose (reference) and 
combination (test) were assessed using f1 and f2 difference and similarity factor testing, 
using the equations [346]: 
ଵ݂ = ([෍ |ܴ௧ − ௧ܶ|]/[෍ ܴ௧]) ∗ 100
௡
௧ୀଵ
௡
௧ୀଵ
 
ଶ݂ = 50 ∗ log ({[1 + (1/݊) ෍(ܴ௧ − ௧ܶ)ଶ]ି଴.ହ ∗ 100)
௡
௧ୀଵ
 
Where Rt and Tt are the % drug dissolved value at each time point for the reference and 
test product respectively and n is the number of time points. 
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6.3 Results and Discussion 
6.3.1 ODT Development 
ODT formulations for amlodipine and atorvastatin single and FDC ODTs were based on 
isoniazid and rifampicin ODTs (see section 5.3.1) and thus the formulation development 
is not repeated here. Formulation compositions for all amlodipine and atorvastatin ODTs 
are shown in Table 6.2 and characterisation is presented in Table 6.3. 
 
 Amlodipine (1%) Atorvastatin (2%) 
Amlodipine + 
Atorvastatin (1% 
+ 2%) 
 f1 f2 f3 
Amlodipine Besylate 6.95  6.95 
Atorvastatin Calcium  10.85 10.85 
Pearlitol Flash 410.55 406.65 399.7 
SSF (1.5%) 7.5 7.5 7.5 
MCC (15%) 75 75 75 
 
 Hardness (N) Porosity Disintegration Time (s) Friability (%) 
f1 108.00 ± 8.35 0.23 ± 0.15 25.33 ± 3.21 0.71 
f2 114.40 ± 4.10 0.25 ± 0.00 24.00 ± 3.00 1.02 
f3 117.77 ± 8.97 0.24 ± 0.02 21.67 ± 1.53 0.73 
 
Table 6.2 ODT formulations for individual dose and FDC ODTs. Values for APIs and 
excipients are given as % w/w for 500mg tablets.  All formulations underwent compaction 
at 2.2 T with a 6 sec dwell time 
Table 6.3 Individual and FDC ODT properties. All formulations underwent compaction at 
2.2 T with a 6 s dwell time (mean ± SD, n=3) 
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6.3.2 HPLC Protocol Validation 
Linearity test solutions were prepared from stocks at six concentrations ranging from 25 
to 0.8 μg/ml. Calibration curves for both drugs alone and in combination are shown in 
Figure 6.1 to Figure 6.2. Validation of protocols by intraday studies for amlodipine, 
atorvastatin and amlodipine/atorvastatin combination (Table 6.4 to Table 6.6), show the 
methods to be accurate and precise. Method accuracy is demonstrated by multilevel 
recovery, ranging from 25 μg/ml to 1.5625 μg/ml. Accurate recovery was exhibited in all 
instances, ranging from 98.58 to 102.46 %. Relative standard deviation (RSD) values 
representing intraday precision for amlodipine, atorvastatin and amlodipine/atorvastatin 
ranged from 1.05 to 7.36 %. Instrument precision, tested for by six consecutive injections 
of the same sample (25 μg/ml), was high, with RSD values from 0.01 to 0.04 %. LOQ 
and LOD values for amlodipine and atorvastatin alone were below 0.6 and 0.2 μg/ml, 
respectively. LOQ and LOD values for amlodipine/atorvastatin combination were lower 
still, falling below 0.2 and 0.1 μg/ml, correspondingly. 
 
 
 
Figure 6.1 HPLC calibration curve for amlodipine besylate, linear over a concentration 
range of 25 to 0.8 μg/ml (n=3). 
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Figure 6.3 HPLC calibration curve for atorvastatin calcium, linear over a concentration 
range of 25 to 0.8 μg/ml (mean ± SD, n=3) 
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Figure 6.2 HPLC calibration curve for simultaneous detection of amlodipine besylate 
and atorvastatin calcium, linear over a concentration range of 25 to 0.8 μg/ml (mean 
± SD, n=3) 
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Amlodipine conc. 
actual (µg/mL) 
Amlodipine conc. 
calculated (µg/mL) RSD (%) Recovery (%) 
25 25.02 ± 1.30 5.19 100.10 ± 5.20 
12.5 12.49 ± 0.57 4.59 99.95 ± 4.58 
6.25 6.16 ± 0.29 4.69 98.58 ± 4.62 
3.125 3.11 ± 0.13 4.13 99.54 ± 4.12 
1.5625 1.59 ± 0.06 3.68 101.83 ± 3.75 
Instrument precision (% RSD)  =  0.02 
Mean % recovery  =  100.00 ± 1.18 
RSD % recovery  =  0.01 
LOD = 0.17 µg /mL 
LOQ = 0.57 µg /mL 
Correlation coefficient = 0.99997 
 
  
Table 6.4 HPLC method validation for detection of amlodipine. Data for linearity 
(correlation coefficient), instrument precision, accuracy (recovery), precision (% RSD), 
LOD and LOQ are displayed (mean ± SD, n=3) 
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Atorvastatin conc. 
actual (µg/mL) 
Atorvastatin conc. 
calculated (µg/mL) RSD (%) Recovery (%) 
25 25.05 ± 1.44 5.76 100.19 ± 5.77 
12.5 12.42 ± 0.66 5.34 99.34 ± 5.31 
6.25 6.23 ± 0.38 6.08 99.72 ± 6.07 
3.125 3.08 ± 0.23 7.36 98.42 ± 7.24 
1.5625 1.60 ± 0.10 6.25 102.46 ± 6.40 
Instrument precision (% RSD)  =  0.04 
Mean % recovery  =  100.02 ± 1.51 
RSD % recovery  =  0.02 
LOD = 0.12 µg /mL 
LOQ = 0.40 µg /mL 
Correlation coefficient = 0.99996 
 
  
Table 6.5 HPLC method validation for detection of atorvastatin. Data for linearity 
(correlation coefficient), instrument precision, accuracy (recovery), precision (% RSD), 
LOD and LOQ are displayed (mean ± SD, n=3) 
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Conc. actual (µg/mL) Conc. calculated (µg/mL) RSD (%) Recovery (%) 
Amlodipine 
   
25 25.04 ± 1.16 4.65 100.15 ± 4.65 
12.5 12.43 ± 0.64 5.10 99.46 ± 5.10 
6.25 6.22 ± 0.35 5.64 99.56 ± 5.64 
3.125 3.12 ± 0.18 5.85 99.89 ± 5.85 
1.5625 1.58 ± 0.09 6.06 100.96 ± 6.06 
Instrument precision (% RSD)  =  0.03 
Mean % recovery  =  100.01 ± 0.60 
RSD % recovery  =  0.01 
LOD = 0.04 µg /mL 
LOQ = 0.13 µg /mL 
Correlation coefficient = 0.99998 
Atorvastatin 
   
25 25.01 ± 0.26 1.05 100.03 ± 1.05 
12.5 12.50 ± 0.16 1.28 99.97 ± 1.28 
6.25 6.23 ± 0.14 2.17 99.72 ± 2.17 
3.125 3.11 ± 0.08 2.42 99.64 ± 2.42 
1.5625 1.56 ± 0.04 2.68 100.03 ± 2.68 
Instrument precision (% RSD)  =  0.02 
Mean % recovery  =  99.88 ± 0.18 
RSD % recovery  =  0.00 
LOD = 0.05 µg /mL 
LOQ = 0.17 µg /mL 
Correlation coefficient = 1 
 
Table 6.6 HPLC method validation for simultaneous detection of amlodipine and 
atorvastatin. Data for linearity (correlation coefficient), instrument precision, accuracy 
(recovery), precision (% RSD), LOD and LOQ are displayed (mean ± SD, n=3) 
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6.3.3 Dissolution 
Dissolution of API from formulations f1-f3 was tested in biorelevant media (Figure 6.4 to 
Figure 6.7). Amlodipine dissolution from single and FDC ODTs in FaSSIF was rapid, with 
>50% dissolution within 2 hrs. Near complete dissolution (94.9%) and complete 
dissolution at (101.2%) was observed in single and FDC, respectively. Amlodipine 
dissolution from single and FDC in FeSSIF peaked at 87.9% and 79.9%, respectively. 
Difference and similarity testing comparing dissolution profiles of amlodipine from single 
and combination formulations are shown in Table 6.7. Difference and similarity testing 
was used as a tool to compare dissolution profiles in order to predict bioequivalence. In 
fasted state media, dissolution of amlodipine from both single and FDC exceeded 85% 
within 15 mins, whilst f1 and f2 testing showed no difference between dissolution profiles. 
Dissolution in FeSSIF did not exceed 85% within 15 mins from either single or FDC, with 
dissolution profiles shown to be different based on f1 and f2 factors. 
Atorvastatin dissolution in FaSSIF was initially rapid, although peaking at 80.0% and 
89.3% for single and FDC respectively. Dissolution profiles in FeSSIF were similar to 
FaSSIF, with dissolution peaking at 76.9% from single and 86.2% from combination 
formulations. Greater atorvastatin dissolution from FDCs was not recognised by f1 and 
f2 testing (Table 6.7), with no difference observed between dissolution profiles for single 
and combination formulations. 
Based on difference and similarity testing only amlodipine in FeSSIF failed to show 
similar bioequivalence, although >85% dissolution was only observed once. This would 
suggest that a FDC ODT would likely display similar performance in vivo to a single dose, 
although based upon current guidelines this is not assumed for BCS class II compounds. 
Furthermore, through development of this simple formulation to consistently deliver 
greater than 85% dissolution (for class I amlodipine) it may be possible to achieve 
biowaiver status. 
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Figure 6.4 Amlodipine (5 mg) dissolution profiles of single and FDC formulations in 
fasted state biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution 
performed using USP 2 paddle apparatus (mean ± SD, n=3) 
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Figure 6.5 Amlodipine (5 mg) dissolution profiles of single and FDC formulations in 
fed state biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution performed 
using USP 2 paddle apparatus (mean ± SD, n=3) 
Amlodipine Single (f1) vs Amlodipine FDC (f3) FeSSIF
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Figure 6.6 Atorvastatin (10 mg) dissolution profiles of single and FDC formulations in 
fasted state biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution 
performed using USP 2 paddle apparatus (mean ± SD, n=3) 
Atorvastatin Single (f2) vs Atorvastatin FDC (f3) FaSSIF
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Figure 6.7 Atorvastatin (10 mg) dissolution profiles of single and FDC formulations in 
fed state biorelevant media (900 ml, 37°C) from 500 mg ODTs. Dissolution performed 
using USP 2 paddle apparatus (mean ± SD, n=3) 
Atorvastatin Single (f2) vs Atorvastatin FDC (f3) FeSSIF
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Compound  >85% dissolution ≤15 min f1 f2 Result 
Amlodipine 
FaSSIF Yes 5.08 70.80 Pass 
FeSSIF No 15.92 45.40 Fail 
Atorvastatin 
FaSSIF No 14.16 53.81 Pass 
FeSSIF No 13.24 54.59 Pass 
 
6.3.4 Permeability Studies 
TEER values for Caco-2 cells are the same as in section 5.3.4. Amlodipine and 
atorvastatin transport across Caco-2 monolayers alone and in combination was 
measured in both A-B and B-A directions. Drug transport from A-B is shown for 
amlodipine (Figure 6.8), atorvastatin (Figure 6.9) and amlodipine and atorvastatin 
combination (Figure 6.10 and Figure 6.11, respectively). The gradient of the linear 
portion of the curve was used to calculate Papp values, summarised in Table 6.8.  
Papp values for amlodipine closely mimic those observed by Rausl et al. [424] from both 
A-B and B-A. Atorvastatin Papp values and efflux ratio are similar to those reported by 
Wu et al. [425]. An efflux ratio of 1.14 for amlodipine indicates passive diffusion of the 
compound across Caco-2 monolayers, whereas an efflux ratio of 5.02 for atorvastatin 
suggests active efflux of the API in the B-A direction. Atorvastatin efflux, mediated 
primarily by P-glycoprotein, has been described previously in the Caco-2 model [425, 
426] and other cell lines [427].  
When combined with atorvastatin, Papp values for amlodipine decreased significantly 
from A-B (P<0.001) and B-A (P<0.05), although the efflux ratio remained largely 
unchanged at 0.96. A decrease in atorvastatin Papp value when in combination with 
Table 6.7 Comparison of dissolution profiles for each compound from single and FDC 
formulations in FaSSIF and FeSSIF media, by difference factor f1 and similarity factor f2 
testing. Dissolution profiles are considered similar if the f1 value is below 15 and the f2 
value is above 50.   
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amlodipine from A-B was not significant (P>0.05) but was significant in the B-A direction 
(P<0.001), with the efflux ratio again maintained at a similar level.  
 
 
 
 
 
Figure 6.8 Cumulative mass transfer of amlodipine alone (20 μg/ml) across Caco-2 
monolayers (pH 7.4) simulating f1. Papp values calculated using the gradient of the 
linear portion of the curve (mean ± SD, n=3) 
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Figure 6.9 Cumulative mass transfer of atorvastatin alone (40 μg/ml) across Caco-2 
monolayers (pH 7.4) simulating f2. Papp values calculated using the gradient of the 
linear portion of the curve (mean ± SD, n=3) 
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Figure 6.10 Cumulative mass transfer of amlodipine (20 μg/ml) whilst in combination 
with atorvastatin across Caco-2 monolayers (pH 7.4) simulating f3. Papp values 
calculated using the gradient of the linear portion of the curve (mean ± SD, n=3) 
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Compound Papp (10-6 cm s-1) Efflux Ratio 
 A-B B-A  
Amlodipine 8.34 ± 0.32 9.51 ± 1.70 1.14 
Atorvastatin 2.03 ± 0.96 10.18 ± 0.71 5.02 
Amlodipine Combination 5.40 ± 0.48 5.18 ± 0.29 0.96 
Atorvastatin Combination 0.87 ± 0.18 4.59 ± 0.44 5.29 
 
6.3.5 Clinical Trials Simulation 
The initial simulation of the kinetics of amlodipine and atorvastatin (derived from data 
presented in Table 6.1) were used to optimise the Peff and Vss from clinical data sets 1 
and 2 for each API. Optimised Peff and Vss were estimated as 1.35 x10-4 cm/s and 6.12 
Table 6.8 Papp vales for amlodipine and atorvastatin alone and in combination in A-B and 
B-A directions across Caco-2 monolayers at pH 7.4 in both compartments (mean ± SD, 
n=3) 
 
Figure 6.11 Cumulative mass transfer of atorvastatin (40 μg/ml) whilst in combination 
with amlodipine across Caco-2 monolayers (pH 7.4) simulating f3. Papp values 
calculated using the gradient of the linear portion of the curve (mean ± SD, n=3) 
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x10-4 cm/s for amlodipine and 13.78 l/kg and 4.78 l/kg for atorvastatin, respectively. 
Furthermore, a RAFP-gp of 8.7 was estimated to account for atorvastatin efflux (P-
glycoprotein) [421, 425] contribution within the small-intestine. 
Subsequent validation of atorvastatin and amlodipine using validation data sets 3 and 4 
for each API was successful and generally centred around the mean simulated profiles 
and within the 5th and 95th percentiles of the simulated profiles (see Figure 6.12 and 
Figure 6.13). 
 
 
 
Figure 6.12 Simulated mean plasma profile after a: (a) 80 mg and (b) 10 mg oral dose 
of atorvastatin (solid black line). The corresponding observed data points are shown 
by red open circles. The grey lines represent the 5th and 95th percentiles for the 
predicted values. All simulations were performed using the minimal PBPK model. 
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Simulations to predict the in vivo performance of ODTs in healthy volunteers were used 
to compare the bioavailability between single and FDC formulations under fasted and 
fed conditions using dissolution data determined in section 6.3.3. For amlodipine the 
formulation state (single or combined) or dosing state (fasted or fed) had no statistically 
significant impact on pharmacokinetics (Figure 6.14 A and B). Amlodipine plasma 
concentrations reached a geometric mean Cmax of 2.4-2.93 ng/ml in all conditions (Table 
6.9), yielding a median AUC in the range of 53-60 ng/ml.h. 
Fed state subjects exhibited a longer median tmax from 7.12 h to 8.12 h in single dose 
and 7.45 to 8.46 h in combination dose profiles. This increased tmax in fed subjects is 
likely a result of delayed gastric emptying and subsequent release of drug into the 
duodenum [428] and has been reported previously for amlodipine [429]. 
At the level of the small-intestine, predicted mean fraction dose absorbed (fa) for 
amlodipine correlated with dissolution profiles, showing significantly different (p<0.0001) 
values between single and combination formulations, 0.92 ± 0.05 and 0.95 ± 0.04 
(fasted) and 0.91 ± 0.04 and 0.85 ± 0.05 (fed), respectively.  
 
 
Figure 6.13 Simulated mean plasma profile after a 10 mg oral dose of amlodipine 
(solid black line). The corresponding observed data points are shown by red (set 3) 
or green (set 4) open circles. The grey lines represent the 5th and 95th percentiles 
for the predicted values. All simulations were performed using the minimal PBPK 
model. 
Chapter 6 – Fixed Dose Combination ODTs to Treat Cardiovascular Disease: 
Physiologically Based Pharmacokinetic Modelling to Assess Bioavailability 
259 
Atorvastatin plasma profiles similarly showed no statistically significant difference 
(p>0.05) in pharmacokinetic parameters (Table 6.10) between single and combination 
doses in fasted subjects (Figure 6.14 C). Atorvastatin plasma concentration increased 
rapidly after dosing with a median tmax of 2.25 h in fasted and 2.56 h in fed states with a 
similar geometric mean Cmax of 1.6-1.7 ng/ml and similar AUC (~16-17 ng/ml.h) for fasted 
states. However, under fed conditions there was a significant (p<0.05) increase in Cmax 
for both single (2.66 ng/ml) and combined (2.96 ng/ml) doses, with an associated 
increase in the AUC (p<0.0001). Differences between single and combination doses in 
fed subjects were not statistically significant. 
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  Amlodipine Fasted Amlodipine Fed 
Parameters Single Combined Single Combined 
AUC (ng/ml.h) 53.42 (32.12-75.69) 55.12 (30.12-74.11) 60.11 (42.75-81.94) 55.36 (35.69-78.91) 
Cmax (ng/ml) 2.45 (1.15) 2.57 (1.23) 2.87 (1.67) 2.89 (1.17) 
tmax (h) 7.12 (5.92-8.21) 7.45 (5.21-9.72) 8.12 (6.96-9.54) 8.46 (7.95-9.87) 
 
  Atorvastatin Fasted Atorvastatin Fed 
Parameters Single Combined Single Combined 
AUC (ng/ml.h) 16.24 (2.78-64.45) 17.15 (3.04-62.99) 25.77 (5.47-75.17) 29.46 (6.73-87.72) 
Cmax (ng/ml) 1.61 (1.27) 1.72 (1.31) 2.66 (1.80) 2.96 (1.97) 
tmax (h) 2.25 (1.51-7.86) 2.28 (1.45-5.31) 2.56 (1.45-5.25)  2.71 (1.45-5.72) 
Table 6.9 Summary of pharmacokinetic parameters for amlodipine (5 mg) under fasted and fed conditions. Geometric mean (SD) reported for 
Cmax and median (range) for AUC and tmax 
Table 6.10 Summary of pharmacokinetic parameters for atorvastatin (10 mg) under fasted and fed conditions. Geometric mean (SD) reported for 
Cmax and median (range) for AUC and tmax  
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Identical mean fraction dose absorbed (fa) between single and combination formulations 
were seen for atorvastatin under fasted state (0.91 ± 0.07). However, under fed 
conditions fa was lower (p<0.0001) for single compared to combination, at 0.81 ± 0.11 
and 0.91 ± 0.09, respectively. It may be prudent to assume that the enhanced AUC and 
Cmax for atorvastatin may be due to a positive food effect, given its BCS class II status 
and therefore lipophilic nature [430, 431]. However, the impact of fasted/fed status on 
the fa identified that the absorption across the gut lumen is delayed for both single and 
combination formulations (Figure 6.15 A). As the cumulative fraction dose absorbed is a 
reflection of events along the entire small-intestine lumen the impact of food may delay 
the absorption of atorvastatin into the intestinal enterocytes. However, when considering 
the mass of dosed atorvastatin within the stomach (10 mg) (Figure 6.15 B) significantly 
greater quantities of atorvastatin remain undissolved under fed conditions for a longer 
period of time. 
When considered in the context of dissolution and taking the duodenum as an exemplar, 
the estimated dissolution rates within the duodenum under fasted states are significantly 
faster than that under fed state, which results in a significantly larger duodenal luminal 
Cmax (17972 ng/ml) compared to the fed state (5002 ng/ml) (Figure 6.15 C, upper panels). 
This suggests that the differences between fasted and fed plasma concentrations are a 
result of changes in the dissolution process of the solid dosage form, otherwise 
uncaptured when considering the f1 and f2 tests, due to the dynamic and mechanistic 
nature of the ADAM-PBPK model. 
As a result of this reduced dissolution under fed states, the absorption rate of atorvastatin 
in the duodenum is higher under fasted states with a maximal rate of 3.05 mg/h 
compared to 1.77 mg/h under fed states, both at 0.28 h (Figure 6.15 C, lower left panel). 
A consequence of this is a lower overall atorvastatin concentration within the enterocytes 
and potentially reduced gut metabolic clearance ab orally (Figure 6.15 C, lower right 
panel). Whilst the fa is relatively invariable ab orally for fasted or fed conditions (Figure 
6.16 A), simulations confirmed a noticeable decrease in the fraction of drug metabolised 
within the enterocytes is observed under all fed conditions (Figure 6.16 B). Atorvastatin 
possesses a low oral bioavailability (F < 10%) and this is primarily a function of its high 
first pass metabolism. Under fed conditions this decrease in regional ab oral fraction of 
dose metabolised would result in an increased overall oral bioavailability (Foral=faxfgxfh) 
and is therefore primary cause of the increased Cmax observed under fed conditions for 
both single and combined formulations. 
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When considering the physical process of drug absorption, it is important to 
conceptualise the small-intestine and associated distribution of metabolic enzymes ab 
orally. With this in mind, CYP3A4 expression would be greatest duodenally and decrease 
longitudinally ab orally [432, 433]. As a result of this, the delayed absorption of drug 
across the gut wall (as a result of reduced dissolution) under fed states would result in a 
longer residency of solid (undissolved) drug in the proximal small intestine lumen, which 
would be susceptible to transit along the gut lumen until dissolution was complete, 
resulting in absorption of atorvastatin more distally.  
 
  
 
Figure 6.14 Simulated mean plasma profile after a 5 mg oral dose of amlodipine (A 
and B) and 10 mg oral dose of atorvastatin (C and D) under fasted and fed conditions. 
Single API formulations indicated in black and fixed dose combinations in red.  Solid 
lines represent trial mean and dashed lines represent the 5th and 95th percentiles for 
the predicted values. All simulations were performed using the minimal PBPK model.   
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Figure 6.15 (A) Mean cumulative fraction dose absorbed; (B) Mean solid drug mass 
in the stomach (left panel) and mean dissolved stomach drug concentration (right 
panel); (C) duodenal dissolution rate (upper left panel), duodenal luminal 
concentration (upper right panel), duodenal absorption rate (lower left panel) and 
duodenal enterocyte concentration (lower right panel).  Black solid line represents 
fasted (single/combined), red solid line represents fed (single) and red dashed line 
represents fed (combined) formulations. 
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Atorvastatin is a BCS Class 2 compound where solubility/dissolution is the rate limiting 
step for absorption, coupled with often high metabolism. The oral bioavailability of 
atorvastatin is relatively low, indicating significant metabolic clearance [434]. Fed state 
often results in slower gastric emptying and the presence of food alters luminal 
composition through an increase in bile salts. Indeed, post-prandial changes can often 
contribute to an increased bioavailability of many class 2 compounds. A review by Gu et 
al [430] compared food effects on 92 sets of clinical data and demonstrated that 71% of 
BCS Class II compounds resulted in an enhancement of bioavailability following meals. 
 
Figure 6.16 Ab oral regional distribution of (A) median fraction dose absorbed and (B) 
median fraction dose metabolised for atorvastatin. Black bars represent fasted 
(single/combined) formulations, red bars represent fed (single) formulations and 
orange bars represent fed (combined) formulations. 
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Although dissolution studies in FaSSIF and FeSSIF are useful, the mechanistic nature 
of the ADAM model, coupled with a detailed ab oral consideration of geometric, 
physiological and biochemical variations allows a greater understanding of the role of 
small-intestine physiology on the process of oral drug absorption; an understanding that 
would otherwise not be captured in in vitro dissolution studies or subsequent statistical 
analysis (i.e. f1 and f2 testing).  
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6.4 Conclusion 
An ODT formulation was developed and characterised, demonstrating acceptable 
performance for hardness, friability and disintegration time and was subsequently used 
for formulation of low dose ODTs for amlodipine and atorvastatin, alone and in FDC. 
Clinical trial simulations using an ADAM-PBPK model were able to predict the in vivo 
pharmacokinetics of amlodipine and atorvastatin for comparison of the performance of 
FDCs against single dose formulations. In vitro dissolution data was incorporated to 
more accurately model the performance of the developed formulation and Papp values to 
model intestinal absorption.  
Dissolution profiles showed no differences based on f1 and f2 testing between FDC and 
single dose formulations, with the exception of amlodipine in FeSSIF. All FDC 
formulations were shown to be bioequivalent based on clinical trial simulations in fasted 
and fed subjects (AUC, Cmax and tmax), despite the failure of amlodipine in FeSSIF based 
on f1 and f2, adding incentive for the use of in silico simulation. Furthermore, the 
demonstration of bioequivalence through f1 and f2 and PBPK simulation for atorvastatin, 
a class II compound, adds weight to the argument for the applicability of class II inclusion 
in biowaiver applications, ideally in combination with PBPK modelling. Atorvastatin 
enjoyed a greater Cmax and AUC in the fed state, due to an extended transit along the 
gut lumen as a result of poor dissolution. The attenuating expression of CYP3A4 distally 
along the gut meant that less atorvastatin was thus metabolised in the fed state. This 
food effect on the pharmacokinetic parameters for atorvastatin was not evident from in 
vitro investigation alone, further demonstrating the power and applicability of mechanistic 
PBPK modelling. 
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7.1 Conclusions 
Oral delivery is the most widely utilised delivery route and owes its popularity to its non-
invasiveness and general ease of administration. A host of different oral drug delivery 
systems have been developed, each with their own strengths and limitations, however 
the directly compressed tablet remains the most favoured. For the patient, directly 
compressed tablets benefit from good stability under storage, transportability and 
simplicity, whilst they are attractive for manufacturers due to the low costs and complexity 
involved in production. Despite their wide acceptance many consumers, particularly 
paediatrics, suffer from dysphagia, a difficulty in swallowing, and are only able to swallow 
tablets with the aid of water. This difficulty results in problems with patient compliance 
and has driven the development of novel dosage forms such as ODTs, that eliminate the 
need for swallowing by disintegrating rapidly within the mouth. 
ODTs offer all the benefits of conventional tablets and several more, such as their 
applicability to dysphagia sufferers, accessibility, good mouth-feel, no risk of choking or 
asphyxiation, rapid absorption and potential for improved bioavailability. For 
manufacturers, ODTs provide new business opportunities including product 
differentiation, promotion, patent extension and life cycle management. In addition to 
achieving good mouth feel and taste, the major challenge in formulation of a directly 
compressed ODT is balancing rapid disintegration whilst maintaining robust mechanical 
properties, thus avoiding the need for specialised packaging. Careful selection of 
functional excipients, processing techniques and process parameters make this 
possible. Achieving this means that high drug loading is often not feasible, particularly 
for APIs that show poor water solubility and poor compactability. 
Polymeric film coating of tablets is widely embraced to impart tablets with desirable 
aesthetic and functional properties. Aqueous polymeric suspensions or solutions are 
increasingly favoured over organic solvent based, due to concerns over safety and 
escalating costs, although offer additional challenges such as the requirement for greater 
drying efficiency. Coating of ODTs has not been explored, and is unattractive due to the 
stresses that the coating process conveys on mechanically weak cores.  
FDC formulations are recommended for management of disease states where a 
combination of APIs with synergistic or additive effects are included in a single 
formulation. Like ODTs, they also improve compliance by simplifying therapy and can 
result in improvements in efficacy. Paediatric populations are poorly provided for with 
safe and appropriate child friendly formulations, due to a historic lack of consideration 
for physiological and behavioural differences between adults and children and the ethical 
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issues regarding paediatric clinical trials. Paediatric formulation development is 
encouraged and incentivised by bodies such as the FDA and EMA, whilst the 
development of FDCs at paediatric relevant doses is recommended by the WHO. 
Currently, no FDC ODT combinations are available on the market. 
The principal aim of this thesis is to investigate and engineer solutions to formulate ODTs 
for high dose drugs and study the applicability of ODTs for FDC formulations.  
Flucloxacillin sodium was chosen as a model API that would present high dose 
challenges for an ODT. Initial work involved identifying excipients commonly used in and 
suitable for compressed ODTs. This involved formulation of a placebo ODT that was also 
used to investigate the impact of process parameters on key tablet properties. Increasing 
compaction force expectedly improved mechanical properties including tablet hardness 
and friability, whilst slowing disintegration. Indications of powder fragmentation under 
high compaction forces were attributed to fragmentation of crospovidone with 
subsequent Heckel analysis. Heckel analysis also signified fragmentation of mannitol at 
low compaction force, showing a very high out-of-die mean yield pressure, which 
resulted in unacceptable tablet friability. Optimisation of crospovidone concentration was 
also performed to enhance disintegration further. 
Inclusion of flucloxacillin at 250 mg resulted in tablets with unacceptable properties and 
despite experimentation with different excipients, dose was lowered to 125 mg for further 
development. Different disintegrants and disintegrant combinations were also examined, 
although it was concluded that crospovidone alone was preferable. Blending alteration 
was shown to have an effect on resultant ODT properties, although any drop in 
disintegration was also met with a drop in tablet hardness and increased friability. The 
inclusion of MCC as a binder to overcome the major limitation of the formulation, namely 
poor mechanical properties, was successful and revealed that an MCC: mannitol ratio of 
2:1 was optimal. Further development of the formulation is necessary to achieve the 
desired properties. 
Aqueous polymeric film coating of ODTs to overcome high friability was investigated and 
was shown to reduce friability to an acceptable level. Increase in tablet hardness of film 
coated ODTs was also demonstrated. The high attrition of tablets during the fluidised 
bed coating process meant that coating was counterintuitive and led to the development 
of a novel stationary coating technique. Briefly, tablets were held stationary under 
vacuum on a perforated platform within the spray zone. Redirection of heated air from 
below the tablet bed over the tablet surface allowed for satisfactory film formation, where 
previously poor drying resulted in over-wetting and poor adhesion of the coating to the 
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tablet core. A post-coating curing step resulted in tablets that displayed hardness values 
as high as double that of uncoated cores. This novel technique was successfully applied 
as a proof of concept, although is not without its own limitations, primarily the requirement 
to manually invert the tablet during coating and issues over drying efficiency. 
With a view to investigate and improve the coating process and address the difficulty in 
evaporation of water from aqueous coating solutions, optimisation of the size of droplets 
produced through atomisation was studied. A DOE approach was used where CPPs 
including atomisation pressure, coating solution concentration and solution flow rate 
were used to model the atomisation process. Optimisation revealed the process 
parameters required to produce droplets of a desired VMD within the range of 20-70 µm. 
This was used to investigate the effect of droplet size on film coat quality and 
characteristics. To visualise the coating on a micro-scale and evaluate its morphology, 
two non-invasive imaging techniques, CLSM and XµCT were employed. This was the 
first study of its kind to directly evaluate the impact droplet size had on film quality through 
imaging of the coat, providing both qualitative and quantitative information. Imaging 
showed that smaller droplets produced thinner, less porous coats that were more uniform 
and homogenous. Information on the atomisation process and droplet size optimisation 
gleamed from this study will aid in future development of stationary coating techniques, 
since smaller droplets evaporate more rapidly. 
The applicability of ODTs for FDC formulations to provide a highly convenient dosage 
form in the interests of patient compliance, was investigated using model APIs for two 
disease states. Amlodipine and atorvastatin at low doses for the treatment of CVD and 
isoniazid and rifampicin at high drug loading for tuberculosis therapy were investigated, 
with all doses at paediatrically relevant levels. An ODT formulation showing acceptable 
tablet properties was developed, where the number of excipients was kept at a minimum 
in the interests of complexity. Dissolution of API from single and combination doses was 
tested in biorelevant media to mimic in vivo performance as closely as possible. FDA 
recommended bioequivalence testing was used to compare dissolution profiles, to 
examine whether API combination resulted in altered dissolution. No differences were 
seen between single and FDC formulation, with the exception of rifampicin release in 
FeSSIF. To examine bioequivalence in much greater detail, PBPK modelling was used 
to simulate healthy adult clinical trials in silico. Modelling included dissolution and Caco-
2 permeability data. Prediction of in vivo pharmacokinetics showed no differences in 
bioavailability between single and combination doses, highlighting the shortcomings of 
dissolution profile comparison in the case of rifampicin. Although no differences were 
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reported between single and combination, a positive food effect was shown for 
atorvastatin, with greater oral bioavailability as a result of reduced CYP3A4 metabolism 
within enterocytes. 
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7.2 Future Work 
Flucloxacillin ODT development showed promise in achieving acceptable properties and 
holds substantial scope for future development. The use of SSF as a lubricant with 
greater water solubility and different grades of crospovidone are such examples, that 
have been touched upon in preliminary work. The use of compaction forces below 1 ton 
should also be explored. The use of granulated flucloxacillin in future work should allow 
for this. Taste masking is another important area for future development and ultimately 
would prevent any successful formulation if this could not be achieved. Preliminary work 
into this involving dry coating of flucloxacillin with sweeteners and flavours, shows 
potentially tremendous promise and would also likely improve flow properties further. 
Development of the novel stationary film coating technique could ultimately provide a 
means to successfully formulate high dose ODTs with poor compactability. Indeed, this 
technology would not need to be limited to ODTs. An overhaul in the technique design 
is necessary to overcome the predominant limitation, namely the need for manual 
inversion of tablets mid process. Further optimisation of drying is also required. This may 
in part be aided through reduction of droplet size, the means to which is possible due to 
the work involving DOE optimisation of the atomisation process.  
Although PBPK modelling was able to predict bioavailability in adults, this was not 
demonstrated in children. Modelling in simulated paediatric populations would be the 
next step and may be achieved through the use of further in silico techniques and 
adjustment of CYP activity using published data for enzyme expression levels, for 
example.  
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